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CHAPTER I 
 
INTRODUCTION 
 
Melanoma Tumorigenesis 
Melanoma is one of the most aggressive solid tumors and median survival of a 
patient with advanced stages of melanoma is 6 to 8 months (Jemal et al., 2010). The 
incidence of melanoma is rising and it is among the ten leading cancer types in both 
males and females (Jemal et al., 2010). Melanoma arises from melanocytes, a 
specialized cell type that makes melanin pigment in an organism. Melanocytes arise 
from neural crest cells (NCC), which originate in the ectodermal layer. Upon signaling by 
ligands such as Wnt and bone morphongenic protein (BMP), NCCs reorganize 
cytoskeleton and undergo changes in cell adhesion properties, thus becoming more 
motile (Ernfors, 2010). Neural crest cells become melanoblasts and migrate along the 
dorso-lateral pathway during development. 
Compared to other cell types within the skin, melanocytes have limited life-span 
and basal keratinocytes control the proliferation of melanocytes. Melanocytes are 
located in the epidermal-dermal junction with 5-10 basal keratinocytes surrounding every 
melanocyte (Hsu et al., 2002). An adhesion molecule such as E-cadherin mediates the 
interaction between keratinocytes and melanocytes to control the homeostasis of 
melanocyte proliferation (Perlis & Herlyn, 2004). Melanocytes synthesize melanin and 
distribute this UV-protective pigment to surrounding keratinocytes in the skin through 
their dendrites.  Melanocytes may become malignant and progress to melanoma 
because of inherited mutations and/or environmental insults such as UV radiation 
(Figure 1). 
 2
Melanoma is commonly associated with many genetic changes such as the loss 
of p16 (INK4a) through mutation, deletion or epigenetic silencing (Bennett, 2008; Dahl & 
Guldberg, 2007; de Snoo & Hayward, 2005), mutation in BRAF that leads to constitutive 
activation of the MEK/ERK pathway, or constitutive activation in the MAP kinase 
pathway. Other common mutations of melanoma include NRAS (Q61L) in 15%-30%, 
phosphatase and tensin homolog (PTEN) loss in 5%-20%, p16 (INK4a) loss in 30%-70% 
and p53 loss in about 10% (Gray-Schopfer et al., 2007). Mutations of β-catenin that lead 
to stabilization of the protein (either at S37 or S45) have also been reported in 20%-30% 
of melanoma cell lines (Rubinfeld et al., 1997). Among these many mutations, 
constitutive BRAF mutant is the most common in melanoma. An activating mutation in 
kinase domain of BRAF has been identified in about 50-60% of malignant melanoma 
(Davies et al., 2002). Although many other BRAF mutations have been identified in 
melanoma, 95% of these BRAF mutations is the valine at residue 600 (Wellbrock et al., 
2004). This dominant active BRAF (BRAFV600E) leads to constitutive activation of the 
MAP kinase pathway, contributing to proliferation, survival and transformation. As a 
result, inhibition of BRAF activity with a kinase inhibitor or RNA interference reduces 
melanoma malignancy (Hingorani et al., 2003), suggesting that this mutation is crucial 
for melanoma growth.  
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Figure 1. Development of melanoma from melanocytes. Melanocytes reside along 
the basal layer of the epidermis. Melanocytes may form a benign nevus or a 
dysplastic nevus when they acquire genetic mutations. Additional mutations allow 
melanocytes to progress from nevi to malignant melanoma.  
Gray-Schopfer et al., Nature Reviews. 2007. 
(Reprint with permission from Nature) 
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Much effort has been made to target constitutive BRAF in malignant melanoma 
to improve the disease outcome. Currently, some drugs targeting BRAF have been in 
clinical trials (Flemming, 2010). Although targeting BRAF may have been ineffective in 
the past, more specific and efficacious drugs have been developed. Recently, Zelboraf 
(from Roche, also known as Vemurafinib or PLX4032), a potent inhibitor of mutant 
BRAF, has been approved by the Federal Drug Administration (FDA) for treatment of 
melanoma patients with proven BRAF mutation. In phase III BRIM3 clinical trials, 
Zelboraf treatment resulted in progression free survival of 5.3 months and in phase II 
BRIM2 the progression free survival was 6.1 months with about 80% response in 
patients with BRAF-mutant metastatic melanoma (Bollag et al., 2010; Chapman et al., 
2011). Thus, targeting BRAF is one of the promising therapeutic options for advanced 
metastatic melanoma.  
However, similar to other oncogenes, BRAFV600E mutation is not sufficient to 
induce transformation in melanocytes. In fact, BRAFV600E mutation induces senescence 
in melanocytes (Dhomen et al., 2009; Michaloglou et al., 2005). BRAFV600E mutation has 
been identified in more than 80% of melanocytic nevi (Kumar et al., 2004; Pollock et al., 
2003), suggesting that not all melanocytes with this mutation become malignant. It is 
believed that up-regulation of p16 prevents melanocytes with BRAFV600E from becoming 
malignant melanoma (Wellbrock & Hurlstone, 2010). Consistent with this idea, another 
common mutation in melanoma is the loss of p16/INK4A or mutation in p16/p19, 
resulting in loss of function of these proteins (McKenzie et al., 2010; Meyle & Guldberg, 
2009). p16 inhibits CDK4 and CDK6 activity, thereby inhibiting the cell cycle and cellular 
growth (Sherr & Roberts, 1995). The function of p16 has been lost in 25% to 60% of 
malignant melanoma (Kamb et al., 1994; Nobori et al., 1994). 
 Possibly due to the survival signal mediated by the MAP kinase pathway, 
molecules in this pathway have been often mutated in melanoma. For example, 
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mutations that activate NRAS have been identified in melanoma. Although not as 
common as BRAF mutation, NRAS mutation has been found in 15-30% of melanoma 
(Davies et al., 2002). Both RAF and RAS are part of the classical RAS/RAF/MEK/ERK 
pathway which relays mitogenic signals from tyrosine kinase receptors to the nucleus to 
activate transcription factors such as Ets and Myc (Gollob et al., 2006), resulting in 
increased proliferation and resistance to apoptotic signals.  
 In addition to the above mentioned mutations, the β-catenin pathway is affected 
in melanoma. β-catenin regulates developmental processes as well as genes important 
for transformation including c-Myc, CyclinD1 and microphthalmia-associated 
transcription factor (MITF). β-catenin is generally an unstable protein which undergoes 
constant proteasomal degradation mediated by adenomatous polyposis coli (APC), 
glycogen synthase kinase 3β (GSK3β) and β-transducin repeat containing protein (β-
TrCP). During development, β-catenin regulates both proliferation and differentiation of 
melanocytes (Larue et al., 2003). In addition to the role in normal development, a role for 
β-catenin has been suggested in melanoma. Some melanoma lesions exhibit genetic 
alterations that activate the β-catenin pathway, such as mutations to stabilize β-catenin 
or mutations resulting in the absence of APC (Rubinfeld et al., 1997).  
In addition to β-catenin, another developmental gene MITF contributes to 
melanoma growth. MITF is a lineage specific transcription factor for melanocytes, and 
promotes melanocyte differentiation and cell cycle arrest. During melanoma progression, 
MITF regulates senescence and proliferation of melanoma (Giuliano et al., 2010). 
 In addition to the above mentioned pathways and genes, other genes 
documented to contribute to melanoma include c-Kit, PTEN, pRB and AKT. Mis-
regulation in these pathways supports growth and proliferation of melanoma. Similarly, 
due to its pleiotropic roles in cellular processes, deregulation of nuclear factor-κB (NF-
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κB) has been reported in melanoma growth (Wood & Richmond, 1995; Yang & 
Richmond, 2001; Yang et al., 2010). 
 
Regulation of Nuclear Factor-κB (NF-κB) 
Nuclear factor κB (NF-κB) is a family of transcription factors that regulate 
essential biological processes such as proliferation, development/differentiation, 
apoptosis and inflammation. It was first described as a B-cell specific transcription factor 
that binds to the promoter region of heavy and kappa-light chain (Singh et al., 1986). 
Later studies show that NF-κB is not restricted to B cells but is ubiquitously expressed in 
many cell types (Sen & Baltimore, 1986; Staudt et al., 1986). The mammalian NF-κB 
family includes five members namely, RelA (p65), RelB, p50, p52 and c-Rel. All of these 
members contain the Rel homology domain which contains DNA-binding sequences, 
dimerization sequences and a nuclear localization signal (NLS). Likewise, the 
transactivation domain is present in all members except p50 and p52 and thus these NF-
κB members by themselves are poor transcription factors. NF-κB proteins may form 
homodimers or heterodimers when acting as transcription factors. A non-conventional 
member of the NF-κB family, Bcl3, may also function as part of the transactivation 
complex. It can bind to NF-κB complexes and act as a transcriptional cofactor for DNA-
bound p50 homodimers or p52 homodimers (Bours et al., 1993; Dechend et al., 1999; 
Franzoso et al., 1992; Nolan et al., 1993). Recently, ribosomal protein S3 (RPS3) was 
identified as an additional member of NF-κB complex. RPS3 is required to bind to the 
promoter regions of some NF-κB regulated genes for optimal transactivation (Wan et al., 
2007). 
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Figure 2. Overview of the canonical and alternative pathways of NF-κB. IKK 
complex IKKα, IKKβ and IKKγ is a main component of the canonical pathway 
whereas, IKKα and NIK are essential for the activation of the non-canonical 
pathway.  
Sun. Cell Research. 2011.  
(Reprint with permission from Nature)
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  Activation of NF-κB pathway is tightly regulated by cytokines, such as tumor 
necrosis factor α (TNFα) and interleukin-1 (IL-1); bacterial products, such as 
lipopolysaccharide (LPS); and viral components, such as double stranded RNA. 
Generally, two major NF- κB pathways can be distinguished: the canonical pathway and 
the non-canonical or alternative pathway (Figure 2). The transcriptional responses 
mediated through the canonical pathway are known to be rapid and transient, whereas 
those of the alternative pathway are slow and long-lasting. For instance, NF-κB 
activation in response to one of the canonical pathway activators, TNFα, peaks within a 
few minutes after stimulation and declines within two hours (Werner et al., 2005). Under 
a steady state of the canonical pathway, NF-κB is sequestered in the cytoplasm by its 
inhibitor IκB (IκBα, IκBβ or IκBε). IκB binds to NF-κB through its ankyrin repeats, 
masking NLS of the transcription factor. Upon stimulation with a ligand, IκB is 
phosphorylated by an IκB kinase (IKK), subsequently ubiquitinated and degraded by the 
proteasome (Figure 2).  
IKKs act as a complex which is composed of two kinases IKKα and IKKβ, and a 
regulatory subunit IKKγ (Nemoto et al., 1998). Although all IKKs act as a complex, only 
IKKβ is indispensable for activation of the canonical pathway (Li et al., 1999b). It 
phosphorylates IκB members (IκBα, IκBβ, IκBε and p105) and liberates NF-κBs p65/p50 
heterodimer to translocate into the nucleus. It appears that IKKα is not essential in this 
signaling event, as observed in IKKα knock-out mice which still have an intact canonical 
NF-κB activity (Hu et al., 1999). Interestingly, some evidence suggests that IKKα may 
act as a negative regulator of NF-κB. Macrophages that lack IKKα, and have mutated 
IKKα exhibit higher NF-κB activity and produce pro-inflammatory cytokines and 
chemokines (Lawrence et al., 2005; Li et al., 2005). Unlike IKKα, studies on IKKγ-/- mice 
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suggest that IKKγ is required for the activation of NF-κB through the canonical pathway 
(Schmidt-Supprian et al., 2000). IKKγ does not have a kinase activity but serves as a 
scaffolding protein in activating the canonical pathway. IKKγ  binds to lysine-63 linked 
ubiquitin on another intermediate, such as receptor-interacting protein (RIP), and brings 
the IKK complex in proximity of the receptor (Wu et al., 2006). When recruited to the 
receptor such as TNFR, IKKα and IKKβ are phosphorylated and activated by upstream 
kinases, such as transforming growth factor beta activated kinase-1 (TAK1) in T-loop 
regions (Adhikari et al., 2007) (Figure 2).  
A less well-understood pathway, the alternative pathway of  NF-κB, is activated 
through IKKα (Senftleben et al., 2001) yet does not require IKKβ and IKKγ. Expressing 
an IKKα mutant, which cannot be activated, in IKKα-/- mice shows that chemokines 
regulated by the alternative pathway are down-regulated (Bonizzi et al., 2004). In these 
mice, nuclear localization of p52 and RelB is defective, suggesting the necessity of IKKα 
activation in this event. Unlike the canonical pathway which can be activated by multiple 
ligands, only a limited number of stimuli, such as CD40 ligand (CD40L), B cell activating 
factor belonging to the TNF family (BAFF), receptor activator of NF-κB ligand (RANKL) 
and the lymphotoxin beta receptor (LTβR) ligands and TNF-related weak inducer of 
apoptosis (TWEAK), stimulate the alternative pathway. An additional kinase, NF-κB 
inducing kinase (NIK), acts as an upstream kinase of IKKα (Senftleben et al., 2001). 
Both NIK and IKKα phosphorylate p100, an IκB of the alternative pathway, at many 
serine residues. Unlike the IκB of the canonical pathway, p100 exerts an intramolecular 
inhibition. Once phosphorylated, the C-terminus of p100 is ubiquitinated by SCFβ-TrCP 
and degraded by the proteasome (Figure 2). As a result, the N-terminus is freed to 
translocate to the nucleus as a transcription factor p52 heterodimerized with RelB. 
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Interestingly, overexpression of NIK in 293 cells is sufficient to induce p100 processing 
to p52 (Xiao et al., 2001). 
Previous research has shown that alterations in the NIK gene, NIK activity or NIK 
protein expression occur in hematological cancers and that targeting NIK reduces tumor 
cell survival (Annunziata et al., 2007; Conze et al., 2010; Keats et al., 2007; Saitoh et al., 
2008). While the importance of NIK in tumorigenesis of solid tumors has been reported 
(Neely et al., 2010; Saitoh et al., 2010), its role in solid tumors is less well-understood 
and detailed mechanisms of how NIK modulates tumor growth have not been fully 
explored. Because of the role of NIK in tumorigenesis and elevated NF-κB activity in 
melanoma, we speculated that understanding how NIK contributes to melanoma tumor 
progression might be useful for therapeutic interventions. In the following sections, we 
review the literature to date on the function and regulation of NIK in relation to its role in 
the NF-κB pathway, as well as some functions of NIK that are independent of the NF-κB 
pathway. We also review the functional significance of NIK in the context of physiological 
processes such as immune regulation, and in disease models such as autoimmunity and 
cancer.  
 
NF-κB inducing kinase (NIK) 
NIK as a kinase of the canonical and non-canonical NF-κB pathways 
NIK was first identified as a kinase that mediates the proximal signaling 
downstream of TNF and IL-1 receptors and the kinase activity of NIK is required for this 
process (Malinin et al., 1997).  NIK also mediates stimulation through other receptors 
such as CD27, CD30, CD40, LTβR and BAFFR (Akiba et al., 1998). When 
overexpressed, NIK leads to activation of NF-κB, therefore protecting cells from 
undergoing TNF-induced apoptosis (Malinin et al., 1997). In reverse, the kinase dead 
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NIK mutant (either KK429/430AA or T559A) has a dominant negative effect and over-
expression of this mutant inhibits activation of NF-κB by TNFα (Lin et al., 1998; Malinin 
et al., 1997). Surprisingly, dominant negative NIK has a differential effect on NF-κB 
activation in transformed cell lines versus primary cells. Adenoviral expression of 
dominant negative NIK in primary macrophages did not have an inhibitory effect on NF-
κB activation in response to TNFα and LPS, as suggested by normal NF-κB dependent 
cytokine production, IκBα degradation and NF-κB DNA (Smith et al., 2001). Although it 
is not clear why dominant negative NIK exerts different effects on different cell types, 
NIK was thought to be an essential kinase for the canonical NF-κB activity.  
NIK has been demonstrated to interact with and activate IKKα and IKKβ. 
However, NIK phosphorylates IKKα to a greater extent than IKKβ (Woronicz et al., 
1997). Thus, NIK serves as an upstream IKK complex kinase responsible for the 
proximal signaling of various cytokine receptors. Since the identification of NIK, many 
other kinases have been identified as IKK kinases acting in concert with NIK. Some of 
them include MAP/ERK kinase kinase 1 (MEKK1) (Nakano et al., 1998; Nemoto et al., 
1998) and TAK1 (Sakurai et al., 1998). TAK1 was identified as an upstream kinase of 
NIK that can activate NIK/IKK/NF-κB signaling downstream of IL-1R (Ninomiya-Tsuji et 
al., 1999). TAK1 phosphorylates NIK at a site other than Ser-549, Thr-552 and Thr-559 
since mutations of these amino acids to alanine still gave rise to phosphorylated NIK 
(Ninomiya-Tsuji et al., 1999). Although one study demonstrated that TAK1 did not 
directly phosphorylate IKKα (Ninomiya-Tsuji et al., 1999), another study suggested that 
TAK1 may directly activate NF-κB, independent of NIK (Sakurai et al., 1998). NIK is also 
downstream of TNF receptor associated factor (TRAF) 2, 5 and 6 and TANK-binding 
kinase-1 (TBK-1) in NF-κB activation upon certain ligand stimulation (Akiba et al., 1998; 
Pomerantz & Baltimore, 1999).  
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IKKα is a preferential substrate for NIK. NIK directly phosphorylates IKKα on Ser-
176 and mutation of this residue to alanine blocks NIK activation of IKKα, thus disrupting 
signals from IL-1 and TNFα stimuli (Ling et al., 1998). Interestingly, NIK still 
phosphorylates the catalytically inactive IKKα (K44M), but does not induce 
phosphorylation of catalytically inactive IKKβ (K44A), suggesting that auto-
phosphorylation is necessary for IKKβ response to NIK (Delhase et al., 1999). T-loop 
mutants of IKKα and IKKβ (SS176/180AA and SS177/181AA, respectively) show similar 
results. Mutations in the T-loop of IKKβ disrupt NIK-induced phosphorylation, and the 
kinase activation status (Delhase et al., 1999). Nevertheless, T-loop mutations in IKKα 
do not affect NIK’s ability to phosphorylate IKKα (Delhase et al., 1999). This suggests 
that NIK is a better kinase for IKKα than for IKKβ (Delhase et al., 1999). Alternatively, the 
catalytic activity of IKKβ may be required to “prime” NIK phosphorylation of IKKβ. 
However, IKKβ is considered a more potent activator of NF-κB since co-expression of 
NIK and IKKα does not activate NF-κB to the same degree over-expression of IKKβ 
alone (Woronicz et al., 1997).  
In contrast to the report by Delhase et al. (Delhase et al., 1999), O’Mahony et al. 
demonstrated that NIK can stimulate phosphorylation of IKKβ (K44A) in an IKKα 
dependent manner (O'Mahony et al., 2000). In fact, IKKα appears to be upstream of 
IKKβ in response to NIK. The IKKα (S176A) mutant is unable to phosphorylate IKKβ in 
response to NIK activation (O'Mahony et al., 2000). Thus, this study suggested a 
directional activation of IKKα towards IKKβ, stimulated by upstream kinases such as NIK 
(O'Mahony et al., 2000). Remarkably, NIK recruitment by IKKα to the IKK complex was 
thought to be required for the basal activation of IKKβ (O'Mahony et al., 2000), despite 
the non-essential role of NIK in response to certain stimuli.  
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From the preferential interaction with IKKα, it can be deduced that NIK is a more 
important kinase for IKKα than IKKβ. Later studies suggest that NIK is only essential for 
the non-canonical pathway, although it plays a role in both the canonical and non-
canonical pathways of NF-κB activation. Data from studies using mouse embryonic 
fibroblasts (MEFs) with NIK knock-out or with a naturally occurring NIK defective mutant, 
alymphoplasia (aly/aly), support this notion. MEFs from these mice exhibit an intact 
response to TNFα, yet a partial defect in response to LTβR ligands (Shinkura et al., 
1999; Yin et al., 2001). In addition to these mouse models, expression of dominant 
negative NIK in human skin fibroblasts only inhibits lymphotoxin α1β2 (LTα1β2)-induced 
NF-κB signaling, but does not affect TNFα-induction (Smith et al., 2001). More careful 
characterization suggests that in NIK-/- MEFs, NF-κB still binds to DNA yet mRNA of 
some NF-κB responsive genes such as IκBα and monocyte chemotactic protein-1 
(MCP-1)/CCL2 are not induced in response to LTβR agonist antibody (Yin et al., 2001). 
Thus, it was speculated that NIK does not affect IκB degradation and nuclear 
translocation but NIK can activate the transcription of NF-κB regulated genes. These 
data are consistent with the findings that RelA and p50 binding to the DNA is normal in 
aly/aly mice (Muller & Siebenlist, 2003). In aly/aly mice, the situation may be more 
complex. In response to LTβR ligation, the vascular cell adhesion molecule-1 (Vcam-1) 
protein expression level remain unchanged in aly/aly cells, assessed by flow cytometry 
analysis (Dejardin et al., 2002; Matsumoto et al., 1999). However, LTβR ligation still 
increases mRNA expression of Vcam-1 by inducing IKK kinase activity in aly/aly MEFs 
(Dejardin et al., 2002). These data suggest that aly mutation does not affect the 
canonical pathway induction via LTβR, but may affect the post-transcriptional regulation 
of Vcam-1 (Dejardin et al., 2002).  
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Notably, NIK deficiency affects activation of both the canonical and non-
canonical pathways in response to certain ligands in specific cell types. For instance, 
NIK deficient lymphocytes are defective in activation of the canonical and non-canonical 
pathways of NF-κB upon treatment with CD40L, BAFF and CD70 (a ligand for CD27) 
(Ramakrishnan et al., 2004). Deficiency of NIK results in defective IκB degradation, RelA 
nuclear translocation, and p100 to p52 processing in response to these ligands 
(Ramakrishnan et al., 2004). Intriguingly, NIK deficiency in B-cells results in slight 
diminution of some NF-κB members such as p100, RelB and c-Rel, all of which are NF-
κB-regulated genes (Ramakrishnan et al., 2004). This observation implies that 
continuous and weak basal NF-κB activation exists in a NIK-dependent manner 
(Ramakrishnan et al., 2004). B-cells from aly/aly mice also exhibit diminished IκB 
phosphorylation in response to CD40 engagement, whereas dendritic cells do not have 
a similar defect (Garceau et al., 2000). Thus, the notion that NIK is non-essential for the 
canonical pathway is somewhat misleading. Signals via CD40 and BAFFR, in fact, rely 
on NIK to induce RelA activation. In other words, NIK is not required for the proximal 
signaling from the receptors inducing only the canonical pathway, yet it is required for 
the signaling from some receptors that activate both the canonical and non-canonical 
arms of NF-κB. Ramakrishnan et al. proposed NIK-dependent and NIK-independent 
mechanisms of receptor activation. Based on their data, they suggested that NIK is 
recruited together with the IKK complex only to the receptors that are NIK-dependent 
(i.e. CD27), whereas it does not associate with the receptors that are NIK-independent 
(i.e. TNFR) (Ramakrishnan et al., 2004). The necessity for NIK in the canonical NF-κB 
pathway may be cell type and ligand specific and how this specificity occurs is yet to be 
determined.  
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The requirement of NIK for the non-canonical pathway is more evident. NIK is 
responsible for the processing of p100 to p52, confirming its role in the non-canonical 
pathway (Xiao et al., 2001). The kinase activity of NIK or IKKα is not required for the 
recruitment of p100 to both kinases however it is required for the ligand-induced 
proteolysis to occur (Xiao et al., 2004). Surprisingly, NIK is not required for the 
constitutive processing of p100 to p52 (Qing et al., 2005). The mechanism by which NIK 
controls p100 to p52 processing is through its stability. Upon stimulation with ligands 
such as CD40L or BAFF, basally translated NIK is stabilized to induce p100 to p52 
processing (Qing et al., 2005). The C-terminus of NIK is crucial for the interaction with 
p100 as well as for inducing the proteolysis of p100 (Xiao et al., 2001). In addition to 
regulating p100 proteolysis, NIK plays a role in histone modification to control gene 
expression together with IKKα. In response to the bacteria endotoxin LPS, NIK induces 
phosphorylation of IKKα, which in turn phosphorylates histone H3 (Park et al., 2006). 
This is one mechanism by which NIK controls LPS-induced NF-κB activation and gene 
expression.  
From the above evidence, it is apparent that NIK is necessary for the non-
canonical pathway. Paradoxically, NIK was first identified as a kinase which activates 
the canonical pathway downstream of TNF and IL-1 receptors. The physiological 
relevance of NIK in the canonical NF-κB activation pathway was re-investigated by 
Zarnegar et al. who demonstrated the role of NIK in amplification of signals from the 
canonical pathway (Zarnegar et al., 2008). They used TRAF3-/- mice to show the 
elevation of the canonical pathway activity as a result of TRAF3 deficiency and NIK 
stabilization (Zarnegar et al., 2008). In concert with findings from NIK over-expression 
studies, NIK activates the canonical pathway when present at a high amount due to 
stabilization. Interestingly, the response of MEFs to TNFα was markedly enhanced 
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when pre-treated with LTβR agonist antibody (Zarnegar et al., 2008). This 
enhancement was not observed in NIK-/- MEFs, suggesting that NIK stabilization in 
response to pre-treatment with LTβR agonist antibody amplified signals upon TNFα 
treatment (Zarnegar et al., 2008). Interestingly, recent study shows that NIK is 
stabilized upon TNF-treatment in RIP-/- MEFs, suggesting that RIP negatively 
regulates the non-canonical pathway through NIK stability (Kim et al., 2011). As the 
canonical and non-canonical pathways are traditionally thought to be inflammatory 
and lymphoid organogenic responses, respectively, it is possible that NIK may have a 
role in integrating signals from those processes.  
In summary, NIK is a kinase that functions in the canonical pathway, but is 
required only for NF-κB activation in response to certain ligands. The physiological 
significance of this selective requirement remains elusive. Possibly, NIK lies at a cross 
road of the canonical and the non-canonical pathway of NF-κB, maintaining the positive 
and negative regulatory balance between these two pathways. For example, NIK 
activates the canonical pathway and thus possibly induces the production of p100, a 
fourth IκB of the NF-κB family (Basak et al., 2007)(negative feedback mechanism). At 
the same time, NIK is the kinase responsible for the processing of this IκB so that it will 
liberate NF-κB heterodimers such as RelA/p50 to activate gene transcription (positive 
feedback mechanism). Another significance of NIK’s role in both pathways is the 
amplification of signals as described above (Zarnegar et al., 2008). It becomes 
exceedingly clear that NIK plays a dynamic role in NF-κB activation, coordinating the 
intricate balance between the canonical and non-canonical regulations of NF-κB. 
Maintaining this balance is crucial for the proper physiological responses. Moreover, 
tipping this balance probably leads to disease processes such as cancer.  
 17
Chemokines, cytokines and genes under the influence of NIK 
NIK influences the production of inflammatory cytokines and chemokines, 
possibly by regulating the non-canonical pathway, or in some contexts, by regulating 
both the canonical and non-canonical pathways. Inflammatory factors such as interferon-
inducible protein-10 (IP10)/CXCL10, MCP-1, KC and regulated upon activation, normally 
T-cell expressed, and presumably secreted (RANTES)/CCL5 are up-regulated in 
TRAF2-/- mice and more so in TRAF3-/- mice, which have a dramatic stabilization of NIK 
protein expression (Vallabhapurapu et al., 2008; Zarnegar et al., 2008). Similarly, the IL-
12 level is elevated in TRAF3 deficient tissues (Zarnegar et al., 2008). However, the 
contribution of the canonical or the non-canonical pathway in up-regulating these 
secreted factors is not clear, since NIK significantly activates the canonical NF-κB 
pathway when it accumulates as a result of the loss of TRAF3 (TRAF3-/- mice) (Zarnegar 
et al., 2008). T-lymphocytes from aly/aly mice fail to secrete IL-2, suggesting that NIK 
regulates IL-2 production (Yamada et al., 2000). Additionally, Sanchez-Valdepenas et al. 
have shown that NIK regulates the phosphorylation of c-Rel, the binding of c-Rel to a 
regulatory region within IL-2 promoter [CD28-responsive enhancer (CD28RE)], and 
controls IL-2 transcription in T-lymphocytes (Sanchez-Valdepenas et al., 2006). Thus, 
NIK may influence cytokine expression in an IKK/IκB/NF-κB pathway independent 
manner. Transcription of other cytokines and chemokines such as IL-6 and IL-8/CXCL-8 
are also likely to be NIK-dependent as kinase-dead NIK inhibits their production upon 
LTβR ligation (Smith et al., 2001).  
Other genes regulated by NIK include TRAF2 and TRAF3, both of which are 
negative regulators of NIK (Sasaki et al., 2008; Wang et al., 1998). Moreover, NIK 
appears to positively regulate its own transcription (Bista et al., 2010). Microarray data 
from a colon carcinoma cell line with TRAF3 depletion by siRNA show that the NIK 
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mRNA level is elevated in these cells (Bista et al., 2010). These data suggest that 
stabilization of NIK protein through loss of TRAF3 leads to a positive feedback loop, 
resulting in enhanced transcription of NIK. Although the universality of this effect remains 
to be elucidated, regulation of NIK appears to have built-in positive and negative 
feedback systems, implying that intricate control is necessary for the appropriate 
physiological responses.    
Intriguingly, NIK affects the expression of members of the NF-κB pathway. RelB, 
p50, and c-Rel expression levels are reduced in aly/aly mice (Yamada et al., 2000) as 
well as in NIK knock-out cells (Ramakrishnan et al., 2004). Although the list of genes 
regulated by NIK described here is not exhaustive, we can conclude that NIK modulates 
chemokines, cytokines and signaling molecules in NF-κB pathways, implying that NIK 
can have a profound effect on NF-κB activation. 
 
Understanding the molecular components of NIK  
NIK was first identified as a mitogen activated kinase kinase kinase (MAP3K) that 
binds to TRAF2 in a two-hybrid screen of a human B-cell cDNA library (Malinin et al., 
1997) and was later shown to phosphorylate IKKα and IKKβ. In the two-hybrid screen, 
NIK did not bind to TNF receptor associated death domain protein (TRADD), Fas-
associating protein with death domain (FADD) or RIP-1 (Malinin et al., 1997). NIK shares 
some homology to the MAP3K. From this homology and from mutagenesis studies, it 
was determined that Thr-559 in the activation loop of NIK is required for its kinase 
activity (Lin et al., 1998). Unlike RIP-1 whose activity is not required for NF-κB activation, 
the kinase activity of NIK is necessary for both basal and TNFα-mediated NF-κB 
activations (Lin et al., 1998; Malinin et al., 1997) as well as for the processing of p100 to 
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p52 (Xiao et al., 2001).  Curiously, NIK can spontaneously homodimerize or oligomerize, 
but TNFα does not further induce oligomerization of NIK (Lin et al., 1998). Thus, 
oligomerization or dimerization of NIK may be crucial only for the basal, but not for the 
ligand-induced kinase activity of NIK. Another layer of regulation of NIK may come from 
the intramolecular interaction of NIK. The amino-terminal (N-terminal) region of NIK 
contains a negative regulatory domain, which interacts with the NIK carboxyl-terminal 
(C-terminal) end. This interaction prevents NIK from binding to its substrates, such as 
IKKα (Xiao & Sun, 2000).   
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Figure 3. Different domains of NIK, which interact with specific substrates and 
regulators. The C-terminus of NIK mainly interacts with substrates such as IKKα 
and p100, and NIK regulators, such as TRAF1, 2, 5 and 6. The N-terminus of NIK 
regulates the stability of the protein by interacting with TRAF3. So far, only one 
phosphorylation site (Thr-559) on NIK has been identified in its kinase domain. Aly 
mutation in the C-terminus impedes the function of NIK. NIK also has sequences 
for nuclear and nucleolar localization signals, which enable the protein to shuttle 
between different cellular compartments.   
Thu and Richmond, Cytokine and Growth Factor Reviews. 2010 
(Reprint with permission from Cytokine and Growth Factor Reviews) 
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Mutant forms of NIK have been generated to provide insight into the functional 
domains of NIK, and to determine how regulation of NIK is achieved. Based on its 
sequence and functions, at least four distinct domains were identified in NIK: the basic 
region, the proline rich region, the kinase domain and the C-terminal TRAF binding 
domain (Xiao & Sun, 2000) (Figure 3). Among these, the C-terminus is responsible for 
many important interactions. The C-terminus binds to IKKα, the downstream kinase of 
NIK, and also mediates homotypic dimerization or oligomerization (Lin et al., 1998). A 
careful characterization of NIK demonstrated that the C-terminal fragment of NIK (aa 
735-945) is necessary and sufficient for binding to IKKα (Lin et al., 1998). Not 
surprisingly, expression of the C-terminus of NIK disrupts the activation of NF-κB by 
TNFα as well as by the wild type NIK over-expression (Lin et al., 1998; Malinin et al., 
1997). In parallel, the kinase dead NIK mutant acts as a dominant negative mutant when 
over-expressed (Lin et al., 1998; Malinin et al., 1997), possibly due to its ability to bind to 
IKKs, while lacking the kinase activity. The kinase dead NIK (KK429/430AA) also cannot 
process p100 to p52 (Xiao et al., 2001), suggesting that NIK kinase activity is required 
for the non-canonical NF-κB pathway.  
The TRAF binding domain of NIK, as the name suggests, mediates the binding of 
NIK to TRAFs such as TRAF1, 2 and 6 (Malinin et al., 1997). Unlike other TRAFs, 
TRAF3 binds NIK in the N-terminal region of NIK (aa78-84). Deletion of this domain 
results in the dramatic stabilization of NIK since TRAF3 mediates its degradation (Liao et 
al., 2004; Sasaki et al., 2008). In addition to domains that regulate NIK stability, the 
protein also has nuclear import and export signals at the N-terminus (aa143-149) and 
the C-terminus (aa770-779/aa795-805), respectively (Birbach et al., 2002). These 
signals enable the nucleo-cytoplasmic shuttling of NIK. A truncation mutant of NIK which 
lacks the nuclear export signal, thereby confining NIK to in the nucleus, still retains some 
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ability to activate NF-κB (Birbach et al., 2002). These data suggest that NIK may be able 
to activate the nuclear IKK complex, or it may have a direct effect on the transcription 
mediated by NF-κB. NIK also appears to localize to the nucleolus, as determined by the 
signal RKKRKKK (aa143-149) from the protein’s N-terminus (Birbach et al., 2004).  This 
short stretch of amino acid sequence is both necessary and sufficient for the nucleolar 
localization of NIK (Birbach et al., 2004). Deleting the nucleolar localization motif 
attenuates NIK’s ability to activate NF-κB (Birbach et al., 2004), suggesting that NIK may 
have additional roles in different cellular compartments, aside from acting as an IKK 
kinase.  
In addition to genetically engineered mutants, there exists a naturally occurring 
mutation of NIK in mice named alymphoplasia or aly mutation, first described by 
Miyawaki et al. in C57BL/6J mice (Miyawaki et al., 1994). Shinkura et al. later mapped 
the gene responsible for this mutation and identified a missense point mutation (G855R) 
in the carboxyl terminus of NIK, which is necessary for TRAF binding (Shinkura et al., 
1999) (Figure 3). Despite the speculation that aly NIK may not bind to one of the TRAFs, 
co-immunoprecipitation experiments suggest otherwise. At least the C-terminus of NIK 
(aa624-947) (TRAF-interacting domain) carrying the aly mutation binds to TRAF 1, 2, 3 
and 6 as equally as the wild type C-terminal fragment binds (Luftig et al., 2001). Yet, the 
C-terminus of aly NIK does not bind IKKα and binds IKKβ with less efficiency compared 
to the wild type C-terminus (Luftig et al., 2001), implying that phenotypes of aly stem 
from the defective NIK/IKKα interaction.  
Interestingly, when over-expressed in 293T cells, aly NIK can still activate NF-κB, 
as manifested by an increased DNA binding of NF-κB in electrophoretic mobility shift 
assay (EMSA) (Shinkura et al., 1999). Since aly NIK fails to bind IKKα, perhaps with its 
over-expression there is sufficient NIK interaction with IKKβ to activate NF-κB. The 
 23
ability of aly NIK to activate NF-κB is in contrast to the kinase dead NIK, which fails to 
activate NF-κB. Perplexing views come from the fact that aly NIK inhibits CD40-
mediated NF-κB activation in B-cells (Luftig et al., 2001). Likewise, this mutant form of 
NIK inhibits NF-κB activation, caused by TNFR1 and 2 over-expression but not LTβR-
mediated NF-κB activation in 293T cells (Shinkura et al., 1999). The studies on the 
ability of the aly NIK to activate or disrupt NF-κB did not distinguish clearly the 
contribution of NIK to the canonical or non-canonical pathway, as the conclusions were 
based on EMSA or luciferase activity. Moreover, how the aly mutation results in a 
dominant negative function of NIK in response to certain ligands remains elusive. Yet, all 
these data suggest that the aly mutation may disrupt NF-κB activation in a ligand-
specific manner.  
Follow-up studies addressed the role of the aly mutation in the non-canonical NF-
κB pathway. The aly mutation disables NIK’s ability to bind either IKKα or p100, resulting 
in a deficient p100 to p52 processing (Luftig et al., 2001; Xiao et al., 2001). MEFs from 
aly/aly mice are defective in inducing mRNA level of VCAM-1 expression upon ligation 
with LTβR agonist antibody (Shinkura et al., 1999). These data are consistent with data 
from NIK knock-out mice, confirming the notion that NIK is indispensable for the non-
canonical pathway of NF-κB. Aly mutation highlights the importance of the physical 
interaction between NIK and its substrate. Despite the presence of the kinase domain, 
NIK function may still be defective when the proper binding does not occur. It is very 
likely that the physical interaction between its substrates as well as the kinase activity is 
required for the ability of NIK to stimulate p100 to p52 processing. In other words, both of 
those criteria are required for the non-canonical pathway, whereas the interaction 
between NIK and its binding partner at the C-terminus may not be absolutely necessary 
for NIK activation of the canonical pathway of NF-κB.  
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Regulation of NIK by stability 
Although NIK functions as a kinase and phosphorylation of NIK is required for its 
ability to activate IKKs and NF-κB, regulation of the NIK protein stability is the major 
mechanism by which NIK function is regulated. Interestingly, mRNA expression of NIK is 
increased in the absence of its 3’ untranslated region, suggesting that NIK expression 
may be mediated at the post-transcriptional level (Malinin et al., 1997). The basal level of 
NIK protein is very low under normal physiological conditions. However, NIK becomes 
stabilized after stimulation with CD40L and BAFF in B-cells (Qing et al., 2005). The 
basal stability of NIK depends on the action of four E3 ubiquitin ligases namely; TRAF2, 
TRAF3, cellular inhibitors of apoptosis 1 and 2 (cIAP1 and cIAP2). Initially, TRAF3 was 
suggested to degrade NIK, since the direct interaction between NIK and TRAF3 
suppressed NIK activation of NF-κB (Liao et al., 2004). Deletion of the TRAF3 binding 
domain (aa78-84) of NIK prevents NIK from being ubiquitinated and degraded (Liao et 
al., 2004). Consistently, in a knock-in mouse with NIK mutant lacking the TRAF3 binding 
domain, NIK was substantially stabilized (Sasaki et al., 2008). Additional studies suggest 
that TRAF3 negatively regulates NIK. TRAF3 is down-regulated in response to CD40L 
and BAFF (Li et al., 2005; Moore & Bishop, 2005). Interestingly, CD40L and BAFF 
treatment protects basally translated NIK from undergoing proteasomal degradation in 
B-cells (Qing et al., 2005). Since both CD40L and BAFF activate the non-canonical 
pathway of NF-κB, and NIK is an essential kinase for this pathway, it can be deduced 
that down-regulation of TRAF3 upon receptor ligation leads to the positive regulation of 
NIK, relaying downstream signals. Consistent with the previous data, TRAF3-/- mice 
have constitutive p100 processing due to the accumulation of NIK (He et al., 2006).   
In addition to TRAF3, TRAF2 is known to play a negative role in p100 to p52 
processing, as TRAF2-/- B-cells have the constitutive processing of p100 (Grech et al., 
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2004). Similarly, cIAP1 and 2 are implicated in the negative regulation of NIK by studies 
using IAP inhibitors. Pharmacological inhibitors of IAPs, which lead to auto-degradation 
of cIAP1 and 2, markedly stabilize NIK and stimulate the activation of NF-κB through the 
non-canonical pathway (Varfolomeev et al., 2007). These data strongly suggest that 
TRAFs and cIAPs are degradative agents of NIK.  
Two recent studies provide biochemical evidence of how TRAF2, TRAF3, cIAP1 
and cIAP2 cooperate to affect the stability of NIK. According to data from 
Vallabhapurapu et al. and Zarnegar et al., TRAF2 preferentially binds to cIAP1/2 and 
TRAF3 preferentially binds to NIK. TRAF2 is required to recruit the TRAF3/NIK complex 
to the TRAF2/cIAP1/2 complex and TRAF3 is required to recruit the TRAF2/cIAP1/2 
complex to TRAF3/NIK. Based on their data with knock-out MEFs, TRAF2 and TRAF3 
cannot compensate for each other’s loss in degrading NIK (Vallabhapurapu et al., 2008; 
Zarnegar et al., 2008). On the contrary, cIAP1 and cIAP2 can compensate for the loss of 
one another in degrading NIK and downstream processing of p100 (Zarnegar et al., 
2008). To add to the complexity of the system, NIK also regulates TRAF2 and TRAF3 
expression at a transcriptional level (Sasaki et al., 2008; Wang et al., 1998). When NIK 
is stabilized in B-cells, it induces mRNA expression of TRAF2 and TRAF3, establishing a 
negative feedback loop for NIK (Sasaki et al., 2008). This negative feedback regulation 
is likely to be the mechanism to ensure the termination of NF-κB signaling after an 
appropriate duration.  
In slight contrast to the requirement of TRAF3 to mediate NIK degradation by 
recruiting the TRAF2/cIAPs complex, Demchenko et al. have shown in the multiple 
myeloma model that TRAF2 is still capable of binding to NIK and inducing degradation 
even when TRAF3 interaction with NIK is absent (Demchenko et al., 2010). The 
investigators of this study argued that TRAF3 enhances the degradation of NIK, yet it is 
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not absolutely required for this process to occur (Demchenko et al., 2010). The different 
results regarding the requirement for TRAF3 may be due to the transformation status of 
the B-cell-derived multiple myeloma cells. Perhaps not all of the four E3 ubiquitin ligases 
are functionally equal in all cell types, some being more important for ablation of NIK 
than others.  
The reason for the necessity of four ubiquitin ligases for the constitutive 
degradation of NIK is not known. Although the field has made a significant progress in 
elucidating the regulation of NIK, many questions remain unanswered. Among four 
ubiquitin ligases that are responsible for NIK degradation, which is/are the actual 
ubiquitin ligase(s) that conjugate ubiquitin to NIK? Liao et al. suggested that using 
purified TRAF3 in an in vitro ubiquitination assay did not result in significant 
ubiquitination of NIK (Liao et al., 2004). Consistent with this finding, Vallabhapurapu et 
al. argued that TRAF3 was simply an adaptor, as they did not observe a necessity for 
the TRAF3 RING domain to mediate NIK degradation (Vallabhapurapu et al., 2008). 
Instead, they proposed that cIAP1/2 may be responsible for K-48 ubiquitination of NIK 
(Vallabhapurapu et al., 2008). In support of this idea, it is demonstrated that RING 
mutant constructs of TRAF2 or cIAP1 do not degrade NIK (Vallabhapurapu et al., 2008; 
Varfolomeev et al., 2007). Hence, only some of these E3 ubiquitin ligases may serve as 
the critical ubiquitin ligase for NIK degradation, whereas others merely serve as scaffold 
proteins. It is quite challenging to reconstitute an in vitro ubiquitination of NIK, possibly 
due to the requirement of all these factors and the ubiquitination activity that they have 
on one another. In addition, we still do not know the identity of the lysine residue(s) on 
NIK required for its ubiquitination that leads to degradation. 
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Figure 4. Mechanisms of NIK degradation mediated by E3 ubiquitin ligases. At a 
resting stage, NIK undergoes ubiquitination and degradation mediated by 
cIAP1/2, TRAF2/3. Upon ligand stimulation, NIK is liberated from the degradative 
complex, thereby stabilized to mediate the downstream signaling such as p100 to 
p52 processing.  
Gyrd-Hansen and Meier, Nature Reviews Cancer, 2010 
(Reprint with permission from Nature) 
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In addition to the basal regulation of NIK, some mechanisms by which NIK is 
stabilized upon ligation of upstream receptors have been demonstrated (Figure 4B). It is 
noted that upon ligand stimulation by CD40L or BAFF, TRAF2 and TRAF3 are degraded 
in a cIAP-dependent manner, resulting in the stabilization of NIK (Vallabhapurapu et al., 
2008; Zarnegar et al., 2008). TRAF3 degradation precedes TRAF2 degradation, 
suggesting that TRAF3 degradation first disassembles the complex bound to NIK to 
relieve the suppression (Vallabhapurapu et al., 2008; Zarnegar et al., 2008). The 
mechanism of how cIAPs become the degradative agents for TRAFs upon ligand 
engagement remains elusive. Another ligand, TWEAK, mediates NIK stabilization in a 
manner slightly different from CD40L and BAFF, at least in the melanoma cell line 
A2058. Upon TWEAK ligation, cIAP1 is degraded, then stabilized NIK potentiates p100 
to p52 processing (Varfolomeev et al., 2007). However, cIAP-dependent negative 
regulation of NIK may not be the complete story. A recent report suggests that cIAP-
independent NIK stabilization may exist, as TWEAK can still stabilize NIK in cIAP1/2 
double knock-out mice (Feltham et al., 2010).  
Another receptor that can activate NIK is the LTβR. It was recently proposed that 
both LTβR and NIK bind to the same site on TRAF2 and 3. Thus, upon stimulation 
through LTβR, the receptor competes for the binding sites on TRAF3, thus replacing NIK 
from the negative regulatory complex and relieving the degradation of NIK (Sanjo et al., 
2010). Similarly, the receptor replaces cIAP1/2 from TRAF2, possibly to ensure the 
disassembly of the degradative complex for NIK (Sanjo et al., 2010). Aside from serving 
as an allosteric competitor, activation through LTβR leads to ubiquitination and 
proteasomal degradation of TRAF3 in a TRAF2-dependent manner (Sanjo et al., 2010). 
Although TRAF2 is also ubiquitinated and degraded upon ligand stimulation via LTβR, it 
is not clear whether TRAF2 undergoes auto-ubiquitination or whether some other E3 
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ligases are responsible for this process. Interestingly, cIAPs were not associated with 
the activated LTβR and TRAF complex (Sanjo et al., 2010). Thus, the mechanism by 
which NIK is stabilized upon ligand induction appears to be unique for individual receptor 
signaling.  
Another interesting question regarding NIK regulation is whether it has a dosage 
dependent effect on NF-κB activation. The first indication that the level of NIK may be 
tightly regulated comes from NIK over-expression and gene knock-out studies. NIK 
potently activates basal as well as ligand stimulated NF-κB upon over-expression 
(Malinin et al., 1997). However, data from NIK knock-out mice suggest that this kinase is 
not required for the activation of the canonical pathway. Thus, the level of NIK likely 
determines whether NIK is selectively activating one or both pathways of NF-κB. For 
example, in TRAF3-/- mice where NIK is stabilized, nuclear accumulation of RelA, p50, 
RelB and p52 is significantly elevated, suggesting that there is a constitutive activity of 
both canonical and non-canonical pathways of NF-κB (Zarnegar et al., 2008). 
Remarkably, the lethality resulting from TRAF3 deletion was significantly rescued by 
deleting just one allele of NIK (Zarnegar et al., 2008). This observation suggests that the 
level of NIK is tightly controlled to regulate physiological processes.  
In accordance with the dosage dependent regulation of NIK, Demchenko et al. 
proposed a model by which the level of NIK protein may be tightly controlled 
(Demchenko et al., 2010). In this model, TRAF2, TRAF3, cIAP1 and cIAP2 cooperatively 
modulate the stability of NIK. Only in the functional presence of all four of them, can 
maximal degradation of NIK be achieved. When one of the E3 ligases is absent or non-
functional, NIK stability increases, resulting in NF-κB activation. These investigators also 
postulated that initial stabilization of NIK robustly activates NF-κB, whereas additional 
stabilization of NIK has minimal additive effect of NF-κB activation (Demchenko et al., 
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2010). The differential effect of NIK on NF-κB activation depending on the dosage may 
help explain why the expression level of NIK is maintained minimal under normal 
physiological conditions.  
In summary, there are three ways to post-translationally regulate the function of 
NIK based on the literature to date; phosphorylation, interaction between NIK and its 
binding partners, and the stabilization of NIK. In addition the 3’UTR of NIK mRNA plays 
a role in regulating the stability of the NIK mRNA. The resulting NIK activity is the net 
effect of the interplay among these regulations.  
 
NIK in the regulation of B-cells  
Based upon data accumulated from studies of the NIK null mice and the aly/aly 
mice, subsequent studies have often focused on NIK’s role in the modulation of the 
immune system. Aly/aly mice were characterized as mice without lymph nodes and 
Peyer’s patches (Shinkura et al., 1996). These mice do not exhibit somatic 
hypermutation during antigen-specific immune response and germinal center formation 
(Shinkura et al., 1996). Presumably because of these defects, aly/aly mice exhibited 
weak antibody response and defective isotype switching (Shinkura et al., 1996). These 
mice also lack allogenic skin rejection, exhibit abnormal spleen and thymic development 
and have defective B-cell proliferation (Miyawaki et al., 1994; Shinkura et al., 1996; 
Yamada et al., 2000). Since NIK is a downstream activator of LTβR and LTβR is 
exclusively expressed by non-lymphoid cells, it was speculated that the phenotypes in 
aly/aly mice are caused by a defective signaling in non-bone marrow derived cells 
(Matsumoto et al., 1999). However, transferring bone marrow from aly/aly mice into 
heterozygous aly mice clearly shows that proper NIK activity is required intrinsically in 
bone marrow-derived cells as well as in stroma. Chimeric mice with bone marrow 
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derived cells from aly/aly mice have poorly developed B-cell follicles in the spleen, with 
lack of follicular dendritic cell clusters and germinal center formation (Yamada et al., 
2000). B-cells from aly/aly mice also have a defect in proliferation and IgM/IgG 
production in response to CD40L, LPS and anti-Ig activation (Garceau et al., 2000). 
Interestingly, up-regulation of surface molecules such as MHC II and intercellular 
adhesion molecule-1 (ICAM-1) is not affected by aly mutation in B-cells (Garceau et al., 
2000).  
In addition to the necessity of NIK activity in bone-marrow derived cells, it is also 
required in stromal cells in the peritoneal cavity so that B1 cells can emigrate. Aly/aly 
mice have defective B-cell emigration from the peritoneal cavity, resulting in 
accumulation of B-cells in the cavity (Kunisawa et al., 2008). These phenotypic defects 
are due to the inability of NIK deficient stromal cells to express VCAM-1 and ICAM-1, 
therefore weakening the interaction between the stromal cells and B-cells (Kunisawa et 
al., 2008).  
Most of the phenotypes in NIK deficient B-cells may be attributable to NIK’s 
function as an activator of IKKα. However, intriguingly, NIK has other roles in addition to 
its role as an IKKα kinase in B-cells. To distinguish IKKα-dependent and IKKα-
independent contribution of NIK to the development of B-cells, mice with IKKα phospho 
deficient mutant (S176A and S180A) were generated (Mills et al., 2007). As these serine 
residues are phosphorylated by NIK, these mutations should mimic the functional 
absence of NIK. Results showed that aly/aly mice have impaired antibody production, 
yet IKKα (S176A/S180A) knock-in mice do not (Mills et al., 2007). B-cells from these 
IKKα knock-in mice proliferate normally in response to natural ligands such as CD40L, 
BAFF or the bacterial product LPS, in contrast to the phenotypes in aly/aly mice 
(Garceau et al., 2000; Yamada et al., 2000). Altogether, these data suggest that NIK 
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may have IKKα and non-canonical NF-κB pathway independent functions, that can 
profoundly affect the cellular physiology, at least in B-cells (Mills et al., 2007).  
In addition to its role in B-cell function, NIK provides survival signals in B-cells. 
Under normal physiological conditions, signal transduction events activated through 
CD40 and BAFFR are necessary for the induction of p100 proteolysis and for the 
promotion of B-cell survival (Claudio et al., 2002; Siebenlist et al., 2005). Consistent with 
this notion, ablation of NIK negative regulators, TRAF2 and TRAF3, specifically in B-
cells markedly enhances the survival of B-cells (Gardam et al., 2008; Grech et al., 2004; 
Xie et al., 2007). Substantial NIK accumulation enables TRAF3-/- B-cells to survive in a 
ligand-independent manner (He et al., 2006), as NIK stabilization bypasses the 
necessity of CD40L and BAFF engagement.  
In support of the genetic studies, treatment of primary B-lymphocytes with 
secondary mitochondria-derived activator of caspase (SMAC) mimetic compounds 
increase the proliferation and survival of these cells (Zarnegar et al., 2008). SMAC 
mimetics degrade cIAPs, negative regulators of NIK, and therefore stabilize NIK 
expression. Although accumulation of NIK enhances the survival of B-cells, it impedes 
the transition from the pro-B to the pre-B cell stage, thus disrupting the normal 
development of B-cells (Vallabhapurapu et al., 2008). NIK also has a suppressive role 
on the expression of the transcription factor Pax5, which regulates the pro-B to pre-B cell 
transition. The mRNA transcript level of Pax5 was reduced in Traf2-/- and Traf3-/- B-cells 
and was restored upon deletion of NIK in these cells (Vallabhapurapu et al., 2008). 
Conversely, transgenic mice with TRAF3 specifically over-expressed in B-cells exhibited 
an expanded plasma cell population despite the low expression of NIK (Zapata et al., 
2009). Yet, their proliferative response to stimuli such as CD40L and BAFF in vitro did 
not differ appreciatively from wild type cells (Zapata et al., 2009). Although it remains 
ambiguous how the level of NIK specifically affects the B-cell population, it is apparent 
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that the NIK level has to be tightly regulated to give rise to a proper differentiation and 
expansion of B-cells.  
 
NIK in the regulation of T-cells 
During the development of T-cells, auto-reactive T-cells have to be eliminated to 
establish self-tolerance. One way to achieve this is through the negative selection of T-
cells as a result of their interaction with the thymic stroma where self-antigens are 
expressed. Generation of thymic chimeras using aly/+ or aly/aly embryonic thymus 
suggests that NIK is required in stromal cells to prevent autoimmune diseases in some 
organs (Kajiura et al., 2004). In addition, aly/aly mice have fewer CD4+CD25+ regulatory 
T-cells (Treg) (Kajiura et al., 2004). Reduction of this T-cell subset correlated with 
downregulation of forkhead box P3 (Foxp3) in CD4+ T-cells and down-regulation of 
autoimmune regulator in thymus, the former being a major transcription factor for Treg 
and the latter being responsible for antigen production to establish self-tolerance (Kajiura 
et al., 2004). 
Additional studies using NIK knock-out mice support the notion that NIK has a 
role in the Treg population. Treg cells have a regulatory role to suppress auto-reactive 
effector T-cells. NIK knock-out mice have a significantly lower ratio of Treg to total CD4+ 
T-cells, although their suppressive function is comparable to the wild-type mice (Lu et 
al., 2005). Similar phenotypes were observed using aly/aly mice (Kajiura et al., 2004). In 
the absence of NIK, the Treg population proliferates more upon stimulation through 
glucocorticoid-induced TNFR family-related gene (GITR), a TNFR family member (Lu et 
al., 2005). Moreover, NIK knock-out mice have a lower subset of specific Treg population, 
defined as CD62Lhigh CD4+CD25+ T cells, resulting in a higher proportion of CD62Llow 
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CD4+CD25+ T cells. The physiological implication of this phenomenon is the impairment 
of the normal regulatory T-cell response, leading to autoimmunity (Lu et al., 2005).  
In addition to its intrinsic role in Treg maintenance, NIK also mediates self-
tolerance by modulating the signals through CD40 and RANK in medullary thymic 
epithelial cells (mTEC) (Akiyama et al., 2008). During the development of T-cells, those 
reacting with the self-antigens are eliminated. mTECs are proposed to mediate this 
elimination of self-reactive T-cells by expressing self-antigens. Precursor mTECs culture 
from aly/aly mice did not exhibit RelB expression or nuclear localization when treated 
with CD40L or RANKL, thus these precursor cells did not fully develop into mTEC 
(Akiyama et al., 2008). As NIK is downstream of CD40 or RANK signaling, NIK function 
is also necessary for the development of these cells (Akiyama et al., 2008).  
Another way NIK is linked to autoimmunity is through its regulation in the Th17 
cell population. Using NIK knock-out mice, it was demonstrated that NIK is necessary for 
Th17 differentiation (Jin et al., 2009). NIK knock-out mice are resistant to a T-cell 
mediated autoimmune disease named experimental autoimmune encephalomyelitis 
(EAE) due to the intrinsic defect in naïve CD4+ T-cell population to differentiate into Th17 
cells (Jin et al., 2009). Intriguingly, along with T-cell receptor (TCR) stimulation, Th17 
differentiation can be co-stimulated by a TNFR family member, herpes virus entry 
mediator (HVEM), a receptor for homologous to Lymphotoxins, exhibits Inducible 
expression, and competes with HSV Glycoprotein D for HVEM, a receptor expressed by 
Tlymphocytes (LIGHT). This signaling is impaired in NIK knock-out T-cells, implying that 
NIK controls Th17 cells via LIGHT ligation (Jin et al., 2009). NIK deficiency does not 
affect T-cell proliferation, yet it attenuates Th17-regulatory genes, such as IL-17, IL-21, 
IL-22, IL-23R and RORγt (Jin et al., 2009). Th17 differentiation process may not be 
through the p100 to p52 proteolysis although this cannot be excluded. Instead, NIK 
deficiency results in diminished Stat3 phosphorylation upon activation through TCR as 
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well as IL-6R (Jin et al., 2009). Thus, NIK is necessary for synergistic Stat3 activation by 
these two receptors. It has already been reported that Stat3 is crucial for Th17 
differentiation (Mathur et al., 2007), and thus NIK is likely to have an impact on Th17 
differentiation via this transcription factor. In addition to its effect on Treg and Th17 
populations, a subset of immature natural killer T-cells (NKT cells), referred to as Vα14i 
NKT, requires NIK-mediated RelB activation for development (Elewaut et al., 2003). 
Thus, NIK plays a pivotal role in various populations of T-cells, modulating their 
development or differentiation.  
NIK not only plays a critical role in T-cell differentiation and development, but it 
also has an effect on T-cell activation. TCR/CD3-stimulated T-cells cannot produce IL-2 
in aly/aly mice (Yamada et al., 2000). In normal T-cells, NIK phosphorylates c-Rel in the 
transactivation domain and activates its transcriptional activity at CD28RE to regulate IL-
2 production upon CD28 ligation (Sanchez-Valdepenas et al., 2006). The signaling 
through TCR and CD28 are thought to cooperate for optimal activation of T cells and 
cytokine production (Acuto & Michel, 2003). NIK has a role in regulating those processes 
through both receptors. Moreover, NIK and protein kinase C (PKC) cooperate in T-cell 
activation, as suggested by the defective proliferation in NIK defective mature T-cells. 
The NF-κB response cannot be sustained in thymocytes from mice with aly mutation in 
response to CD3 conjugation (Matsumoto et al., 2002). In parallel, thymocytes from 
aly/aly mice have a defect in the proliferative response upon stimulation with anti-CD3 
antibody (Matsumoto et al., 2002). Therefore, it is speculated that NIK regulates the 
function of T-cells by modulating NF-κB activation when T-cells respond to antigens and 
in mediating T-cell proliferation (Matsumoto et al., 2002).  
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Other immune regulation of NIK 
Interestingly, in T and B cells isolated from the peritoneal cavity, NIK is 
downstream of secondary lymphoid organ chemokine (SLC)/CCL21 receptor in 
activating NF-κB (Fagarasan et al., 2000). Although it is well established that NIK is 
downstream of some cytokine receptors such as BAFFR, CD40 and LTβR, it was not 
previously connected to a seven-transmembrane G protein-coupled chemokine receptor. 
These peritoneal cavity cells (T- and B-cells) from aly/aly mice exhibit a defective 
homing to the gut-associated lymphatic tissue in vivo (Fagarasan et al., 2000). This 
homing defect partly contributes to the impaired immunoglobulin production of B-
lymphocytes as they fail to migrate to the proper niches to become plasma cells 
(Fagarasan et al., 2000).  
The contribution of NIK in dendritic cells (DCs) has been elucidated by a few 
studies using aly/aly mice. DCs with aly mutation still have intact DC activation in 
response to engagement through CD40 (Garceau et al., 2000). DCs from aly/aly mice do 
not exhibit any difference in cell surface molecules such as MHC I, MHC II, CD80/86, 
CD40, CD70, 41BB-L, and CD150 or upregulation of chemokine receptors such as 
CCR2 and CCR7 (Lind et al., 2008). Nevertheless, they are intrinsically defective in 
cross-priming with CD8+ T cells (Lind et al., 2008). This defect is a result of aly mutant 
DCs inability to process the whole antigen (Lind et al., 2008). DCs with aly mutation also 
fail to induce many genes, some of which are implicated in the survival of DCs [cellular 
FLICE like inhibitory protein (cFLIP) and serpinb9] and antigen processing (cathepsin E 
and Lamp1) (Lind et al., 2008).  
In addition to studying the functionally defective NIK, introducing wild type NIK 
into DCs provides insight into the function of NIK in DCs. It has been proposed that 
induction of NF-κB through over-expression of NIK in DCs can be an effective vaccine 
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adjuvant (Andreakos et al., 2006). When expressed in DCs, NIK induces cytokine and 
chemokine production (such as TNFα, IL-6, IL-12, IL-15 and IL-18, IL-8, macrophage 
inhibitory protein-1 (MIP-1α/β)/CCL3, MCP-1 and MCP-3) (Andreakos et al., 2006). More 
importantly, when over-expressed in DCs, NIK enhances the antigen presentation, Th-1 
type immune response, and antigen specific cytotoxic T-cell response in vivo 
(Andreakos et al., 2006).  
NIK not only participates in the regulation of the adaptive immunity, it also has a 
role in innate immune regulation. NIK stimulates the transcription of cyclooxygenase-2 
(COX-2) by phosphorylating a transcription factor PU.1, which binds to the promoter 
region of COX2 (Azim et al., 2007). When NIK expression was silenced by siRNA, less 
PU.1 was recruited to the COX-2 promoter. In parallel, COX-2 production was impaired 
in NIK siRNA treated macrophages in response to LPS (Azim et al., 2007). NIK also has 
a role in the inflammasome by interacting with a nucleotide binding domain-leucine rich 
repeat (NLR) protein, Monarch-1 (Arthur et al., 2007; Ye et al., 2008). Upon CD40 
ligation, Monarch-1 and NIK association increases, resulting in proteasomal degradation 
of NIK and suppression of p100 to p52 processing in monocytes (Arthur et al., 2007). 
 
The role of NIK in the bone microenvironment 
Osteoclasts and osteoblasts reside in the bone marrow, maintaining the balance 
between bone resorption and bone formation, respectively. This balance is important 
since it affects the general bone structure as well as the bone maintenance associated 
with pathological conditions such as cancer metastasis and arthritis. Research relating 
NIK in osteoclastogenesis has been of interest, as RANKL differentiates monocyte and 
macrophage lineage progenitors to become osteoclasts. RANKL is one of the few known 
activators of the non-canonical pathway that plays a crucial role in the bone 
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microenvironment. NIK deficiency deters the nuclear translocation of RelA and p52 in 
response to RANKL stimulation, due to the role of p100 as an IκB in osteoclast 
precursors (Figure 5). In other words, the lack of p100 proteolysis as a result of NIK loss 
prevents osteoclast formation (Novack et al., 2003). In this scenario, the loss of NIK 
affects both pathways of NF-κB and the phenotypes observed cannot be clearly 
attributed to either the classical or the non-canonical pathway of NF-κB.  
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(Reprint with permission from Cytokine and Growth Factor Reviews) 
Figure 5. The requirement of the function of NIK in inducing the proteolysis of p100 to 
p52 for osteoclastogenesis. The IκB function of p100 deters NF-κB family members 
such as RelA and RelB to translocate to the nucleus. Re-expression of RelB rescues 
the defective osteoclastogenesis in osteoclast precursors but RelA does not, 
suggesting that only RelB is required for the osteoclastogenesis.  
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To distinguish the relative contribution of the two pathways, Vaira et al. re-
expressed RelA or RelB in NIK-/- osteoclast precursors (Vaira et al., 2008). They 
observed that only the re-expression of RelB rescues the differentiation defect of the 
osteoclast precursors, suggesting that RelB is necessary for the expression of factors 
required for osteoclast differentiation (Vaira et al., 2008). NIK itself is not required for the 
differentiation of these cells. Crossing NIK-/- and p100-/- mice gave rise to mice with 
normal osteoclast differentiation (Vaira et al., 2008). This observation suggests that NIK 
stimulation of the proteolytic processing of p100, a negative regulator of osteoclast 
differentiation, is necessary for the osteoclastogenesis (Figure 5). Amazingly, TNFα 
induces TRAF3 stabilization in osteoclasts (Yao et al., 2009), possibly destabilizing NIK, 
diminishing p100 processing and promoting osteoclastogenesis (Tanaka & Nakano, 
2009). Unlike osteoclastogenesis, tumor-induced osteolysis in a B16 melanoma model 
requires both NIK and RelB, evidenced by the inhibition of tumor-induced bone loss in 
RelB-/- and NIK-/- mice injected with B16 melanoma cells (Vaira et al., 2008). Therefore, 
the non-canonical pathway of NF-κB may have a therapeutic value in bone metastatic 
cancers.  
As NIK function is needed for osteoclast differentiation, its role has been studied 
in an inflammatory arthritis model. Bone degradation in arthritis is performed by 
osteoclasts. Inhibiting the inducer of osteoclastogenesis, RANKL, ameliorates bone 
erosion in certain arthritis models (Kong et al., 1999; Pettit et al., 2001). In serum 
transfer arthritis model, NIK is not required for inflammation, but for bone erosion (Aya et 
al., 2005). By using B-and T-cell transfer into recombination activating gene-/- (RAG2-/-) 
mice, Aya et al. elegantly demonstrated that NIK is necessary in T-cells, but not in-B 
cells, for antigen-induced arthritis (Aya et al., 2005).  
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 Interestingly, NIK determines the fate of bone marrow stem cells through a 
peroxisome proliferator-activated receptor γ (PPARγ)-dependent mechanism. Gene 
targeting of PPARγ in mice revealed that PPARγ induces adipogenesis (Kubota et al., 
1999). Cytokines such as TNFα and IL-1 can prevent mesenchymal stem cells from 
differentiating into adipocytes. The adipogenesis suppression mediated by these 
cytokines is through activation of TANK-1 binding protein (TBK1)/TAK1/NIK signaling 
(Suzawa et al., 2003). Over-expression of NIK in ST2 cells, a mesenchymal cell line, 
diminishes PPARγ transactivation activity by increasing NF-κB association with PPARγ 
and reducing its DNA binding (Suzawa et al., 2003). When the activity of PPARγ is 
suppressed, mesenchymal stem cells become osteoblasts instead of becoming 
adipocytes (Takada et al., 2007). Therefore, NIK may indirectly contribute to osteoblast 
genesis.  
 
The importance of NIK in cancer: death versus survival (cIAPs and NIK) 
Although traditionally thought of as pro-survival factors, cIAPs have anti-
proliferative and anti-survival function in B-lymphocytes due to their role in degrading 
NIK (Zarnegar et al., 2008). It is clearly demonstrated that NIK provides survival signals, 
especially in B-cells. For example, B-cells with TRAF2 and TRAF3 deficiency (Gardam 
et al., 2008; Grech et al., 2004; Xie et al., 2007), as well as B-cells expressing a NIK 
mutant that lacks the TRAF3 domain (Sasaki et al., 2008), have prolonged survival due 
to the accumulation of NIK. B-cells from these mice become independent of CD40 or 
BAFFR signaling.  
On the contrary, SMAC mimetic compounds, which inhibit cIAPs and stabilize 
NIK, are used to induce cell death in many cancer cells. The detailed mechanism of how 
SMAC mimetic compounds mediate cell death has been previously described 
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(Varfolomeev et al., 2007). These compounds potentiate auto-ubiquitination and 
degradation of cIAPs. As a result, both the canonical and the non-canonical pathways 
are activated, increasing the production of TNFα along with other chemokines such as 
IL-8 and MCP-1. The activation of two NF-κB pathways cannot be inhibited by the use of 
a TNF-blocking agent such as TNFR1-Fc. Nevertheless, cell death induced by SMAC 
mimetic drugs can be inhibited by blocking TNFR signaling, implying that this signaling is 
necessary for cell death (Varfolomeev et al., 2007). In support of these data, another 
study also observed the activation of NF-κB (both canonical and non-canonical) and cell 
death in the presence of cIAPs antagonists (Vince et al., 2007). The investigators of this 
study speculated that the ability of cIAP antagonists to induce the canonical NF-κB 
pathway is likely due to the prolonged association of RIP-1 with TNFR when cIAPs are 
absent (Vince et al., 2007). When cIAPs are degraded, NF-κB activation may no longer 
be cytoprotective to counteract TNFα-induced cell death.  
Another independent study regarding SMAC mimetics examined their effect on 
tumor growth in vivo. Similarly, this study also demonstrated that TNFR signaling can 
lead to apoptosis, induced by SMAC mimetics (Petersen et al., 2007) and this cell death 
is also RIP-1 dependent, in agreement with the study by Vince et al. (Vince et al., 2007). 
SMAC mimetic-induced TNFα production triggers the signaling of TNFR to form a RIP-
dependent death-inducing complex in addition to its signaling through pro-survival NF-
κB activation (Petersen et al., 2007). The death signal possibly prevails over the survival 
function of NF-κB, leading to cell death in cancer cells (Petersen et al., 2007). 
In these studies using SMAC mimetics, NIK is stabilized upon treatment with the 
pharmacological cIAP inhibitors, yet cell death is still induced. On one hand, NIK is 
thought to be a pro-survival mediator as it is a potent activator of NF-κB. On the other 
hand, the role of some of NIK negative regulators, such as TRAF2, cIAP1 and cIAP2 
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during the anti-apoptotic mediation of NF-κB has been documented (Wang et al., 1998). 
Although cIAPs are traditionally viewed as pro-survival factors, they antagonize the pro-
survival function of NIK. Interestingly, B-cells expressing a NIK mutant with the deletion 
of the TRAF3 binding domain are much more susceptible to FasL-induced cell death as 
they have elevated Fas expression (Sasaki et al., 2008). Therefore, it is possible that 
stabilization of either NIK or cIAPs is necessary for the survival of different cell types. 
NIK undergoes continuous proteasomal degradation that is executed in part by cIAPs in 
non-transformed cells, thus NIK may not mediate survival in this context. However, in the 
event of transformation, malignant cells may become dependent on the stabilization of 
NIK. Therefore, for the safe use of SMAC mimetics in cancers and to target NIK as a 
cancer therapeutic, the question of how the coordination between NIK and cIAPs favors 
death versus survival needs further exploration. 
 
NIK in hematological malignancies 
Mis-regulation of NIK in multiple myeloma has been well documented by several 
studies. Genetic screening of multiple myeloma tumor samples and cell lines suggest 
that many genetic mutations occur in these tumors, leading to activation of the canonical 
and non-canonical NF-κB pathways. More importantly, genetic or epigenetic alterations 
that lead to NIK stabilization have been demonstrated in multiple myeloma (Annunziata 
et al., 2007; Keats et al., 2007). Some negative regulators of NIK, such as TRAF2, 
TRAF3, cIAP1 and cIAP2, have inactivating mutations in multiple myeloma (Annunziata 
et al., 2007; Keats et al., 2007). In addition, activating mutations have also been 
identified in positive regulators of NIK, such as CD40 and LTβR (Annunziata et al., 2007; 
Keats et al., 2007).  
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Another type of mutation is an activating mutation in NIK itself. Three of five 
multiple myeloma patient samples have chromosomal translocations between the NIK 
locus and either the IGH or IGL locus (Annunziata et al., 2007). Some multiple myeloma 
cell lines also have chromosomal translocations or gene amplification, leading to 
enhanced NIK expression (Annunziata et al., 2007). Furthermore, allelic deletions of 
TRAF3 and mutations resulting in a truncated form of TRAF3 that cannot bind to NIK 
were also identified (Annunziata et al., 2007; Keats et al., 2007). As a result, multiple 
myeloma tumors from patients as well as cell lines exhibit a high NF-κB index 
(Annunziata et al., 2007; Keats et al., 2007). Although plasma cells, from which multiple 
myeloma is derived, normally display high NF-κB activation, this activation is ligand-
dependent. Therefore, it is thought that the mutations mentioned above render multiple 
myeloma cells with the ability to undergo ligand-independent proliferation and survival 
(Annunziata et al., 2007; Keats et al., 2007). 
In support of this notion, manipulations of NF-κB regulators alter the pro-survival 
phenotype. For instance, TRAF3 was re-introduced in cell lines with either bi-allelic 
deletions or inactivating mutations. Re-expression of TRAF3 ablates the constitutive 
processing of p100 to p52 as well as nuclear translocation of RelA, p50, p52 and RelB, 
resulting in the growth arrest of these tumor cells (Annunziata et al., 2007; Keats et al., 
2007). It was reported that the TRAF3 level was altered in many leukemia and 
lymphoma cell lines, suggesting the possibility of NIK involvement in these malignancies 
(Zapata et al., 2000). NIK silencing provides direct evidence for the contribution of NIK to 
multiple myeloma. Knocking down NIK in multiple myeloma cell lines with high NIK 
expression induced cell death, whereas cells with low NIK expression were unaffected 
(Annunziata et al., 2007). These data suggest that multiple myeloma cells with elevated 
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NIK expression are indeed dependent on NIK expression for their survival (Annunziata 
et al., 2007).  
In support of the pro-survival role of NIK, expressing NIK mutant without the 
TRAF3 binding domain in B-cells lead to hyperplasia and independence of BAFFR 
signaling (Sasaki et al., 2008). Since signaling from the BAFFR is crucial for B-cell 
survival, BAFFR-independence as a result of NIK stabilization is one of the events 
important for B-cell malignancy.  
Despite the increasing evidence that malignancy of myeloma can be attributed to 
NIK, the mechanism by which NIK is mediating tumorigenesis is still elusive. The 
literature to date suggests that both the canonical and non-canonical pathways may be 
crucial for the ability of NIK to elicit transformation. shRNA-mediated depletion of NIK in 
multiple myeloma cell lines with TRAF3 or cIAPs mutation abrogates both canonical and 
non-canonical NF-κB pathway activation (Annunziata et al., 2007; Demchenko et al., 
2010). Interestingly, silencing of IKKα using shRNA was not toxic to NIK over-expressing 
multiple myeloma cells, suggesting that NIK does not mediate tumorigenesis via the 
non-canonical pathway (Annunziata et al., 2007). When NIK was over-expressed in 
multiple myeloma cell lines with low NF-κB activity, the gene signature induced by NIK 
was almost identical to the cell lines with IKKβ over-expression, implying that NIK over-
expression mediated NF-κB gene transcription to induce tumorigenesis can be through 
the canonical pathway (Demchenko et al., 2010). However, in another cell line, the NIK 
over-expression-induced gene signature does not correlate well with IKKβ over-
expression-induced signature (Demchenko et al., 2010). Hence, it remains elusive how 
NIK over-expression may lead to malignant cell phenotypes.  
Another hematological malignancy in which NIK plays a role is T-cell leukemia 
and Hodgkin Reed-Sternberg cells. A genetically engineered mouse model suggests a 
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role for NIK and NF-κB in development of T lymphocyte malignancy. In thymocytes, NIK 
plays a role in Notch3 mediated NF-κB activation in a ligand-independent manner, 
resulting in high proliferative and tumorigenic potential of these cells (Bellavia et al., 
2000; Vacca et al., 2006) . However, in the absence of pre-TCR/pTα, NIK does not 
participate in the IKK complex and p100 to p52 processing is only dependent upon IKKα 
(Vacca et al., 2006).  
In concert with the data from the mouse model, the transcript level of NIK is 
highly upregulated in leukemia cell lines as well as in patients (Saitoh et al., 2008). 
Protein expression of NIK in these cells was observed only with proteasomal inhibitor, 
MG132, treatment suggesting that the turn-over rate of NIK is rapid in this type of tumor 
(Saitoh et al., 2008). Although NIK knock-down did not affect cell growth in vitro, 
depletion of NIK significantly decreased tumor size in a mouse model (Saitoh et al., 
2008). Perhaps, NIK expression allows the tumor cells to grow in an in vivo tumor 
environment by affecting other cells in the tumor micro-environment that promote tumor 
growth, and this difference may not be apparent in culture where growth is more 
conducive or where stromal cells are absent. Although this study highlights the 
importance of NIK in T-cell leukemia, it remains unclear what aspect of tumor 
development NIK affects.  
In parallel, forced expression of NIK in rat fibroblasts transformed them, as 
assessed by anchorage independent growth. However, the investigators of this study 
noted that retroviral overexpression of NIK was toxic to the cells. Thus, they used 
fibroblasts expressing a gene under the transcriptional control of NF-κB, which confers 
resistance to an antibiotic blasticidin only when NF-κB is constitutively active. Only under 
this selection pressure did NIK over-expression lead to transformation. The ability of NIK 
to transform these fibroblasts depends on NF-κB activation since over-expressing the 
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super-suppressor IκB hindered colony formation of NIK over-expressed cells in a soft 
agar assay (Saitoh et al., 2008).  
 
NIK in solid tumors  
In addition to hematological tumors, some reports suggest the role of NIK in solid 
tumors, albeit less extensively. For instance, constitutive activation of the non-canonical 
pathway of NF-κB as well as NIK accumulation upon MG132 treatment was 
demonstrated in pancreatic cancer cells (Nishina et al., 2009). When NIK expression 
was reduced by siRNA, cell growth and p100/p52 processing were also diminished, 
suggesting that those processes are attributable to NIK over-expression in these 
pancreatic cancer cells (Nishina et al., 2009). However, NIK does not regulate the 
canonical pathway in these cells (Nishina et al., 2009). Similar to pancreatic cancer cells, 
non-small cell lung cancers have elevated NIK expression. Depletion of NIK diminishes 
constitutive NF-κB activation of both pathways, as well as some survival or metastatic 
genes such as survivin and matrix metalloprotease-9 (MMP-9) (Saitoh et al., 2010). 
Therefore, depending on cancer types, NIK may regulate one or both NF-κB pathways. 
Moreover, over-expression of NIK is responsible for the constitutive activation of NF-κB 
in basal-like subtype breast cancer cell lines (Yamaguchi, et al., 2009).  
Additionally, one study suggests that NIK may be required for invasion and 
migration of a murine melanoma cell line (Rangaswami et al., 2004). In this model, 
osteopontin (OPN) leads to enhanced production of MMP-9, possibly mediated by NIK 
activation (Rangaswami et al., 2004). In support of the murine melanoma model, in 
human melanoma cells with constitutive NF-κB activity, there is increased association of 
NIK with the IKK complex in melanoma as compared to normal melanocytes based upon 
co-immunoprecipitation assays (Dhawan & Richmond, 2002). Interestingly, melanoma 
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cells show higher expression of LTβR, an upstream activator of NIK. Silencing the 
expression of the LTβR reduces the growth and invasion of melanoma cells (Dhawan et 
al., 2008).  
Although some advances have been made in understanding NIK’s tumorigenic 
potential, additional studies are necessary to understand the possible contribution of NIK 
in solid tumors. Additional in vivo models are gravely needed to elucidate the function of 
NIK in carcinogenesis. Moreover, the mechanism by which NIK mediates tumorigenesis 
is poorly understood. NIK is likely to be affecting both NF-κB pathways during 
malignancy, possibly as a result of shifting the balance between the positive and 
negative feedback mechanisms. It cannot be excluded that NIK may have NF-κB 
independent functions in contributing to tumorigenesis. As NIK is not an essential kinase 
for the canonical NF-κB pathway under physiological conditions, a thorough 
understanding of its function may provide avenues for therapeutic interventions in cancer 
treatment.   
 
Concluding remarks 
NIK functions as a kinase crucial for the non-canonical pathway of NF-κB and 
contributes to various cellular processes, ranging from the regulation of adaptive and 
innate immunity to cancer growth and survival. Although significant advances have been 
made during the past 13 years since NIK was first cloned, many questions remain 
unanswered. Most importantly, regulation of NIK function is not completely clear. Is 
stabilization of NIK required for the phosphorylation and activation of NIK? Which 
ligase(s) is/are responsible for ubiquitination of NIK? Although the data are suggestive 
that endogenous NIK is ubiquitinated under basal conditions, this has not been formally 
demonstrated. Answering these questions will be valuable to understand the importance 
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of NIK in disease models such as cancer and autoimmunity, to eventually develop 
therapeutic interventions. NIK is an attractive therapeutic target since its function is not 
essential for activation of the canonical pathway of NF-κB, though NIK can affect this 
pathway upon stabilization. It appears that cells under physiological conditions do not 
require abundant NIK expression as evidenced by the low level of NIK in most cell types 
and the survival of systemic NIK knock-out mice. However, in pathological contexts, 
such as cancer, NIK becomes stabilized. Thus, attenuating the function of NIK is a 
potentially promising strategy for cancer therapy. Yet, targeting NIK to alleviate cancer 
should proceed with caution due to its role in physiological functions of the patient such 
as antibody production, T-cell regulation and osteoclastogenesis.   
 
Summary and Dissertation Goals 
 Since the discovery of NIK, we have become to understand its regulation and 
functions in different physiological processes. However, many areas, including the role 
of NIK in tumorigenesis, remained to be explored. In addition, our lab has previously 
shown that higher amount of NIK immunoprecipitates with the IKK complex in melanoma 
compared to normal melanocytes (Dhawan & Richmond, 2002). We have also shown 
that an upstream receptor of NIK, LTβR, contributes to melanoma tumor growth 
(Dhawan et al., 2008). Based on the current literature and previous studies from our 
group, we hypothesize that NIK promotes melanoma malignancy. The goal of this thesis 
is to better elucidate the significance of NIK over-expression in melanoma and molecular 
mechanisms by which NIK mediates melanoma tumorigenesis. In addition, we also give 
brief insights into how systemic immune system and tumor immunology may be altered 
when NF-κB activation is targeted for melanoma therapy. 
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CHAPTER II 
 
NIK MODULATES MELANOMA TUMOR GROWTH BY DOWN-REGULATING 
EXPRESSION OF PRO-SURVIVAL FACTORS THROUGH THE β-CATENIN 
PATHWAY 
 
Rationale 
Previous studies from our laboratory have shown that NF-κB activity is crucial for 
melanoma growth. Inhibiting IKKβ by pharmacological agents or genetic ablation to 
reduce NF-κB activity leads to significant reduction of melanoma tumor growth (Yang et 
al., 2006a; Yang et al., 2007a; Yang et al., 2010). Although IKKβ is a good potential 
target for melanoma therapy, its crucial role in the immune system may raise concerns 
for systemic therapy in patients. Therefore, we explored the possibility of targeting 
another kinase, NIK that is not essential for many physiological processes or for the 
activation of NF-κB. The expression of NIK is up-regulated in melanoma compared to 
normal melanocytes. NIK knock-out mice are viable (Yin et al., 2001) and they do not 
exhibit any lethal phenotypes despite some defects in lymphoid development and 
osteoclastogenesis. Moreover, it is consistently reported that NIK contributes to 
tumorigenesis of cancers such as multiple myeloma and lymphomas as mentioned in 
Chapter I. Based on the above knowledge, we hypothesized that NIK contributes to 
melanoma tumorigenesis and that NIK may be a potential therapeutic target for 
melanoma treatment.  
(Part of this Chapter is published in Thu et al., Oncogene, 2011) 
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Materials and Methods 
Cell culture 
  Melanoma cells were cultured in DMEM/F12 containing 10% fetal bovine serum 
(FBS) at 37ºC with 95% air/5% CO2 in a water jacketed incubator. Normal human 
epidermal melanocytes were obtained from Vanderbilt Skin Research Core or were 
purchased from Clonetics and cultured in Media 254 containing supplements for 
melanocytes (Cascade Biologics S-002-5) under the same conditions. Cell lines were 
obtained from ATCC and were tested for mycoplasma monthly. Nik+/+ and Nik-/- MEFs 
were cultured in DMEM containing 10% FBS, 2% L-glutamine, at 37ºC with 95% air/5% 
CO2 in a water jacketed incubator. HEK293 cells were cultured in DMEM containing 10% 
FBS at 37ºC with 95% air/5% CO2 in a water jacketed incubator.  
 
Generating NIK knock down cell lines 
Melanoma cells (Hs294T or WM115) were infected with lentivirus carrying NIK 
shRNA, (Sigma Mission shRNA pLKO.1_733 or_731) or IKKα shRNA (Sigma Mission 
shRNA pLKO.1_508). Forty-eight hours after infection, cells were cultured in media 
containing puromycin (Sigma P9620) at a concentration of 2ug/ml to select for cells 
expressing the NIK shRNA, the IKKα shRNA or the control non-targeting shRNA. 
 
IKK kinase assay 
Non-silencing or knock-down cells were starved overnight and treated with 
vehicle or TNFα (20ng/ml) (PreproTech 300-01A) for 30 min. Using 200 µg of 
cytoplasmic extract prepared from untreated or treated cells, IKK kinase assay was 
performed as previously described (Yang et al., 2007b).  
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Cytokine array 
Non-silencing or knock-down cells were cultured for 24 h in the same amount of 
serum free DMEM/F12 to obtain conditioned media. Cytokine array (RayBioTech: AAH-
CYT-G2000-8) was performed according to the user manual using 50µl of collected 
conditioned media. Serum free media was used as a negative control.    
 
Bromodeoxyuridine (BrdU) incorporation 
BrdU incorporation was performed using the BrdU staining kit (BD Biosciences 
559619). Briefly, cells were cultured until they reached 70-80% confluency, and then 
incubated with BrdU for 4 h in serum containing media. Following BrdU incorporation, 
cells were fixed, permeabilized and stained with anti-BrdU antibody conjugated with 
FITC, according to the manufacturer’s protocol. After staining, samples were analyzed 
by flow cytometry (Beckman Coulter).  
 
Cell cycle analysis 
Non-silencing and NIK knock-down cells were synchronized by thymidine block 
(2mM for 16h). After indicated amount of time of release from thymidine block, cells were 
collected, fixed with 70% ethanol and stained with propidium iodide (PI) staining buffer 
[0.1% Triton X-100, 0.2mg/ml of RNAse, 20µg/ml of PI, 1mM of 
ethylenediaminetetraacetic acid (EDTA)] for 30min at room temperature (RT), followed 
by flow cytometry analysis. Experiments were performed at least three times and 
statistical significance was determined by using t-test. Significance was assumed if the 
p-value ≤0.05. 
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Annexin V staining 
Non-silencing and knock-down cells were plated at equal density and treated 
with TNFα (1000ng/ml) (PeproTech 300-01A) where indicated. After the 8h of TNFα 
treatment, the assay was performed as described in the user manual (TACS Annexin V 
4830-01-K R&D Systems). Samples were subjected to flow cytometry analysis 
(Beckman Coulter), following the Annexin V staining.  
 
Western blot and immunoprecipitation 
Cells were lysed with the buffer containing 10% glycerol, 50mM Tris pH 7.7, 
150mM NaCl, 0.5% NP40 and a cocktail of protease (Sigma P8340) and phosphatase 
inhibitors (Sigma P2850 and P5726). Proteins were separated by electrophoresis and 
immunoblotted with appropriate antibodies (antibody information described later). 
Dilutions of antibodies used are as recommended by the manufacturers and the rest of 
the Western blot procedure was as previously described (Yang et al., 2007b). 
Immunoblots were repeated at least three times, scanned for band density, and mean 
density values were quantified using ImageJ (NIH).  
Primary antibodies used were NIK (Novus NB120-7204), p100/p52 (Upstate 05-
361), RelA (Santa Cruz sc-109) phospho-p65 (Ser536) (Cell Signaling 3033S), IκBα (BD 
Transduction Laboratories 610690), β-catenin (Abcam ab2365), Bcl2 (Santa Cruz sc-
7382), Survivin (Cell Signaling 2808), cIAP1 (Alexis: ALX-803-335), Bcl-xl (Santa Cruz 
sc-634), FLIP (Cell Signaling 3210), actin (Santa Cruz sc-1616 or 1616R) or tubulin 
(Sigma T2220). Secondary antibodies are (Molecular Probes Alexa Fluor 680 or 800 
A21058/ A21084; Rockland 611-732-127 or Jackson Laboratories 115-035-146 (goat 
anti-mouse), 705-035-003 (donkey anti-goat), 111-035-144 (goat anti-rabbit). 
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Transfection of HEK293 cells with Flag-NIK (kindly shared by David Goeddel) or 
β-catenin (purchased from Open Biosystems: MHS1010-9205712) (1.5µg each DNA) 
was performed using Fugene (Roche 11814443001) according to the manufacturer’s 
protocol. Forty-eight hours after transfection, cells were lysed with IP lysis buffer: 10% 
glycerol, 50mM Tris pH 7.7, 150mM NaCl, 0.5% NP40 and a cocktail of protease (Sigma 
P8340) and phosphatase inhibitors (Sigma P2850 and P5726). Flag-NIK was 
immunoprecipitated using an antibody against Flag (Sigma F1804, 1µg/1mg of total 
protein) whereas, β-catenin was immunoprecipitated using an antibody against β-catenin 
(Abcam: ab2365, 1µg/1mg of total protein). Immunoprecipitation was performed as 
detailed in Chapter IV. 
 
Cytoplasmic/ nuclear extraction 
 Cytoplasmic and nuclear extraction was performed using NE-PER Nuclear 
Extraction Reagents (Pierce: 78833), following the manufacturer’s protocol except the 
changes mentioned here. Briefly, cells were harvested, washed with 1xPBS and lysed 
using CERI buffer for varying amounts of time depending on the cell line (WM115 ns 
shRNA and shNIK: 2h, Nik+/+ and Nik-/- MEFs: 30min). At the end of cytoplasmic lysis, 
CERII buffer was added to the lysate, supernatant was collected and nuclei were 
washed with 1xPBS three times. Nuclei were then lysed with NER buffer as described in 
the manufacturer’s protocol. Lysates were subjected to sodium dodecyl sulfate (SDS)-
gel electrophoresis under reducing conditions followed by Western blot for 
immunodetection of specific proteins. LaminA/C (Cell Signaling 4777) or Oct-1 was used 
as a nuclear marker. GAPDH (Cell Signaling 2118) was used as a cytoplasmic marker.  
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Quantitative Real-time PCR 
RNA was isolated from non-silencing and knock-down cells using the RNeasy kit 
(Qiagen 74104) according to the manufacturer’s protocol. Subsequently, cDNA was 
synthesized from one µg of the isolated RNA using the iScript cDNA Syn RT-PCR kit 
(BioRad 1708890) according to the user manual. The resulting cDNA was then amplified 
by quantitative real-time PCR using IQ Real Time Sybr Green PCR supermix (BioRad 
1708880) and BioRad IcyclerIQ Multicolor Real-Time PCR Detection System. cDNA 
levels were normalized to actin that was amplified with the following primers: 5’-
caccacaccttctacaatgag-3’, and 5’-atagcacagcctggatagc-3’.  NIK primers were: 
5’tgcggaaagtgggagatcctgaat-3’, and 5’-tgtactgtttggacccagcgatga-3’. For Bcl2, cIAP1, 
survivin, and genes from microarray analysis, primers were purchased from 
SABiosciences. qRT-PCR arrays for NF-κB pathway is from SABiosciences: PAHS-025. 
Data are shown as fold changes in NIK knock-down cells compared to the non-silencing 
control, and each gene was normalized to the loading control (actin or tubulin).  
 
Orthotopic tumor implant studies in mice 
Non-silencing vector control or NIK knock down WM115 cells (3x106 per mouse) 
were subcutaneously injected into athymic-Foxn1nu/nu nude mice (Harlan Laboratories) 
and allowed to grow until palpable tumors developed (about three weeks). Once 
palpable tumors formed the size was measured every two days with a microcaliper. 
Three weeks from the day of initial palpable tumor detection (or when tumors reached 
1.5 cm in one dimension), mice were sacrificed and final tumor volumes were measured 
by Hank’s balanced salt solution (HBSS) volume displacement.   
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Immunofluorescence 
 Cells on coverslips were fixed with 4% paraformaldehyde and permeabilized with 
0.2-0.5% of Triton-X 100 in 1xPBS for 5min. Fixed and permeablized cells were blocked 
with 10% normal donkey serum in 1xPBS for 30 minutes and incubated with β-catenin 
antibody (abcam ab2365, 1:100) for 2h at RT, followed by three washes with 0.1% 
Tween-20 in 1x phosphate buffered saline (PBS) (1xPBST) and incubation with 
secondary antibody conjugated with Cy2 (Jackson ImmunoResearch 715-225-150, 
1:100) for 2 h at RT. Then, coverslips were washed three times and stained with 
Hoechst nuclear stain during the last wash. Coverslips were then air dried and mounted 
onto glass slides. Images were taken using a 63x oil lens Plan-Apochromat on Zeiss 
Axioplan 2 microscope and Hamamatsu Orca ER fluorescence camera. Images were 
processed using Metamorph Software (Molecular Devices).  
 
Immunofluorescence staining of Tissue Microarray (TMA) 
Human patient samples for TMA were collected according to the protocol 
approved by Institutional Review Board of Vanderbilt University. Two or three cores were 
cut from each paraffin embedded, formaldehyde fixed tissue block and mounted into the 
TMA mold in a random fashion. Benign nevi (n=30), dysplastic nevi (n=22), primary 
melanoma lesions (n=15), and metastatic melanoma (n=13) lesions contributed to the 
tissue microarray block using protocols developed by Kononen et al. (Kononen et al., 
1998), with the assistance of the Human Tissue Pathology Core at Vanderbilt University. 
The specificity and sensitivity of the NIK antibody to be used for immunofluorescent 
staining of TMAs was first validated in human melanoma xenograft tumor sections from 
WM115 tumors with or without NIK knock-down.  TMA paraffin embedded block was cut 
into sections of 4µm thickness and immunofluorescent staining was performed as follow. 
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After antibody validation, paraffin embedded nevus and melanoma tissues were 
deparaffinized  by washing  two times in Xylene  for 10 min each wash, followed by 
washing in a series of ethanol dilutions (100%, 90%, 80%, 70%, 50% ethanol). Then 
tissues were permeabilized in 1x Tris buffered saline with Tween-20 TBST (0.05% 
Tween-20) for 15min, washed with 1xTBS and rinsed with dH2O. Antigen retrieval was 
performed by boiling tissue slides in 10mM sodium citrate pH 6.0 for 12 min. After the 
slides were cooled down, tissues were blocked with the blocking buffer containing 10mM 
Tris-HCl pH 7.4, 0.1M MgCl2, 0.5% Tween-20, 1% bovine serum albumin (BSA) and 5% 
goat serum.  Slides were then incubated with NIK antibody (Novus 120-7204, 1:100) in 
the blocking buffer overnight at 4°C. Slides were then washed with 1xTBST for 3x10min 
each and incubated with Alexa Flour 488 goat anti-rabbit secondary antibody (Invitrogen 
A-11008, 1:1000) for 2 h at RT. Slides were washed again with 1xTBST for 3x10 min 
each, counterstained with Hoechst and mounted with Prolong Gold antifade reagent 
(Invitrogen P36930). Images were scanned and quantitated using Ariol SL-50 imaging 
system (Genetix). Quantitative data are presented as (area of NIK staining/area of 
Hoechst staining)x100. Damaged tissue cores were excluded from quantitation. 
Statistical significance was determined by using ANOVA. Significance was assumed if 
the p-value ≤0.05. 
 
Immunohistochemistry 
 Five micron sections of tissue were placed on charged slides, paraffin was 
removed by xylene and ethanol washes, and tissues were rehydrated.  For caspase-3 
staining, endogenous peroxidase was neutralized with 0.3% H2O2 for 20 min followed by 
Ultra V block for 5 min (Labvision) for blocking of nonspecific staining.  For Ki-67 
staining, sections were rehydrated and placed in heated Target Retrieval Solution 
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(Labvision). Endogenous peroxidase was neutralized with 0.03% H2O2 followed by a 
casein-based protein block (DakoCytomation) to minimize nonspecific staining.  Then, 
sections were incubated with rabbit anti-human cleaved caspase-3 (Promega) or Ki-67 
(Vector Laboratories VP-K451) for 60 min.  The Dako Envision+ HRP/DAB+ System 
(DakoCytomation) was used to provide a substrate to develop peroxidase linked 
antibody and produce localized, visible staining. The slides were lightly counterstained 
with Mayer’s hematoxylin, dehydrated and coverslipped using Vectashield Mounting 
Solution (H-1000). 
 
Gene Expression Microarray Analysis  
RNA was isolated from cells using the RNeasy kit (Qiagen 74104) according to 
the manufacturer’s protocol. Affymetrix WT Sense reactions, using the Affymetrix WT 
Sense reaction kit (#900652), were assembled and run following Affymetrix protocol.  
Briefly, a sample mix of 200ng total RNA from NIK knock-down WM115 cells and from 
NIK shRNA control WM115 cells, and poly-A spike in controls (included in kit), were 
brought to a 5 µl final volume with nuclease free H2O.  First Strand Synthesis Master mix 
was added to the sample mix and incubated at 42º C for 1 h, enzymes were heat 
inactivated 10 min at 70ºC, followed by a cooling to 4º C for 2 min.  Subsequently, 
Second Strand Synthesis Master mix was added to the sample mix, and incubated at 
16ºC for 2 h.  The reactions were heat-inactivated by 10 min incubation at 75ºC.  The 
resulting cDNA was then processed in an IVT reaction to generate cRNA.  The cRNA 
was used in first strand synthesis reactions to generate target of the correct sense for 
hybridization to the Affymetrix Gene and Exon arrays. The reactions were set up with 
10µg cRNA, random hexamer, and first strand synthesis reagents to make cDNA.  The 
targets were then treated with RNase to remove template RNA and cleaned up over kit 
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supplied columns, or Agencourt SPRI beads, following manufacturer’s protocol 
(RNAClean, #000494).  A total of 5.5µg of the clean cDNA target was then enzymatically 
fragmented and end-labeled using the Affymetrix kit reagents. The cRNA, cDNA, and 
fragmented and end-labeled targets were assessed by Agilent bioanalysis to insure that 
the amplified targets met the recommended smear range, and fragmentation and end-
labeling were complete. For both Exon and Gene arrays, the requisite amount of target 
was then added to hybridization cocktail to give a final target concentration of ~25ng/µl 
in the hybridization cocktail.  The targets in hybridization cocktail were heat denatured at 
99ºC for 5 min, cooled to 45ºC for 5 min, centrifuged and then loaded on the Affymetrix 
Hu Gene 1.0STcartridge arrays for a hybridization period of 16 h at 45ºC, with rotation of 
60RPM. The cartridge arrays were washed, stained and scanned per standard 
Affymetrix Protocols using Affymetrix Hybridization Wash and Stain kit reagents 
(#900720). 
 
Chromatin Immunoprecipitation 
 Chromatin immunoprecipitation (ChIP) was performed following the protocol 
using Simple Enzymatic ChIP kit (Cell Signaling #9002). Briefly, cells were cross-linked 
using 1% paraformaldehyde, permeablized and chromatin was digested with 
microccocal nuclease at 37ºC for 20min. Chromatin was immunoprecipitated using IgG, 
histone, or β-catenin (ab2365) antibodies for 2 h at 4ºC. Immunoprecipitated chromatin 
was purified and PCR was performed using the following primers amplifying the survivin 
promoter: 3’-GGGGCGCTAGGTGTGGG-5’, 5’-TTCAAATCTGGCGGTTAATGGC-3’ (β-
catenin_human); 5’-CTTCTGCTTCCCTTCCAACC-3’, 5’-
GCCTTGCGCAAGGGTGTGATT-3’ (β-catenin_mouse). PCR was performed with 30-35 
cycles.  
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Statistical analysis 
Non-parametric statistical analyses (Mann-Whitney or ANOVA) were performed 
using the Graphpad Prism software (La Jolla, CA). Statistically significant differences 
were assumed if the p-value ≤ 0.05. 
 
Results 
Evaluation of NIK expression in non-malignant nevi and melanoma lesions 
 To determine whether NIK levels are elevated in melanoma compared to non-
malignant nevi, we examined NIK expression in tissue microarray of nevi (n=30), 
dysplastic nevi (n=22), primary melanoma (n=15) and metastatic melanoma (n=13) 
lesions by immunofluorescence staining. Intriguingly, NIK expression was higher in 
dysplastic nevi (p<0.05) and in primary and metastatic melanoma tissues compared to 
benign nevi (p<0.05) (Figures 6a and b). Likewise, Western blot analysis on lysates of 
10 human melanoma patient tumors and 4 melanoma cell lines (Hs294T, SKMel5, 
SKMel28, WM115) showed that NIK protein expression was elevated in some 
melanoma tissues (M2, M5, M6, M7) and all melanoma cell lines compared to normal 
human epidermal melanocytes (NHEM) (Figures 6c and d). Nevertheless, NIK mRNA 
expression in melanoma cells was not significantly up-regulated in melanoma (Figure 
7a), suggesting that NIK over-expression may be due to protein stability.  
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Figure 6. NIK expression is up-regulated in melanoma tissues and cells. A. Left to 
right: first column:  Immunofluorescent analysis of NIK expression in benign (n=30), 
and dysplastic (n=22) nevi, primary (n=15) and metastatic (n=13) melanoma tissue 
samples from TMA.  NIK positive cells are green, based upon Alexa 488 anti-rabbit 
antibody recognition of NIK antibody. Nuclei are blue based upon Hoechst stain. 
Second column: Enlargement of area denoted by box in the adjacent left panel 
showing fine cellular details of the histology of the lesions. Third column: H&E stain 
of the tissues shown in the first column. Fourth column: Enlargement of area 
denoted by box in the adjacent left panel showing fine cellular details of the 
histology of the lesions. [Scale bar =100µm]   
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B. Quantitation of NIK staining from TMA, based upon scans of images from 
duplicate or triplicate core samples of each lesion using the Ariol SL-50 imaging 
system (Genetix) calculated as described in Materials and Methods: (area of NIK 
staining/area of Hoechst) x100. Statistical significance was determined by 
ANOVA, where p<0.05 indicates significance. C and D.  Western blot analysis of 
NIK expression in melanoma tissues (C) and cell lines (Hs294T, SKMel5, 
SKMel28, WM115) (D) compared to normal human epidermal melanocytes 
(NHEM). Densitometric scans from triplicate assays were quantitated, normalized 
to the loading control and calculated as fold difference from NHEM cells. E. 
Western blot and F. qRT-PCR analysis of NIK expression in NIK knock-down 
cells compared to the non-silencing (ns) control in Hs294T and WM115. Ns 
shRNA is a mock shRNA with the same vector backbone as the NIK shRNA. G. 
Western blot analysis of NIK in different passages of Hs294T_shNIK1 and 
WM115_shNIK1 cells (p=passage). Densitometric scans from triplicate assays 
were quantitated, normalized to the loading control and calculated as fold 
difference from ns. 
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Figure 7. NIK mRNA expression in melanoma, NIK protein expression and BrdU 
incorporation in NIK knock-down WM115 cells and apoptosis of IKKα knock-down 
WM115 cells. A.qRT-PCR analysis of NIK mRNA in NHEM and melanoma. Fold 
changes were calculated by normalizing to the loading control and comparing it to 
NHEM. B. Western blot analysis of NIK knock-down WM115 clones treated with 
MG132 (40µM or 80µM) or DMSO. Densitometric scans from triplicate assays were 
quantitated, normalized to the loading control, and calculated as fold difference from 
non-silencing control cells. C. BrdU incorporation analysis of WM115 cells with 
another NIK-targeting shRNA (shRNA2) compared to the non-silencing control. 
Error bars are ± S.E.M. (n=6) D. Apoptosis analysis of IKKα knock-down WM115 
compared to the control. Error bars are ± S.E.M. (n=12) In Figures C and D, insets 
are Western blot showing the efficiency of NIK knock-down. Statistical significance 
was determined by Mann-Whitney test, where p<0.05 indicates significance. 
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Development of melanoma cell lines with NIK knock-down 
To understand the importance of NIK over-expression in melanoma, NIK was 
knocked down in two melanoma cell lines, Hs294T (derived from a metastatic 
melanoma) and WM115 (derived from a primary melanoma) with NIK targeting shRNA. 
Quantitative RT-PCR (qRT-PCR) and Western blot analyses showed that NIK 
expression was efficiently reduced at the mRNA and protein levels in Hs294T and 
WM115 (Figures 6E and F). Surprisingly, NIK knock-down was gradually lost within the 
population of Hs294T and WM115 cells selected to stably express the shRNA (Figure 
6G), suggesting that NIK depletion slowed growth or enhanced death of melanoma cells 
and resulted in overgrowth of the cells without NIK knock-down. 
 
Generation of clonal and polyclonal NIK knock-down cells 
 To prevent the selection against NIK depleted cells, a clonal population of NIK 
deficient WM115 cells was selected by in-cell-Western, followed by confirmation using 
Western blot. As NIK expression level is regulated by the proteasome, non-silencing and 
clonal knock-down [shNIK1(c)] cells were treated with a proteasome inhibitor (MG132) to 
stabilize NIK expression. MG132 treatment did not significantly stabilize the level of NIK 
protein in WM115 with NIK shRNA (Figure 7B), confirming the efficiency of NIK 
silencing. This NIK depleted WM115 clone was used to examine the functional 
significance of NIK in melanoma cells. In some experiments, polyclonal NIK knock-down 
WM115 cells [shNIK1(p)] were included to ensure that the observed phenomena were 
not simply due to clonal variation. Likewise, Hs294T cells with NIK knock-down by 
shRNA were also included in some experiments to evaluate the effect of NIK depletion in 
another melanoma cell line.  
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NIK deficiency in melanoma cells decreased proliferation and increased apoptosis 
The loss of NIK-depleted cells from polyclonal lines over-time suggests that NIK 
may regulate proliferation and/or apoptosis. Consistently, NIK deficient cells exhibited a 
significant lag in doubling time compared to non-silencing control cells (Figure 8A). Both 
Ki67 and BrdU staining suggest that the percentage of cells undergoing proliferation was 
lower in knock-down populations than in the non-silencing control (Figures 8B and C). 
This phenotype was confirmed in WM115 with another shRNA targeting NIK (shNIK2) 
(Figure 7C). Depletion of NIK in another melanoma cell line Hs294T also resulted in 
decreased proliferation, determined by Ki67 staining (Figure 8B).  
To determine whether NIK deficiency affected apoptosis, Annexin V and PI 
staining were performed. For these experiments, only polyclonal NIK knock-down cells in 
early passages were used, as we reasoned that the clonal knock-down cell line had 
already developed a mechanism to maintain equilibrium between survival and death. At 
a basal level, the proportion of apoptotic cells was two-fold higher in the knock-down 
population than in the control (Figure 8D, white bars). This suggests that over time the 
cumulative number of cells undergoing apoptosis would be much greater, providing an 
explanation for the growth disadvantage of NIK deficient cells. Interestingly, knocking 
down IKKα in WM115 did not induce apoptosis (Figure 7D), suggesting that NIK-
mediated apoptosis is not likely to result from decreased IKKα activity. 
 
NIK knock-down cells were sensitive to TNFα-induced cell death  
 It has been documented that NF-κB activation and NIK activity protect cells from 
TNFα-induced cell death (Malinin et al., 1997; Van Antwerp et al., 1998; Wang et al., 
1996). To determine whether NIK deficient WM115 cells were sensitive to TNFα-induced 
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apoptosis, WM115 non-silencing or NIK knock-down cells were treated with TNFα 
(1000ng/ml) for 8h and apoptosis was determined by Annexin V and PI staining. TNFα 
treatment markedly increased the percentage of apoptotic cells in NIK deficient 
population (Figure 8D, dark bars).  
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Figure 8. Depletion of NIK decreases growth and survival of melanoma cells. A. 
Growth curves of NIK knock-down and non-silencing Hs294T and WM115 cells. Error 
bars are ± S.E.M. In Hs294T graph, S.E.M.<0.02. (n=9) B. Quantification of Ki67 
staining in NIK deficient Hs294T or WM115 cells compared to the non-silencing 
control. Error bars are ± S.E.M. (n=10) C. BrdU incorporation analysis of NIK knock-
down WM115 cells compared to WM115 with non-silencing control. Error bars are ± 
S.E.M. (n=7) D. Apoptosis analysis of basal and TNFα-treated NIK knock-down 
WM115 compared to the control. Percentage of apoptosis is defined by % of cells 
that are Annexin V+ and Annexin V+ PI+. Error bars are ± S.E.M. (n=9) In Figures C 
and D, insets are Western blot showing the efficiency of NIK knock-down. 
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NIK deficient WM115 cells exhibit a defect in cell cycle progression  
In addition to a defect in proliferation and apoptosis, NIK knock down WM115 
cells exhibited a delay in cell cycle progression compared to the control, most prominent 
at 12h after the release from thymidine block (Figure 9). It appears that NIK depleted 
cells have a delay in progression from G1 to S (Figure 9). By 12 h after release, cells 
with the control shRNA have completed the cell cycle, whereas a significant percentage 
of NIK knock-down cells are still in G1 and S phase (Figure 9).  
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Figure 9. NIK depletion delays cell cycle progression in WM115 cells. Left panel: 
Percentage of unsynchronized and synchronized (thymidine block, 16h) cells in each 
phase of cell cycle. Error bars are ± S.E.M. (n=3) Right panel: Time course graphs 
showing the progression of cell cycle in ns and NIK depleted WM115 populations. 
Times indicated (0h, 4h, 8h, 12h) were hours after the release from the thymidine 
block of 16h. Scales for number of non-silencing control WM115 cells: 
unsynchronized: 0-4500, 0h: 0-1600, 4h: 0-1000, 8h: 0-2500, 12h: 0-5000. Scales for 
number of clonal shNIK1(c) WM115 cells: unsynchronized: 0-4000, 0h: 0-2200, 4h: 0-
1200, 8h: 0-600, 12h: 0-1500.  
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NIK depletion in WM115 cells reduced xenograft tumor growth in nude mice 
 In agreement with in vitro results, depletion of NIK significantly decreased 
melanoma tumor growth and burden in nude mice (Figure 10A and B). NIK deficiency in 
tumor samples was confirmed by both Western blot and qRT-PCR analyses (Figures 
10C and D). Immunostaining of Ki67 or cleaved-caspase 3 was lower in NIK knock-down 
tumor sections than non-silencing control tumor sections (Figures 10E and F). These 
data suggest that tumors from NIK knock-down WM115 grew and turned over slower 
than control tumors. In summary, NIK deficiency substantially attenuated melanoma 
tumor growth of WM115 cells both in vitro and in vivo. To determine molecular 
mechanisms by which NIK depletion reduced tumor growth, gene expression changes 
and signaling pathways were next examined. 
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Figure 10. NIK depletion significantly reduces tumor burden in a melanoma 
xenograft model of NIK knock-down WM115 [shNIK1 (c)] and non-silencing 
WM115. A. Tumor growth over 24 days. B. size of tumors at the 24 day end point. 
Error bars are ± S.E.M.  (ns n=21 and shNIK1(c) n=22). C. Western blot and D. 
qRT-PCR analyses of NIK in tumor samples. Fold changes in Figure D were 
calculated by normalizing to the loading control and comparing it to ns. E. Ki67 
(proliferation marker) and F. cleaved caspase-3 (apoptosis marker) staining of non-
silencing control WM115 tumors compared to WM115 with NIK knock-down. Error 
bars are ± S.E.M. (n=5). Statistical significance was determined by Mann-Whitney 
test, where p<0.05 indicates significance. 
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NIK depletion altered expression of genes important for melanoma tumor growth  
 To elucidate potential mechanisms by which attenuation of NIK expression 
contributed to reduced tumorigenicity of melanoma cells, the global gene expression 
profile of polyclonal and clonal NIK knock-down WM115 cells as compared to the non-
silencing control was examined by using gene expression microarray analyses. While 
results of these experiments suggested clear fold differences in the expression of many 
genes, the differences were not statistically significant when stringent statistical analyses 
(p<0.05) were applied, possibly due to the variations between polyclonal and clonal 
knock-down populations. However, using less stringent criteria for analysis (p<0.15), 
several genes that play a crucial role in tumor growth or progression (CXCR4, c-MYC, c-
MET, CCND2, LIN28B) (Pastorino et al., 2003; Puri et al., 2007; Scala et al., 2006; 
Scala et al., 2005; Viswanathan et al., 2009) were markedly reduced in NIK knock-down 
cells (Table 1). NIK knock-down cells also exhibited up-regulated expression of genes 
such as XIAP-associated factor 1 (XAF1), which plays a negative role in cancer cell 
survival (Plenchette et al., 2007). Similar trends of gene expression were observed with 
control and NIK depleted melanoma tumor samples (Table 1). qRT-PCR analysis of 
selected genes revealed statistically significant changes in expression for several genes 
identified by microarray analyses (fold changes relative to the non-silencing control): c-
MYC (-3.39), c-MET (-4.30), CXCR4 (-620.35), CCND2 (-58.08), XAF1 (5.78) and 
LIN28B (-3.2x107) with p-values <0.05 for all genes) (Table 1). Taken together, 
microarray and qRT-PCR data suggest that NIK depletion altered the expression of 
genes crucial for tumor growth.  
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Table 1. Gene expression microarray data from NIK depleted cells and tumors 
confirmed by qRT-PCR (normalized to non-silencing control) to examine gene 
expression changes which are indicative of less tumorigenecity compared to the 
control.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Microarray 
(cells) p-value 
Microarray 
(tumors) p-value qRT-PCR 
p-
value 
c-Myc -3.90 0.14 -2.20 0.06 -3.39 p<0.05
c-Met -3.72 0.12 -6.80 0.002 -4.30 p<0.05
CXCR4 -14.50 0.08 -5.80 0.01 -620.35 p<0.05
CCND2 -9.60 0.13 -1.04 0.92 -58.08 p<0.05
Xaf1 3.78 0.17 3.65 0.01 5.78 p<0.05
CD36 7.80 0.07 1.70 0.003 5.11 p<0.05
TSC22D3 -10.40 0.04 -7.30 0.02 -33.05 p<0.05
TRIM22 5.30 0.15 1.03 0.73 5.26 p<0.05
ZNF711 -11.20 0.06 -7.10 0.003 -28.57 p<0.05
LIN28B -18.02 0.09 -5.20 0.02 -32436417 p<0.05
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NIK depletion in WM115 did not reduce the canonical NF-κB activation 
 To further explore the mechanism by which NIK knock-down affects NF-κB 
pathways, the canonical NF-κB activation in NIK knock-down melanoma cells as 
compared to the control was determined by IKK kinase assay and by examining nuclear 
p-p65 (Ser536) (Figures 11A and B). TNFα treatment was used as a positive control. 
Both assays suggest that the basal and TNFα-induced canonical NF-κB activity was not 
diminished by NIK knock-down (Figures 11A and B).  
Similarly, the levels of some NF-κB-regulated chemokines and cytokines (IL-6, 
IL-8/CXCL8, CCL2 and CXCL1) in the conditioned media from either WM115 clonal or 
polyclonal knock-down cells were not consistently reduced between these two cell lines 
as compared to the control (Figures 11C and D). The above data suggest that NIK 
depletion did not diminish the canonical NF-κB activation in WM115 melanoma cells.   
 
NIK depletion decreased the non-canonical NF-κB activation   
 In contrast to the canonical NF-κB activation, depletion of NIK in WM115 cells 
reduced the basal processing of p100 to p52 and nuclear localization of p52 (Figures 
11E and F). NIK deficient cells still responded to the ligation through LTβR although to 
the less extent than the control (Figure 11F). Knock-down of NIK in another melanoma 
cell line, Hs294T, resulted in a similar phenotype (Figures 11E and F).  
To determine whether NIK deficiency in melanoma cells exhibited expected 
changes in the gene expression profile associated with NIK activity, we compared the 
gene expression from NIK knock-down WM115 cells to the gene expression pattern from 
lymphoma, where cIAP2-MALT1 fusion protein induces NIK activation (Rosebeck et al., 
2011). In agreement with their observations, genes (such as TLR4, IL1β, PTX3) up-
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regulated in cIAP2-MALT1 negative tumors (NIK low) were increased in NIK deficient 
melanoma, whereas genes (such as HMOX1, PIM2, CXCR4) up-regulated in cIAP2-
MALT1 positive tumors (NIK high) were decreased in NIK deficient cells compared to the 
control (p<0.05 except PTX3) (Figure 11G). Based on above data, we conclude that 
knocking-down NIK reduced the non-canonical NF-κB activation in melanoma cells.  
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Figure 11. Knocking-down NIK in WM115 melanoma reduces the non-canonical 
but not the canonical NF-κB activation. A. Basal IKK activity in NIK knock-down 
WM115 compared to WM115 non-silencing control in an in vitro kinase assay. 
Densitometric scans from duplicate assays were quantitated and normalized to the 
total immunoprecipitated IKKs. B. Nuclear p-p65 in NIK knock-down WM115 
compared to the non-silencing control (c=cytoplasm, n=nucleus). Densitometric 
scans from four assays were quantitated and normalized to the loading control. 
TNFα-treatment was used as a positive control in both A and B. 
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C and D. Cytokine array data from conditioned media of NIK knock-down cells 
(clonal and polyclonal) compared to the non-silencing control. Signal intensity for 
each cytokine was normalized to the internal positive control. Error bars are ± 
S.E.M. (n=4) Statistical significance was determined by Mann-Whitney test, where 
p<0.05 indicates significance. E. Nuclear and cytoplasmic localization of p52 in non-
silencing and NIK knock-down WM115 and Hs294T (c=cytoplasm, n=nucleus). 
Densitometric scans from triplicate assays were quantitated, normalized to the 
loading control, and calculated as fold difference from ns. F. The proteolytic 
processing of p100 to p52 in non-silencing and NIK knock-down WM115 and 
Hs294T. Cells were treated with LTβR agonist antibody or IgG (2µg/ml) for 16h. 
Densitometric scans from triplicate assays were quantitated, normalized to the 
loading control, and calculated as fold difference from ns. G. qRT-PCR analysis of 
gene expression in NIK deficient WM115 cells normalized to the control, compared 
to study by Rosebeck et al., 2011. 
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Some NF-κB regulated genes were transcriptionally up-regulated in NIK knock-down 
WM115 
Since NF-κB transcriptional activity was still active in knock-down cells, the 
mRNA expression of several key NF-κB regulated chemokines and cytokines was 
examined using qRT-PCR analysis in both clonal and polyclonal NIK knock-down or 
control cells. The mRNA expression of chemokines and cytokines examined [IL-1α, IL-
1β, IL-6, IL-8, IL-10, CCL2, CXCL1 and vascular endothelial growth factor (VEGF)] was 
up-regulated in NIK knock-down cells (Table 2). In contrast to other studies (Viemann et 
al., 2004), mRNA expression of pro-survival factors (cIAP1,  cFLIP, A20) and NF-κB 
negative regulators (IκBα, p100 and A20) did not change significantly in NIK knock-down 
cells despite the activity of NF-κB (Table 2). These data suggest that NIK may be 
involved in differential regulation of some NF-κB-regulated genes. 
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NF-κB inhibitors  
mRNA Fold p-value 
A20 1.5 p>0.05 
IκBα -2.2 p<0.05 
p100 -1.1 p>0.05 
Chemokines and cytokines 
mRNA Fold p-value 
 IL1A 38.8 p<0.05 
 IL1B 15.2 p<0.05 
 IL6 45.1 p<0.05 
 IL8 56.8 p<0.05 
IL10 -2.2 p>0.05 
CCL2 (MCP-1) 57.7 p<0.05 
CXCL1 57.4 p>0.05 
VEGF 2.9 p>0.05 
Survival factors 
mRNA Fold p-value 
cIAP1 -1.1 p>0.05 
cFLIP 7.1 p>0.05 
A20 1.5 p>0.05 
Table 2. qRT-PCR anslysis of gene expression in NIK knock-down WM115 
cells compared to the non-silencing control.  
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NIK knock-down attenuated the expression of pro-survival factors 
 One of the mechanisms by which tumor cells escape apoptosis is by up-
regulating the expression of survival factors. To understand the apoptotic phenotype of 
NIK depleted cells, protein expression of a panel of pro-survival factors was examined. 
Some anti-apoptotic proteins such as BCL-XL and cFLIP expression remained 
unchanged (Figure 12A). However, pro-survival proteins such as cIAP1, survivin, BCL2 
were markedly decreased in NIK knock-down WM115 cells (Figure 12A). Depletion of 
NIK in another melanoma cell line, Hs294T, also diminished the protein expression of 
survivin (Figure 12A). qRT-PCR demonstrates that there is no difference in cIAP1 mRNA 
in NIK-depleted melanoma cells, though both BCL2 and survivin mRNA levels were 
significantly diminished (Figure 12B).  While NIK depletion may affect cIAP1 at a post-
transcriptional level, the above data suggest that NIK regulates pro-survival proteins 
BCL2 and survivin at the transcriptional level. A similar decrease in pro-survival proteins 
and mRNA was observed in Nik-/- MEFs, suggesting that NIK regulates the expression of 
these proteins and that the regulation is not melanoma specific (Figures 12C and D).  
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Figure 12. NIK modulates the expression of pro-survival factors. A. Protein 
expression of survival factors such as BCL2, cIAP1 and survivin in NIK knock-down 
WM115 (both clonal and polyclonal) compared to the non-silencing control. Similar 
to WM115, Hs294T cells with NIK knock-down exhibited decreased protein 
expression of survivin.  Densitometric scans from triplicate assays were quantitated, 
normalized to the loading control, and calculated as fold difference from ns. B. 
mRNA levels (qRT-PCR) of BCL2, survivin and cIAP1 in NIK depleted and non-
silencing WM115 cells. Fold changes were calculated by normalizing to the loading 
control and comparing it to ns. C. Western blot and D. qRT-PCR of BCL2 and 
survivin in Nik+/+ and Nik-/- MEFs. In Figure C, densitometric scans from triplicate 
assays were quantitated, normalized to the loading control, and calculated as fold 
difference from WT. In Figure D, fold changes were calculated by normalizing to the 
loading control and comparing it to WT. 
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NIK modulated melanoma tumorigenesis by regulating β-catenin activity 
 Although NIK knock-down WM115 cells exhibited decreased non-canonical NF-
κB activity, this pathway has not been directly linked to the expression of pro-survival 
proteins such as survivin. Therefore, we postulated that NIK modulates the expression of 
survivin through an alternative pathway. Firestein et. al. have identified NIK (MAP3K14) 
as one of the kinases that regulates β-catenin activation in colorectal cancer cells 
(Firestein et al., 2008). To explore the possibility of β-catenin regulation by NIK, we 
examined the expression of genes which are typically targeted by β-catenin in NIK 
knock-down melanoma cells and Nik-/- MEFs by qRT-PCR. Data suggest that deficiency 
of NIK attenuated expression of β-catenin regulated genes such as AXIN2 and TCF7 
(Figures 13A and B). Interestingly, down-regulation of β-catenin targets, such as c-MYC, 
c-MET and CCND2 in NIK knock-down WM115 cells (Table 1), further supports the idea 
that NIK regulates β-catenin activity (Cohen et al., 1998; Matsumoto et al., 2002; Scala 
et al., 2006).  
In addition, the expression of some pro-survival factors such as survivin can be 
transcriptionally regulated by β-catenin (Zhang et al., 2001). To determine whether NIK 
modulates the expression of survivin through affecting β-catenin transcriptional activity, 
ChIP analysis was performed using β-catenin antibody to monitor β-catenin binding to 
the survivin promoter. Both NIK knock-down melanoma cells and Nik-/- MEFs exhibited a 
decreased β-catenin binding to the promoter of the survivin gene (Figure 13C and D), 
supporting the notion that NIK regulates survivin expression, and possibly other β-
catenin targets such as c-MYC, c-MET and CCND2, through β-catenin activity.  
 To understand how NIK may affect β-catenin activity, nuclear and cytoplasmic 
extraction and immunofluorescence staining of β-catenin was performed in NIK knock-
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down melanoma cells and Nik-/- MEFs. The ratio of nuclear to cytoplasmic pool of β-
catenin is less in NIK deficient cells as shown by both analyses (Figure 13E and F), 
implying that NIK regulates sub-cellular localization of β-catenin.   
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Figure 13. NIK regulates survivin expression through β-catenin activity. A and B. 
Expression of traditional β-catenin transcriptional targets such as AXIN2 and TCF7 
in NIK knock-down WM115 (A) and Nik-/- MEFs (B). Fold changes were calculated 
by normalizing to the loading control and comparing it to ns or WT. C and D. ChIP 
analysis using β-catenin antibody and primers flanking the survivin promoter 
exhibited decreased β-catenin occupancy at the survivin promoter in NIK knock-
down WM115 (C) and Nik-/- MEFs (D). Amount of DNA bound to IgG, β-catenin or 
Histone was calculated as percentage of the 2% input. E and F. Immunofluorescent 
staining and Western blot analyses showing sub-cellular localization of β-catenin in 
NIK knock-down WM115 (E) and Nik-/- MEFs (F). Images for immunofluorescence 
staining were taken using a 63x oil lens and pseudo-colored.  Densitometric scans 
of Western blot from triplicate assays were quantitated and normalized to the 
loading control. 
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Effect of NIK on stability and post-translational modification of β-catenin 
 Since NIK influences the activity of β-catenin, we determine the mechanisms by 
which NIK may modulate β-catenin. Previous literature suggest that β-catenin activity 
can be regulated by stability, sub-cellular localization and post-translational modification 
such as phosphorylation. In normal physiological conditions, the cytoplasmic pool of β-
catenin undergoes proteasomal degradation mediated by a destruction complex 
composed of GSK3β, APC, Axin2 and casein kinase I (CKI). In the presence of positive 
signals such as Wnt signaling, cytoplasmic β-catenin becomes stabilized and 
translocates into the nucleus to mediate transcription of its target genes. 
Based on the changes within the β-catenin pathway in NIK deficient cells, we 
postulated that one or more of the above mentioned mechanisms may be utilized by NIK 
to modulate β-catenin activity. Hence, we examined each possibility of β-catenin 
regulation in cells with altered NIK expression.  
First, to determine whether β-catenin and NIK interact, we performed co-
immunoprecipitation between Flag-NIK and β-catenin over-expressed in HEK293. Figure 
14A shows that Flag-NIK and β-catenin indeed interact (Figure 14A). To examine the 
basal level of β-catenin in cells with altered NIK expression, cells were treated for 4h 
with 10µM of MG132, a proteasomal inhibitor, and the β-catenin expression level was 
determined by Western blot analysis. In HEK293 with Flag-NIK and β-catenin over-
expression, cells with Flag-NIK exhibited stabilized exogenous β-catenin compared to 
cells with β-catenin over-expression only (Figure 14B). MG132 treatment stabilizes β-
catenin in cells without Flag-NIK overexpression whereas it does not further stabilize β-
catenin in cells with Flag-NIK overexpression, implying that NIK inhibits β-catenin 
proteasomal degradation (Figure 14B). Consistent with these findings, NIK knock-down 
WM115 cells do not exhibit stabilized β-catenin in response to MG132 treatment 
 86
whereas, this treatment increased β-catenin expression in non-silencing cells (Figure 
14C). However, no apparent difference in β-catenin expression was observed in Nik-/- 
MEFs (Figure 14D). These data suggest that NIK may not be required for stability of β-
catenin although it can increase the stability of the protein.  
As β-catenin can be ubiquitinated and degraded by the proteasome, we asked 
whether ubiquitination status of β-catenin is different in cells with altered NIK expression. 
We examined the level of β-catenin ubiquitination in NIK over-expressed (Flag-NIK over-
expressed) and NIK deficient cells (NIK knock-down WM115 cells and Nik-/- MEFs). To 
normalize the effect of degradation after ubiquitination, cells were first treated with 
MG132 (where indicated) before β-catenin was immunoprecipitated and immunoblotted 
for ubiquitin. Interestingly, β-catenin is ubiquitinated less in NIK over-expressed cells 
(Figure 14E) whereas, the reverse is true in NIK deficient cells (Figure 14F and G). 
These data suggest that NIK can alter the ubiquitination status of β-catenin.  
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Figure 14. NIK alters the stability and ubiquitination status of β-catenin. A. Flag-NIK 
interacts with β-catenin in HEK293 over-expressing both proteins. B. Flag-NIK 
overexpression stabilizes β-catenin expression in HEK293. HEK293 cells 
overexpressing FlagNIK, β-catenin or both were treated with dimethyl sulfoxide 
(DMSO) and MG132 and β-catenin expression was analyzed by Western blot. C. 
and D. NIK knock-down WM115 cells (C) or Nik+/+ and Nik-/- MEFs (D) were treated 
with DMSO or MG132 (10µM) for 4h and β-catenin expression was analyzed by 
Western blot. E. β-catenin was immunoprecipitated from HEK293 cells 
overexpressing Flag-NIK or empty plasmid were treated with MG132 and 
immunoblotted for ubiquitin. F and G. NIK knock-down cells (F) or Nik-/- MEFs (G) 
were treated with DMSO or MG132 (10µM) for 4h. From these lysates, β-catenin 
was immunoprecipitated and immunoblotted for ubiquitin.  
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NIK favors nuclear localization of β-catenin 
 As nuclear β-catenin is associated with its transcriptional activity and sub-cellular 
distribution of β-catenin is altered in NIK deficient cells, we further examined localization 
of β-catenin in NIK deficient cells. Nik-/- MEFs were treated with leptomycin B (LMB), an 
inhibitor of exportin 1/CRM1-dependent nuclear export, and cellular β-catenin distribution 
was deteremined by immunofluorescence staining. NIK deficient cells are defective in 
nuclear accumulation of β-catenin in response to LMB treatment compared to cells with 
NIK expression (Figure 15). This data suggest that NIK deficient has defect in nuclear 
import of β-catenin. 
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Figure 15. NIK deficient cells exhibit defect in nuclear localization of β-catenin 
compared to cells with wild-type NIK. Immunofluorescent staining showing sub-
cellular localization of β-catenin in Nik+/+ and Nik-/- MEFs. Cells were treated with 
either EtOH or LMB (100nM/ml) for 5h and β-catenin localization was determined 
by immunofluorescent staining with antibody against β-catenin. Hoechst stain was 
used to depict nuclei. Images were taken using a 63x oil lens and pseudo-colored.  
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Discussion 
  In this study, we demonstrate for the first time that NIK regulates melanoma 
tumor cell growth and survival. We also demonstrate that the mechanism for this effect 
on tumor growth involves NIK regulation of pro-survival gene expression, in part through 
modulation of nuclear β-catenin transcriptional activity.  NIK depletion decreases 
proliferation and increases apoptosis in melanoma cells in vitro and sensitizes 
melanoma cells to TNFα-induced apoptosis. NIK knock-down also affects the 
progression of cell cycle and this effect may be likely at G1 to S phase transition. 
Interestingly, CCND2, a cyclin which is responsible for G1 to S transition, is down-
regulated in NIK knock-down melanoma.  
 Although the canonical NF-κB pathway is not decreased in NIK knock-down 
cells, pro-survival proteins such as BCL2, cIAP1 and survivin are diminished, suggesting 
that the canonical NF-κB pathway lacks the cyto-protective function in response to TNFα 
when pro-survival effectors are absent. Other studies have also reported that cell death 
can be induced by TNFα in the presence of NF-κB activation when other survival signals 
such as those of cIAPs are disrupted in cancer cells (Petersen et al., 2007; Varfolomeev 
et al., 2007; Vince et al., 2007).  
Consistent with in vitro data, a melanoma tumor xenograft model shows that NIK 
silencing markedly decreases melanoma tumor growth. Ki67 staining of tumor tissues 
suggests that decreased proliferation accounts for the decreased growth of NIK deficient 
tumors. Despite the significant decrease in tumor volume, NIK deficient tumors showed 
diminished cleaved caspase 3 staining. It is possible that NIK depleted cancer cells 
undergoing apoptosis were already eliminated by the time tumors were harvested, or the 
turn-over rate of melanoma tumors with the control shRNA was faster due to the limited 
nutrients in the microenvironment, resulting in less cleaved caspase 3 staining in tumors 
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with NIK knock-down. Overall, NIK depletion markedly decreases the net melanoma 
tumor growth.   
Similarly, studies from other groups suggest that NIK mediates proliferation and 
survival of multiple myeloma, T-cell leukemia and lymphoma (Annunziata et al., 2007; 
Conze et al., 2010; Demchenko et al., 2010; Keats et al., 2007; Saitoh et al., 2008). As a 
result, depleting NIK in these cancers leads to decreased tumor growth (Annunziata et 
al., 2007; Keats et al., 2007; Saitoh et al., 2008). Consistent with the previous literature, 
our data clearly demonstrate that NIK contributes to melanoma tumor growth. However, 
prior studies have not demonstrated which downstream effectors of NIK mediate 
tumorigenesis. Here, we demonstrate that NIK mediates expression of genes that are 
pro-tumorigenic and pro-survival in melanoma and thus, depletion of NIK leads to 
melanoma tumor cell apoptosis.  
 
NIK regulates specific patterns of gene expression 
Gene expression data from NIK deficient melanoma cells compared to NIK 
expressing melanoma cells suggest that NIK modulates the expression of genes such as 
CXCR4, c-MET, c-MYC, LIN28B and XAF1, all of which are important for melanoma 
and/or tumor malignancy. For instance, high CXCR4 expression predicts poor prognosis 
in malignant melanoma (Scala et al., 2005). The c-MET tyrosine kinase receptor and the 
c-MYC transcription factor stimulate survival and proliferation (Lai et al., 2009; Ruggero, 
2009). It was reported that both of these genes were amplified in metastatic melanoma 
from patients (Moore et al., 2008). Specifically, both c-MET and c-MYC are proposed to 
be targets for melanoma therapy (Pastorino et al., 2003; Puri et al., 2007). Depletion of 
NIK significantly diminishes the transcriptional expression of CXCR4, c-MET and c-MYC.  
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In addition, XAF1, which plays a negative role for cellular survival by 
counteracting the function of the survival factor XIAP (Liston et al., 2001), is increased at 
the mRNA level in NIK depleted WM115 cells. Consistently, it is reported that XAF1 
expression is significantly decreased in melanoma (Ng et al., 2004). Remarkably, a 
potent tumor promoter, LIN28B, is down-regulated in NIK knock-down WM115 cells. 
LIN28B de-represses oncogenes such as K-RAS and c-MYC through a miRNA, let-7 
(Viswanathan et al., 2009).  
Since changes in CXCR4, c-MET, c-MYC, LIN28B and XAF1 observed in 
cultured NIK knock-down melanoma cells were retained in NIK knock-down tumors, our 
data indicate that these genes contribute to tumorigenicity. Based on its ability to 
regulate the expression of genes important for melanoma progression, we propose that 
NIK is a promising target for melanoma therapy.  
 
NIK modulates melanoma growth by altering the expression of survivin through β-
catenin activity 
Up-regulation of survival factors is one of the mechanisms by which cancer cells 
resist apoptosis (Baldwin, 2001). Previous studies suggest that pro-survival proteins 
such as BCL2, cIAP1 and survivin contribute to tumorigenesis of melanoma. As a result, 
functional disruption of these proteins impairs melanoma tumor cell growth or survival 
(Grossman et al., 2001; Hilmi et al., 2008; Lecis et al.). Consistent with these findings, 
BCL2, cIAP1 and survivin levels were markedly decreased in NIK deficient melanoma 
cells. Yet, the canonical NF-κB transcriptional activity, which typically regulates the 
expression of survival proteins (Baldwin, 2001), is not diminished in NIK deficient 
melanoma cells, in agreement with the genetic data (Yin et al., 2001). The activity of the 
non-canonical pathway is down-regulated in NIK deficient melanoma cells and it possibly 
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contributes to downstream effects of NIK on melanoma growth. However, it has not been 
directly linked to the expression of genes such as survivin. Interestingly, Nik-/- MEFs 
which do not exhibit a defect in the canonical NF-κB activation (Yin et al., 2001), also 
have decreased survivin expression. Therefore, we hypothesize that the decrease in 
pro-survival gene expression is attributable to a non-NF-κB function of NIK.  
Here our data suggest that NIK regulates β-catenin activity, a novel mechanism 
by which NIK may mediate cancer progression. This non-NF-κB-function of NIK is 
similar to findings of other NF-κB kinases such as IKKα and β which have NF-κB-
independent functions (Chariot, 2009). Specifically, NIK depletion reduces β-catenin 
binding to the promoter region of survivin, diminishing the expression of survivin. Down-
regulation of β-catenin transcriptional targets in NIK deficient cells based on microarray 
data (c-MYC, CCND2, c-MET) and down-regulation of traditional β-catenin targets 
(AXIN2 and TCF7)  in NIK deficient cells further support the notion that NIK mediates β-
catenin activity. In addition, several studies have reported that β-catenin activity 
contributes to melanoma tumor growth (Dhomen et al., 2009; Rubinfeld et al., 1997; 
Sinnberg et al., 2010). Although our data suggest that NIK regulates the subcellular 
localization of β-catenin, detailed mechanisms by which NIK activates β-catenin are yet 
to be determined. As a kinase, NIK may affect the phosphorylation of β-catenin 
regulators such as GSK3β. Alternatively, NIK may directly or indirectly regulate the 
nuclear transport of β-catenin.  
 
NIK regulation of β-catenin 
 Data from NIK over-expressed and deficient cells suggest that NIK can modulate 
stability and ubiquitination status of β-catenin. It is important to note that β-catenin 
expression is not significantly altered in NIK deficient cells although it is stabilized upon 
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Flag-NIK over-expression. These data suggest that β-catenin stability can be modulated 
by NIK, but NIK is not necessary for stabilization of β-catenin. Kinases such as Akt can 
mediate β-catenin activity by phosphorylating and degrading its negative regulator 
GSK3β. Residues on the N-terminus of β-catenin such as Ser33, Ser37, Thr41 and 
Thr47, phosphorylated by CKI and GSK3β, are involved in regulating the stability of β-
catenin. It is already reported that NIK can influence the activation status of Akt through 
PTEN (Kim et al., 2004). Therefore, it is possible that NIK may modulate β-catenin 
stability indirectly by affecting PTEN and Akt.  
  In addition to NIK modulation of β-catenin activity through effects on the stability 
of this protein, β-catenin activity may also be directly regulated through its nuclear 
localization. It has been reported that APC and Axin can regulate nuclear localization of 
β-catenin, thereby affecting the activity of β-catenin (Cong & Varmus, 2004; Henderson, 
2000). In addition to APC and Axin, other novel proteins can regulate nuclear 
translocation of β-catenin. These proteins include Chibby (Li et al., 2010) and menin 
(Cao et al., 2009), both of which export β-catenin out of the nucleus. We propose here 
that NIK may also be important for the appropriate nuclear localization of β-catenin. 
Although stabilized β-catenin accumulates in the nucleus, whether the 
stabilization of β-catenin is required for nuclear accumulation of β-catenin still remains 
unclear. A recent study suggests that positive regulators of the β-catenin pathway such 
as lithium chloride (LiCl), an inhibitor of GSK3β, decrease nuclear export of β-catenin 
(Jamieson et al., 2011). Interestingly, the S45A mutant of β-catenin, which cannot be 
phosphorylated by GSK3β, still enters the nucleus, suggesting that GSK3β regulates 
nuclear β-catenin accumulation independent of N-terminal phosphorylation (Jamieson et 
al., 2011). This study also shows that lymphoid enhancer-binding factor 1 (LEF-1) 
retains nuclear β-catenin, therefore favoring the nuclear activity of β-catenin (Jamieson 
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et al., 2011). Therefore, one potential mechanism by which NIK may affect β-catenin 
activity could be through altering the dynamics of nuclear transport of β-catenin. 
Intriguingly, a NIK-interacting protein, DEAD box polypeptide 5 (DDX5) reported in 
Chapter III, favors nuclear translocation of β-catenin through GSK3β (Yang et al., 
2006b). 
 
NIK as a therapeutic target in cancer 
Results from our experiments have therapeutic implications in melanoma as well 
as in other cancers, since both NIK and β-catenin are also involved in multiple myeloma 
and colon cancer (Annunziata et al., 2007; Keats et al., 2007; Malbon, 2005). Studying 
the mechanism by which these two proteins interact may further elucidate how to 
interfere with the progression of those cancers for which NIK and β-catenin are mis-
regulated. 
Recently, significant progress has been made in melanoma therapy for those 
patients that exhibit BRAF mutation (Dhomen et al., 2009). However, it is imperative to 
also increase our understanding of other pathways that are involved in melanoma 
growth so that therapies for patients that cannot be effectively targeted with BRAFV600E 
inhibitors can be effectively treated. Due to its non-essential role in the canonical NF-κB 
activation and its ability to regulate survival factors, NIK is an attractive target to induce 
melanoma cell death without substantially reducing NF-κB activity, which is important for 
normal cellular processes. However, effects of systemic inhibition of NIK on the immune 
cells must be taken into consideration when devising any clinical trials with NIK 
inhibitors. 
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CHAPTER III 
 
PRODUCTION OF MONOCLONAL ANTIBODIES AGAINST NIK 
 
Introduction 
 Commercially available antibodies against NIK do not exhibit high 
immunoreactivity and do not immunoprecipitate endogenous NIK. In addition, there is no 
commercial monoclonal antibody against NIK. Therefore, we decided to generate 
monoclonal antibody against NIK, in collaboration with the Vanderbilt Monoclonal 
Antibody Core. We initially screen sera from mice immunized with purified NIK protein. 
Using the positive sera, we generated hybridoma clones producing NIK antibodies by 
fusing B cells with myeloma cells.  
 
Materials and Methods 
Molecular cloning and bacteria expression of recombinant MBP-NIK 
 Full length NIK was cloned into pAT-108 vector using SalI and NotI sites to 
produce maltose binding protein (MBP)-tagged NIK. The construct was subsequently 
transformed into competent BL21 bacteria. As a control, the construct with MBP tag only 
was used. Production of MBP or MBP-NIK protein was induced with 0.4mM of isopropyl-
beta D-thiogalactopyranoside (IPTG) at 37ºC for 2-4 h. The protein expressed from this 
induction was purified by using amylose resin. Briefly, bacteria carrying MBP or MBP-
NIK were lysed and soluble lysate was incubated with amlysose resin for 1 hour at 4ºC. 
Bound MBP or MBP-NIK was eluted from amylose resin by incubating with maltose 
buffer. Purified MBP and MBP-NIK (full length) were used to immunize mice. 
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Immunization and Fusion 
Four A/J or BALB/c mice were immunized with the antigen described above.  For 
primary injections, 50 µg of purified antigen were emulsified in 50% PBS, 50% Freund’s 
complete adjuvant and injected subcutaneously into the nape of the neck (50%) and 
intramuscularly to the gluteal muscles (50%).  In subsequent booster injections, Freund’s 
incomplete adjuvant was substituted for Freund’s complete adjuvant.  Fourteen days 
after each booster injection, serum was collected from each mouse and assayed for 
reactivity with the antigen by enzyme-linked immunoadsorbent assay (ELISA), and 
Western blot analysis as described below.  
The mouse with the highest level of reactivity was chosen for final boosting by 
intraperitoneal injection of the antigen diluted in 1xPBS.  Four days after the final 
immunization, spleen cells were harvested and electro-fused/fused by standard methods 
with SP2/0 myeloma cells.  The products of the fusion were plated for under selection for 
fourteen days in semi-solid media (Stemcell Technologies).  Resulting colonies were 
picked and distributed individually into 96-well plates.  Hybridomas producing antigen-
specific antibodies were initially identified by ELISA, and subsequently verified by 
Western blot analysis as described below.  Clones producing antibodies with the desired 
properties were subcloned to ensure monoclonality and cryopreserved.   
   
Western Blot 
  HEK293 cells were lysed with the lysis buffer containing 10% glycerol, 50mM Tris 
pH 7.7, 150mM NaCl, 0.5% NP40 and cocktail of protease and phosphatase inhibitors 
(Sigma 8340, 2850 and 5726) at 4ºC. Proteins were separated by sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), transferred to nitrocellulose 
membranes, and blocked with 5% non-fat dried milk in 1xTBS at RT for 1h. The 
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membranes were immunoblotted using slot blot apparatus with mouse sera or 
supernatant from hybridoma cells (undiluted or diluted 1:1 with 5% non-fat dried milk in 
1xTBS) or control primary antibodies: NIK (Novus: NB120-7204) and actin (Santa Cruz: 
sc-1616 or 1616R) for 4 h at RT or overnight at 4ºC. The membranes were washed three 
times with 1xTBS containing 0.05% Tween-20 followed by incubation with secondary 
antibodies conjugated with IR680 and IR800 (Molecular Probes A21058 or A21084) for 
one hour at RT. Subsequent to washing three times with 1xTBS containing 0.05% 
Tween-20, membranes were scanned using the Odyssey system (Licor). 
 
Immunoprecipitation 
 HEK293 or HEK293 transfected with Flag-NIK cells were lysed as mentioned 
above and pre-cleared with 30-40 µl of protein A/G Sepharose beads for 1h at 4ºC. 
Then, 1ml of hybridoma supernatant or 1-1.5µg of antibody per 1mg of total protein was 
used to immunoprecipitate NIK for 1-2 h at 4ºC, followed by pull-down with 30-40µl of 
protein A/G Sepharose beads for another hour at 4ºC. The same amount of IgG was 
used as a negative control. The immunoprecipitate was washed three times with the 
lysis buffer, eluted with 4x Laemmli loading buffer, resolved by 8% SDS-PAGE and 
analyzed using Western blot analysis.  
 
Immunofluorescence 
 HEK293 cells plated on coverslips were fixed with 4% paraformaldehyde or 
methanol and permeabilized with 0.2% of Triton-X 100 in 1xPBS. The cells were then 
blocked with 10% normal donkey serum in 1xPBS for 30 minutes at RT and incubated 
with supernatant from hybridoma cultures (undiluted) for 2 h at RT. After the secondary 
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antibody incubation, slides were washed three times with 0.1% Tween-20 in 1xPBS and 
stained with Hoescht nuclear stain during the last wash. Coverslips were air dried and 
mounted onto glass slides. Images were taken using a 20x oil lens Plan-Apochromat on 
Zeiss Axioplan 2 microscope and Hamamatsu Orca ER fluorescence camera. Images 
were processed using Metamorph Software.  
 
Results and Discussion 
 Bacterial expression of recombinant MBP (50kD) or MBP-NIK (154kD) was 
amplified by IPTG treatment (Figure 16A). Proteins were isolated over amylose resin 
and eluted with maltose buffer as described in Methods and purity was characterized by 
SDS-PAGE with coomassie staining (Figure 16A). We observed that bacterially purified 
MBP-NIK resulted in some lower molecular weight forms of NIK despite the use of 
protease inhibitors during lysis and the attempts to use lower temperature during IPTG 
induction. This data suggests that bacteria were not able to transcribe or translate the 
full length protein due to high molecular weight or that the full length protein was 
unstable (Figure 16A). Purified MBP-NIK (both full length and smaller fragments) was 
used to immunize mice to produce NIK antibody as described in Materials and Methods.  
Sera from mice immunized with NIK antigen were examined for immunoreactivity 
with MBP-NIK and endogenously expressed NIK by Western blot analysis. Results show 
that sera from all immunized mice react with purified and recombinant NIK (Figure 16B 
and C). However, only sera from four mice (all BALB/c mice) exhibit antigenicity towards 
endogenous NIK (Figure 16D). Among these, splenic B cells from a BALBL/c mouse, 
which exhibited the strongest antigenicity, were subsequently isolated and hybridoma 
cells were generated from these B cells. Supernatant from these hybridoma cells was 
screened for recognizing endogenous and recombinant NIK expression by Western blot. 
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Among many clones tested, two of them (8H3A2 and 10A2E12) recognize both 
endogenous (asterisk) and exogenous (arrow) NIK in Western blot analysis (Figure 17A 
and B). The signal intensity from the endogenous band of NIK protein (104kD) 
recognized by 8H3A2 clone was weak compared to 10A2E12, while both clones reacted 
strongly with recombinant NIK protein (Figure 17A and B). The commercial rabbit 
polyclonal NIK antibody (Novus Biological) shows a similar pattern of NIK expression at 
the same molecular weight (compare Figure 17A and B, top and bottom panels).  
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Figure 16. Purification of NIK antigen and characterization of sera from mice 
immunized with NIK antigen. A. Coomassie stain of purified MBP or MBP-NIK. 
Protein expression was induced by using IPTG and proteins were eluted with 
amylose. B-D. Immunoblot of purified MBP-NIK (B), Flag-NIK over-expressed 
HEK293 lysate (C) and Hs294T lysate (D) using sera from mice immunized with 
antigens.  
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Immunoprecipitation experiments reveal that both 8H3A2 and 10A2E12 
monoclonal antibodies can precipitate exogenously expressed Flag-NIK (Figure 17C and 
D, arrows). Although endogenous NIK also appears to be precipitated by these 
antibodies, the intensity of the band is weak (Figure 17C and D, asterisks), suggesting 
that these antibodies may not be optimal in immunoprecipitation. Immunofluorescent 
staining using these antibodies shows a strong positive staining specific for Flag-NIK 
expressed in these cells (Figure 17E). However, 8H3A2 antibody does not show 
immunoreactivity towards endogenous NIK expressed by HEK293 cells in 
immunofluorescence (Figure 17E). 10A2E12 appears to recognize endogenous NIK in 
immunofluorescence although the specificity of this staining should be further 
characterized using NIK knock-down cells (Figure 17E). 
 
Conclusions 
 We characterized two monoclonal antibodies against NIK, 8H3A2 and 10A2E12. 
These two antibodies recognize the endogenous NIK by Western blot although the 
specificity of the recognition should be further verified by using NIK deficient cells. To 
date, we were not successful in detecting endogenous NIK expression in melanoma 
cells with wild type NIK or NIK silencing, described in Chapter II. Our monoclonal NIK 
antibodies may not be superior to commercially available polyclonal antibody from 
Novus biological because polyclonal NIK antibody recognizes multiple epitopes of the 
protein. However, for assays that specifically require monoclonal antibodies, our 
monoclonal NIK antibody will be useful since, to our knowledge, there is no commercially 
available monoclonal NIK antibody.  
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Figure 17. Characterization of NIK monoclonal antibodies, 8H3A2 and 10A2E12. 
A and B. Western blot analysis of HEK293 over-expressing an empty plasmid or 
Flag-NIK using 8H3A2 (A) or 10A2E12 (B) NIK monoclonal antibodies. Lower 
panels are immunoblots using polyclonal NIK antibody. (Blocking conditions: 1 and 
2) 5% milk in 1xTBS 3) 5% milk in 1xPBS 4) 5% milk in 1xTBST; Antibody 
incubation: 1) 5% milk in 1xTBS 2) 1% milk in 1xTBS 3) 1% milk in 1xPBS 4) 1% 
milk in 1x TBST. C and D. Immunoprecipitation of NIK using 8H3A2 (A) or 
10A2E12 (B) NIK monoclonal antibodies and immunoblotted with NIK polyclonal 
antibody. E. Immunofluorescence staining of HEK293 over-expressing Flag-NIK 
using 8H3A2 (A) or 10A2E12 (B) NIK monoclonal antibodies. Flag antibody was 
used to confirm the specificity NIK monoclonal antibodies. Hoechst staining was 
used to depict nuclei. Images were taken using a 20x oil lens and pseudo-colored.  
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CHAPTER IV 
 
CHARACTERIZATION OF NIK ASSOCIATING PROTEINS 
 
Introduction 
Although the role of NIK in activating the NF-κB pathway has been extensively 
studied, its functions in relation to other signaling pathways have been largely 
unexplored. Therefore, identifying NIK associating partners using an unbiased approach 
will give insights on novel functions of NIK. As NIK has been implicated in cancer such 
as multiple myeloma and melanoma as described in Chapter II, identification of NIK 
associating proteins will be useful to better understand the tumorigenic functions of NIK.  
Yeast-two-hybrid and mass spectrometry analyses have identified expected as 
well as novel NIK interacting proteins. Other NIK regulating proteins, which are not 
detected by mass spectrometry or yeast-two-hybrid analyses, have been also identified. 
Many of these NIK interacting proteins were identified based on their ability to modulate 
NF-κB activity. Some NIK interacting proteins, namely IKKα/β and p100, are expected 
based upon our knowledge that NIK functions to regulate NF-κB signaling. However, 
other NIK protein/protein interactions, such as interaction with heat shock protein 90 
(Hsp90), are somewhat unexpected. Although some of these proteins have been known 
to interact with the NF-κB pathway, their functions in relation to NIK have not been fully 
explored. Elucidating the nature of these interactions may reveal novel functions for NIK 
and may uncover key information on the modulation of NIK protein.   
NIK interacts with IKKα and IKKβ (details discussed in Chapter I) in addition to its 
negative regulators, cIAP1, cIAP2, TRAF2 and TRAF3, all of which are E3 ubiquitin 
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ligases (details discussed in Chapter I). In addition to TRAF2 and 3, NIK associates with 
other TRAF family members, TRAF1, 5 and 6, and those interactions have been 
implicated in TNFα and IL-1 induced NF-κB activation (Song et al., 1997). It was also 
demonstrated that IKKγ can bind to NIK (Bouwmeester et al., 2004; Li et al., 1999a). 
These interactions modulate NF-κB activation in response to different stimuli.  
A number of the NIK interacting proteins modulate the stability of NIK protein. In 
addition to the E3 ubiquitin ligases, NIK binds to a negative regulator named Monarch-1, 
which induces the proteasomal degradation of NIK (Arthur et al., 2007). Another NIK 
interacting protein, Hsp90, also affects NIK stability by protecting NIK from autophagic 
degradation (Qing et al., 2007). From the literature, we can deduce that many layers of 
degradative mechanisms may be in place to maintain a physiologically appropriate 
expression of NIK.  
In addition to destabilizing interactions, NIK can associate with a negative 
regulator that does not affect its stability. A yeast-two-hybrid screen of a human brain 
cDNA library using the N-terminus of NIK identified a novel NIK interacting protein 
named TRAFs and NIK-associating protein (TNAP). A glutathione S transferase (GST)-
pull down assay reveals that TNAP directly interacts with NIK (Hu et al., 2004). TNAP 
can markedly decrease basal, TNFα-induced and NIK over-expression-mediated NF-κB 
activation (Hu et al., 2004). TNAP attenuates the kinase activity of NIK, as evidenced by 
reduced phosphorylation of the NIK substrate, IKKα (Hu et al., 2004), yet it does not 
appear to affect NIK stability. Furthermore, TNAP negatively regulates p100/p52 
processing as well as NIK-mediated RelA phosphorylation, suggesting that it inhibits 
both canonical and non-canonical NIK activities (Hu et al., 2004). Another protein 
identified from this yeast-two-hybrid screen is NIK and IKKβ binding protein (NBIP). NIK 
directly binds to NBIP along with IKKβ, and NBIP potentiates NF-κB activation induced 
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by these two kinases upon cytokine treatment (Hu et al., 2005). Similar to TNAP, Raf 
kinase inhibitor protein (RKIP) antagonizes NIK in its ability to activate NF-κB by 
interacting with the kinase (Yeung et al., 2001). In addition to NIK, RKIP inhibits the 
ability of TAK1, another IKK kinase, thus hampering NF-κB activation (Yeung et al., 
2001). Yet, RKIP may not directly associate with these kinases, based upon negative 
data from the in vitro pull down assay using recombinant proteins (Yeung et al., 2001).  
Intriguingly, NIK interacts with death effector domain (DED)-containing proteins 
such as caspases 8, 10 and cFLIP, all of which activate NF-κB, possibly through their 
interaction with NIK and IKKs (Chaudhary et al., 2000). Over-expression of dominant 
negative NIK disrupts the activation of NF-κB, mediated by these proteins (Chaudhary et 
al., 2000). Similarly, NIK associates with the viral DEDs-containing protein vFLIP from 
human herpesvirus 8 (HHV8), which has an ability to activate NF-κB (Chaudhary et al., 
1999). These results suggest that NIK has a potential role in the signaling from death 
receptors, determining survival or cell death through NF-κB activation.  
Interestingly, epidermal growth factor receptor (EGFR) binds to NIK and RIP-1, 
forming a signaling complex to induce NF-κB activation (Habib et al., 2001). Over-
expression of a dominant negative NIK disrupts EGFR-induced NF-κB (Habib et al., 
2001). Thus, NIK may mediate cellular processes through tyrosine kinase receptor 
signaling. Consistently, screening NIK associating proteins by using antibody arrays 
identified new binding partners of NIK that are also part of the EGFR complex (Chen et 
al., 2003). Flag-NIK expressing HEK293 was incubated with the antibody array and 
novel NIK binding partners were identified in the screen. In an over-expression system, 
NIK binds to growth factor receptor bound (Grb) family members such as Grb7, Grb10 
and Grb14 (Chen et al., 2003). Endogenous NIK also interacts with Grb7 and estrogen 
receptor 2 (Erb2), suggesting that NIK is part of the EGFR complex (Chen et al., 2003). 
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Experiments using NIK knock-out MEFs strongly suggest that NIK is required for EGFR 
activation of NF-κB (Chen et al., 2003). As EGFR is over-expressed in many breast 
cancer types, NIK may have a regulatory role in breast cancer progression.  
Moreover, another activator of NIK, cancer Osaka thyroid-1 (Cot-1/Tpl-2) 
physically associates with NIK and IKKα (Lin et al., 1999). Cot-1 induces 
phosphorylation of NIK, resulting in the activation of IKKα (Lin et al., 1999). Kinase 
deficient NIK disrupts Cot-1-induced activation of IKKα and subsequent NF-κB activation 
in CD3/CD28 stimulation pathway (Lin et al., 1999).  
Mass-spectrometry analysis of NIK associating proteins has been performed 
using the tandem affinity purification (TAP) tag system (Bouwmeester et al., 2004). 
Some interesting proteins that were identified in this analysis include ribosomal proteins, 
DDX and Cdc37 [for complete list, see (Bouwmeester et al., 2004)]. The functional 
significance of these interactions has not been fully explored. Biochemical and functional 
studies are necessary to identify new roles of NIK in the context of its interacting 
partners.  
  Here, we identified NIK associating proteins by mass spectrometry analysis using 
Flag-tagged NIK over-expressed in HEK293 cells. Due to its effect on tumorigenesis and 
non-essential role in the canonical NF-κB activation, we speculated that NIK plays a role 
in other signaling pathways in addition to NF-κB activation. We reasoned that some of 
these interacting proteins may give insights into the contribution of NIK to tumorigenesis 
of melanoma or other tumors such as multiple myeloma. 
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Materials and Methods 
Immunoprecipitation and mass spectrometry 
 Flag-NIK was overexpressed in HEK293 cells using Fugene 6 (Roche 
11814443001) according to the manufacturer’s protocol. 48h after transfection, cells 
were lysed with IP lysis buffer: 10% glycerol, 50mM Tris pH 7.7, 150mM NaCl, 0.5% 
NP40 and a cocktail of protease (Sigma P8340) and phosphatase inhibitors (Sigma 
P2850 and P5726). Flag-NIK was immunoprecipitated from this lysate using an antibody 
against Flag (Sigma F1804). Prior to immunoprecipitation, Flag antibodies were 
conjugated to NHS-activated Sepharose beads (GE health care 17-0906-01) to minimize 
the amount of IgG contamination in samples eluted from Sepharose beads. 
Immunoprecipitated samples were eluted from Sepharose beads using 4x Laemmli 
loading buffer and subjected to gel electrophoresis.  Lysates run on the gel were either 
transferred to the nitrocellulose membrane to be immunoblotted with NIK antibody (sc-
6363), TRAF3 (sc-949 or sc-1828), IKKα/β (sc-7607) or subject to staining with Colloidal 
Coomassie (Invitrogen LC-6025). Once the efficiency of immunoprecipitation was 
confirmed, each lane was cut and subjected to tandem mass spectrometry analysis in 
collaboration with Vanderbilt Mass Spectrometry Research Center. An in gel tryptic 
digest was performed and the resulting peptides were subjected to tandem mass 
spectrometry by linear ion trap. The results were analyzed using Sequest and peptide 
identity was searched against the IPI human protein database. These assays were 
performed three times on Flag-NIK immunoprecipitates from HEK293 cells.  
Immunoprecipitates using IgG in Flag-NIK over-expressed HEK293 and 
immunoprecipitates using Flag antibody in empty vector expressed HEK293 were 
included as negative controls.  
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Molecular Cloning of NIK truncated mutants and full length Hsp90 
 Truncated mutants of NIK were generated by using PCR amplification of 
truncated portions from full-length NIK (kindly shared by David Goeddel, Tularik). The 
primers used were forward primer: 5’-aaggggggatccatggcagtg-3’; reverse primers: NIK_I: 
5’-acgctcgagttagccctctgtag-3’; NIK_II: 5’-gctctcgagttaccgtttcttccg-3’; NIK_III: 5’-
gggctcgagttaggggcct-3’; NIK_IV: 5’-gctctcgagttagtgtgggccagg-3’; NIK_V: 5’-
gcgctcgagttacgtggc-3’; NIK_VI: 5’-ttgctcgagttaccggttcac-3’. These NIK mutants were 
cloned into pGEX-6P-1 vector (GST-tag vector) using BamHI and XhoI sites. To 
generate His-Hsp90, full-length human Hsp90 construct (kindly shared by Len Neckers, 
NCI) was double digested with BamHI and SmaI sites and shuttled into pQE-80L vector 
(His-tag vector) using the same restriction sites.  
 
Purification of GST-NIK truncated mutants or His-Hsp90 
GST-NIK truncated mutants: An over night culture of BL-21 bacteria transformed with 
GST-NIK truncated mutant DNA was diluted to 1:10 with lysogeny broth (LB)+Ampicillin 
(Amp) (0.1mg/ml) and grown at 37ºC to an OD600 reading=0.6-0.8. The production of 
recombinant protein in the bacterial culture was subsequently induced by addition of 
IPTG (0.2mM) for 6h at 37ºC. After the induction, bacteria were pelleted, re-suspended 
in 10ml of 1xPBS with protease inhibitor (Sigma P8465) and lysed by sonication (10sec, 
4 times). After lysis, 0.5% of Triton X-100 was added to the lysate, which was 
subsequently incubated with 50µl of glutathione beads at 4ºC for 1h. After separating the 
unbound from the bound lysate, beads were re-suspended in 1xPBS and used in GST 
pull down assays or stored at -80ºC for future use.  
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His-Hsp90: An over night culture of BL-21 bacteria transformed with His-Hsp90 was 
diluted to 1:20 with LB+Amp (0.1mg/ml)+chloramphenicol (34ug/ml) and grown at 37ºC 
to an OD600 reading=0.6-0.8. The production of recombinant protein in the bacterial 
culture was induced by addition of IPTG (0.1mM) for 2h at 37ºC. After the induction, 
bacteria were pelleted, re-suspended in 10ml of 1xPBS with EDTA-free protease 
inhibitor (Roche 04693159001)+20U DNAse+2mM β-mercaptoethanol (β-ME) and lysed 
by sonication (10sec, 4 times). Lysate with 10mM of imidazole (pH 8.0) was incubated 
with TALON beads (equilibrated with binding buffer containing 50mM NaH2PO4, 500mM 
NaCl, 20mM imidazole, pH 8.0, 2mM β-ME) for 1h at 4ºC. After the unbound lysate was 
separated from the bound lysate, beads were washed with binding buffer overnight at 
4ºC. His-Hsp90 was eluted from the beads with the elution buffer containing 50mM 
NaH2PO4, 500mM NaCl, 250mM imidazole, pH 8.0 and 2mM β-ME. Eluted protein was 
dialyzed overnight at 4ºC and used in direct binding assays or stored at -80ºC for future 
use.  
 
GST pull down 
 500pmol of full length His-Hsp90 was incubated with 5pmol of GST or GST-NIK 
truncated mutants immobilized on glutathione beads and incubated for 1h at 4ºC. After 
the beads were centrifuged and the unbound portion was removed, beads were washed 
3 times with 1xPBS. His-Hsp90 directly bound to GST-NIK truncated mutants was 
resolved by 10% SDS-PAGE and analyzed by Western blot analysis.  
 
 112
Results 
To identify new NIK-interacting proteins by mass-spectrometry, Flag-NIK was 
first immunoprecipitated with Flag antibody, then subjected to polyacrylamide gel 
electrophoresis, transferred to nitrocellulose membrane, and immunoblotted with NIK 
antibody to verify the efficiency of the immunoprecipitation (Figure 18A). Once the 
efficiency of the immunoprecipitation was confirmed, immunoprecipitates were 
separated on a 8% acrylamide gel, stained with Colloidal Coomassie (Figure 18B) and 
subjected to in-gel trypsin digest, followed by tandem mass spectrometry. Negative 
controls included Flag-NIK over-expressed HEK293 cell lysate immunoprecipitated with 
IgG and empty plasmid expressed HEK293 cell lysate immunoprecipitated with Flag 
antibody. Consistent with previous studies, IKKα/β and TRAF3 co-immunoprecipitated 
with Flag-NIK, verifying the reliability of our immunoprecipitation conditions and 
techniques (Figure 18C). 
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Figure 18. Verification of Flag-NIK co-immunoprecipitation with known 
interacting proteins. A. Immunoprecipitation of Flag-NIK using Flag antibody and 
immunoblotting with NIK antibody. B. Coomassie staining of Flag-NIK 
immunoprecipitates. C. Co-immunoprecipitation of Flag-NIK, IKKα/β and TRAF3 
in HEK293. Flag-NIK was immunoprecipitated using antibody against Flag and 
immunoblotted with NIK, IKKα/β and TRAF3 antibodies. Immunoprecipitation 
from Flag-NIK over-expressing lysates using IgG or immunoprecipitation from 
lysates without Flag-NIK over-expression using Flag antibody were used as 
negative controls
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Proteins identified by immunoprecipitation with Flag-NIK followed by mass 
spectrometry in at least 2 separate experiments were as follows:  HSP90, IKKα, IKKβ, 
IKKγ, NIK, RPS3, ADP/ATP translocase, ATP-dependent RNA helicase DDX5,  isoform 
of polyadenylate-binding protein,  NCL protein, heterogeneous nuclear ribonucleoprotein 
M isoform a,  cDNA FLJ 45706fis, interleukin enhancer-binding factor 2,  isoform 5 of 
interleukin enhancer-binding factor 3, insulin receptor substrate 4, insulin-like growth 
factor 2 mRNA binding protein (Table 3). It is reassuring that proteins reported to interact 
with NIK such as IKKα , IKKβ and IKKγ (Li et al., 1999a; Ling et al., 1998; Nakano et al., 
1998) were identified (Table 3). We next determined whether some of these interactions 
can be verified in immunoprecipitation and direct binding assays.  
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Proteins identified in three 
runs 
Proteins identified in two runs 
Heat Shock Protein 90α 
(Hsp90α) 
ADP/ATP translocase (1 and 2) 
NF-κB inducing kinase (Zlotnik 
et al.) 
ATP-dependent RNA helicase 
Similar to 40S ribosomal protein 
SA 
CDNA FLJ 45706 fis, clone FEBRA 2028457, 
highly similar to Nu 
Ribosomal Protein S3 (RPS3) Hsp90 co-chaperone Cdc37 
 IKKα 
 Interleukin enhancer-binding factor 2 
 Isoform of Polyadenylate-binding protein 1 
 Isoform 5 of Interleukin enhancer-binding factor 3 
 NCL protein 
 NEMO/IKKγ 
 Probable ATP-dependent RNA helicase DDX5 
 Heterogeneous Nuclear Ribonucleoprotein M 
Isoform a 
 Insulin Receptor Substrate 4 
 Insulin-like Growth Factor 2 mRNA Binding 
Protein 1 
Table  3. NIK associating proteins identified by mass spectrometry analysis. Proteins 
identified in two and three runs were listed. 
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Verification of NIK-associating proteins 
Our preliminary data suggest that Flag-NIK interacts with both endogenous and 
exogenous Hsp90, as shown by the co-immunoprecipitation (Figure 19A and B). To 
examine whether NIK directly interacts with Hsp90 and to characterize which domains of 
NIK interacts with Hsp90, we generated truncated mutants of NIK with GST tag and full-
length Hsp90 with His tag. Schematic of NIK truncated mutants (NIK I-VI) are shown in 
Figure 19C. We purified GST-tagged truncated mutants of NIK (NIKI, NIK II and NIK IV) 
(Figure 19D and E) and full length His-tagged Hsp90 (Figure 19F). Our preliminary data 
from GST-binding experiments suggest that Hsp90 directly binds to GST-NIKII (Figure 
19F).  
 117
 
Figure 19. Verification of Flag-NIK co-immunoprecipitation with known 
interacting proteins. A and B. Co-immunoprecipitation of Flag-NIK and 
endogenous Hsp90 (A) and exogenous His-Hsp90 (B). C. Different domains of 
NIK: BR (basic region), PRR (proline rich region) and kinase domain (Xiao, et 
al. 2000). The regions of primers to generate truncated mutants of NIK are 
shown in dark arrows. D, E and F. Coomassie stain of purified GST-NIKI (D), 
GST-NIKII (E) and His-Hsp90 (F) resolved on SDS-PAGE gels. Protein 
expression was induced by IPTG and purified using GST or TALON beads. G. 
Coomassie stain of direct binding between GST-NIKII and His-Hsp90.  
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Previous studies suggest that Hsp90 regulates the stability of NIK. NIK physically 
interacts with Hsp90 through its C-terminal domain (Qing et al., 2007), although whether 
this interaction is direct or indirect is yet to be examined. Treatment of cells with the 
Hsp90 inhibitor geldanamycin dissociates NIK and Hsp90, and results in marked NIK 
degradation (Qing et al., 2007). Thus, Hsp90 appears to have a positive regulation on 
the stability of NIK. In contrast, another study demonstrated that Hsp90 is required for 
the negative regulatory role of Monarch-1 to induce NIK degradation (Arthur et al., 
2007). Thus, depending on the context, Hsp90 can positively or negatively regulate the 
stability of NIK. By modulating NIK stability, these proteins regulate p100 to p52 
processing and possibly the expression of downstream target genes. Intriguingly, Hsp90 
and another protein identified in mass spectrometry, Cdc37, are part of the IKK complex 
and geldanamycin treatment impairs TNFα-induced NF-κB activation (Chen et al., 2002). 
These two proteins are essential components of NF-κB activation.   
It is interesting to note that Hsp90 has been reported to be involved in melanoma 
malignancy. Its co-chaperone tetratricopeptide repeat containing protein (TTC4) is over-
expressed in melanoma and other cell lines derived from cancerous tissues, such as 
breast, colon and ovaries (Crevel et al., 2008). In melanoma, mutated TTC4 retains the 
interaction with Hsp90 (Crevel et al., 2008), suggesting that Hsp90 may be playing an 
important role in melanoma. Consistent with this notion, immunohistochemistry identifies 
Hsp90 expression in primary melanoma as well as in melanoma cell lines, and its 
inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) reduces proliferation rates, 
migratory and invasive abilities (Faingold et al., 2008). Similarly, monoclonal antibody 
against Hsp90 inhibits melanoma invasion and metastasis (Stellas et al., 2007). Hsp90 
is also required for stabilizing mutated BRAF (Grbovic et al., 2006), which is found in 
about 50-70% of melanoma lesions (Davies et al., 2002). Hence, studying the interaction 
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between Hsp90 and NIK may give more insight into deregulated molecular mechanisms 
of NIK in melanoma.  
  Another protein identified in all three runs, aside from Hsp90, is RPS3. To date, 
we cannot verify the interaction between NIK and RPS3 by immunoprecipitation. 
Recently, RPS3 was identified as part of NF-κB complex (Wan et al., 2007). When 
RPS3 is knocked down, expression of some NF-κB regulated genes are defective, 
suggesting that RPS3 is necessary for the transcription of a subset of NF-κB targeted 
genes (Wan et al., 2007). Recently, it was reported that IKKβ phosphorylates RPS3 and 
regulates RPS3 nuclear translocation (Wan et al., 2011). As NIK is an upstream kinase 
of IKKβ and NIK interacts with RPS3, studying the interaction between NIK and RPS3 
may elucidate novel functions of NIK in NF-κB as well as non-NF-κB pathways.  
 In addition to Hsp90 and RPS3, another interesting protein identified in mass 
spectrometry is DDX5. DDX5, also known as P68 RNA helicase, belongs to the DEAD-
box family of RNA helicases, which have RNA-dependent ATPase activity to unwind 
RNA structures or disrupt RNA-protein interactions (Rocak & Linder, 2004). Intriguingly, 
DDX5 disrupts β-catenin from the Axin complex, which normally mediates β-catenin 
destruction, and leads to nuclear accumulation of β-catenin (Yang et al., 2006b). Based 
upon our observations that NIK may affect the nuclear translocation of β-catenin and that 
NIK binds to DDX5, we postulate that NIK may regulate β-catenin nuclear transport 
through DDX5.  
 Another NIK-interacting protein, interleukin enhancer-binding factor 2, can be a 
part of a transcriptional complex along with p300 (Karmakar et al., 2010) as well as 
control mitotic regulation (Guan et al., 2008). Heterogeneous Nuclear Ribonucleoprotein 
M Isoform a is part of heterogeneous nuclear ribonucleoproteins, which bind to 
heterogeneous nuclear RNA and function in RNA processing (Dery et al., 2011). 
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Interestingly, another NIK interacting protein, ADP/ATP translocase (1 and 2) regulates 
apoptosis through recruiting IkB/NF-kB into mitochondria (Zamora et al., 2004). The 
diverse functions of these NIK interacting proteins suggest that NIK may be involved in 
cellular processes that have not been linked to NIK before. 
 
Conclusions 
 Here, we identify novel NIK associating proteins such as Hsp90, RPS3 and 
DDX5 by using mass spectrometry approach. The candidates from our list of NIK 
associating proteins greatly overlapped with the list reported by Bouwmeester et al 
(Bouwmeester et al., 2004), suggesting that the interactions are likely to be specific. 
Confirming these interactions by using co-immunoprecipitation in cell lysate, GST pull 
down and studying the functional significance will possibly lead to identification of novel 
NIK functions. The interactions between these proteins and NIK may also be important 
for tumorigenesis mediated by NIK.  
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CHAPTER V 
 
DETERMINING THE EFFECT OF NF-κB/IKKβ INHIBITION ON THE HOST IMMUNE 
SYSTEM 
 
Introduction 
 NF-κB is crucial for tumorigenesis of many tumor types, including melanoma 
(Basseres & Baldwin, 2006; Yang & Richmond, 2001).Therefore, targeting the major 
kinase of NF-κB signaling, IKKβ, turns out to be a promising target (Yang et al., 2006a; 
Yang et al., 2007a; Yang et al., 2010). As NF-κB is an important mediator of 
inflammation, cancer and other inflammatory diseases, various drugs targeting NF-κB 
have been developed in an attempt to alleviate diseases where constitituve activation of 
NF-κB may play a causal role. Drugs targeting different levels of the NF-κB pathway 
include both natural products as well as synthetic compounds (Gilmore & Herscovitch, 
2006). Some of these inhibitors are general inhibitors of inflammation whereas others 
are specific inhibitors of the NF-κB pathway (Gilmore & Herscovitch, 2006). Among 
these, some specific inhibitors have drawn attention for the treatment of certain cancers 
and inflammatory diseases. For example, MLN120B is an IKKβ inhibitor that has been 
reported to reduce the growth of multiple myeloma in vitro and in vivo (Hideshima et al., 
2006). Bortezomib (VELCADE), a proteasonal inhibitor that blocks NF-κB activation , 
has been approved for treatment of myeloma (Mulligan et al., 2007) and recently was 
shown to be useful in mouse models of lung cancer (Xue et al., 2011).  Interestingly, the 
Bay-117082 IKK inhibitor had similar effects to bortezomib in the lung model.  
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Similar to MLN120B, BMS-345541 is an allosteric small molecule inhibitor of 
IKKβ, preferably exerts its effect on IKKβ over IKKα and blocks NF-κB mediated 
transcription when administered in mice (Burke et al., 2003). Although BMS-345541 
appears to be a potential drug for melanoma therapy and other cancer therapy, systemic 
effects when used for cancer treatment are still unknown. Inhibiting NF-κB through IKKβ 
may have a potent effect on immune system, notably on B cells as they depend on NF-
κB activity for their development, activation and survival. It is established that NF-κB 
activity protects B cells from undergoing apoptosis when challenged with high amount of 
TNFα (Siebenlist et al., 2005). In addition, NF-κB controls B cells’ proliferation in 
response to stimulators of NF-κB activation. For instance, CD40L- and LPS-induced 
proliferation as well as the regulation of proliferation related genes are greatly diminished 
in cRel-/- and p50-/- cRel-/- B cells (Zarnegar et al., 2004).  
Our lab has also demonstrated that BMS-345541 induces melanoma cells to 
undergo mitochondria-dependent apoptosis, thus inhibiting melanoma growth in mice 
(Yang et al., 2006a).  Yet, in the context of the tumor microenvironment, the effect that 
BMS-345541 may have on the expression of cyotokines and effectors that regulate the 
infiltration of immune cells into the tumor should be considered. For instance, BMS-
345541 may inhibit immune infiltrates, which may support tumor cells proliferation and 
metastasis, thereby improving the cancer therapy. On the reverse side, BMS-345541 
may inhibit the infiltration of leukocytes with anti-tumor activity into the tumor. If this 
occurs, this drug may need to be administered with other immunotherapies to eliminate 
undesirable effects on tumor growth. Thus, to optimize the efficacy of the drug, the effect 
of BMS-345541 on the immune system of the tumor bearing host needs to be 
determined. Many studies suggest that NF-κB and IKKβ activity play an important role in 
both B and T cell development. Figure 20 depicts different stages of B cell development 
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and the role of NF-κB in these stages. Normally, pro-B cells are developed in the bone 
marrow up to an immature B cell stage. Then they complete their development in splenic 
follicles where they can either become resident marginal zone B cells or follicular B cells. 
Follicular B cells can enter the circulation and the follicles of other secondary lymphoid 
organs (Siebenlist et al., 2005). 
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Siebenlist et al., Nat Rev Immunol., 2005. 
(Reprint with permission from Nature) 
Figure 20. The role of NF-κB activation in different developmental stages of B cells. 
NF-κB activity determines the survival and apoptosis of B cells at early stages (pre-B 
cells and immature B cells). In addition, NF-κB activity (both canonical and non-
canonical activation) is required to maintain mature population of B cells.  
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Different transgenic mouse models reveal that IKKβ is important for mature B cell 
homeostasis. First, conditional IKKβ knock-out mice have a reduction in peripheral B 
cells due to their susceptibility to apoptosis (Burke et al., 2003). These mice also have a 
defect in mounting antibody responses to both T-cell dependent and independent 
antigens (Burke et al., 2003). Second, B-cell specific disruption of IKKβ leads to 
disappearance of marginal zone and follicular zone B lymphocytes, suggesting IKKβ is 
needed autonomously in mature B cells for their survival (Pasparakis et al., 2002). Third, 
expressing a dominant negative form of IKKβ, specifically in B cells of mice suggests 
that IKKβ is crucial for B cell proliferation and antibody response (Ren et al., 2002). Yet, 
neither developmental defect nor basal immunoglobulin production was observed in 
these mice (Ren et al., 2002). Pharmacological inhibition of IKKβ in mice with another 
IKKβ inhibitor, MLN120, reveals significant reduction of the number of B cells of all 
stages of development (Nagashima et al., 2006).  
In addition to the B cell population, NF-κB activity is important for some subsets 
of T cells. Adoptive transfer experiments suggest that IKKβ is dispensable for T cell 
development (Schmidt-Supprian et al., 2003). However, regulatory and memory T cells 
depend on IKKβ for their development and survival (Schmidt-Supprian et al., 2003; 
Schmidt-Supprian et al., 2004). Of note, Treg cells suppress helper and cytotoxic T cells 
function in melanoma, thus therapeutic efforts have been made to deplete the regulatory 
T cell population (Lizee et al., 2006). Therefore, the drug targeting IKKβ and thus 
attenuating NF-κB activation may be beneficial for melanoma therapy because of its 
potential effect on both tumor growth and the immunosuppression through Treg.  
In addition to the potential effect of BMS-345541 on the host immune system, the 
drug may alter the immune infiltrate profile within the tumor. The importance of the 
immune system during tumor development has been increasingly appreciated. Tumor 
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tissues are often infiltrated with both innate and adaptive immune cells, and the 
presence of these immune constituents can be pro- or anti-tumorigenic (Mantovani et al., 
1992). NF-κB can regulate various cytokines and chemokines in tumor cells, and these 
factors are involved in recruiting immune cells, such as macrophages, neutrophils and 
dendritic cells to the tumor microenvironment (Rollins, 2006). As a specific example, 
MCP-1/CCL2 is a chemokine regulated by NF-κB (Ueda et al., 1997) and is produced by 
melanoma (Nesbit et al., 2001). Its level influences tumor associated macrophage 
recruitment, angiogenesis and melanoma progression (Gazzaniga et al., 2007; Nesbit et 
al., 2001). Studies have shown that melanoma is infiltrated with other immune cells, 
such as cytotoxic T cells (Ladanyi et al., 2004) and dendritic cells which can participate 
in rejecting the tumor (Preynat-Seauve et al., 2007; Preynat-Seauve et al., 2006; Vermi 
et al., 2003).  
Many studies have suggested that the regulation of NF-κB is crucial not only in 
tumors but also in the ability of immune cells to influence the growth and survival of 
cancer cells. Many studies using genetic mouse models elegantly demonstrated that 
targeted deletion of IKKβ in macrophages in both hepatocellular carcinoma and colitis-
associated colon cancer reduce the tumor burden (Hagemann et al., 2009). These data 
suggest that IKKβ plays a tumor promoting role in macrophages and that inhibiting IKKβ 
in macrophages is likely to be beneficial for cancer treatment. However, it is important to 
note that these models are genetically engineered models in which IKKβ is systemically 
absent throughout tumor development.  
Therefore, in addition to these genetic models, the role of IKKβ in tumor 
associated immune cells has also been studied in other models. For instance, defective 
NF-κB activity has been reported in tumor associated macrophages (TAMs) in a 
fibrosarcoma model (Saccani et al., 2006). This defect prevents TAMs from exerting 
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anti-tumor activity (Saccani et al., 2006). Therefore, this study implies that the activity of 
NF-κB is required for TAMs to become tumor-killing M1 macrophages. Similarly, another 
study using a mouse model of mammary carcinoma also suggests that reactivating NF-
κB in tumor-promoting M2-like TAMs polarize these cells towards M1-like phenotypes 
(Guiducci et al., 2005). In contrast, in a mouse model of ovarian cancer, Hagemann et al 
have demonstrated that tumor promoting macrophages can be reverted to anti-tumor 
immune cells by targeting IKKβ (Hagemann et al., 2008).  
Similarly, the activity of IKKβ is also important for T cells to modulate tumor 
growth. For instance, anergic T cells from tumor bearing mice have defective NF-κB 
activation and therefore, are unable to express cytokines to mediate tumor rejection 
(Ghosh et al., 1994; Sundstedt et al., 1996). From the literature, it is not clear whether 
NF-κB activity in myeloid or lymphoid cells is pro- or anti-tumorigenic. It is very likely that 
the nature of NF-κB activity on tumor growth depends on tumor types as well as the 
tumor stage. Systemically inhibiting NF-κB activity by IKKβ inhibitor to hinder melanoma 
growth may alter the tumor immunology during the development of malignancy. 
Based on the literature and the studies from our lab, it is clear that NF-κB plays a 
critical role in tumorigenesis. Using genetic models and pharmacological inhibition, our 
lab has demonstrated that inhibition of NF-κB through IKKβ is a potential therapeutic 
agent for treatment of melanoma. However, we also predict that inhibiting NF-κB 
systemically may have an impact on the host immune system as well as on the tumor 
immunology in modulating malignancy of melanoma.   
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Materials and Methods 
Xenograft model 
To determine the effect of the IKKβ inhibition on B cells, C57BL/6 mice were 
injected subcutaneously with the C57BL/6-derived MelA/MIP2 mouse melanoma cells. 
For each mouse, 10x106 cells were injected into the right flank. After about two weeks 
when the tumor mass reached a detectable size (~7-8mm), BMS-345541 or solvent 
control was administered by oral gavage at the dosage of 50mg/kg (twice per day) for 15 
days (PBS treatment: n=7, BMS treatment: n=8). Experiment was performed once. 
During the drug treatment, tumor growth of the animal was monitored every five days by 
microcaliper measurements.  
Xenograft experiments using Hs294T human melanoma cells were performed as 
below. Briefly, 3x106 Hs294T cells were injected subcutaneously on the right flank of 
each nude mouse. After, xenograft tumors were allowed to grow for about two weeks, 
the tumor bearing mice were oral gavaged with solvent control or 100 mg/kg of BMS-
345541 (twice per day). Eight mice were in each treatment and the treatment lasted for 
30days (Control and BMS treatment: n=4). Experiment was performed once. 
The weight of the animals and their general health was monitored according to 
standards set by IACUC to ensure that the dosage of the drug did not have a severe 
toxicity. All mice were housed in the Vanderbilt AAALAC accredited animal facility and 
studies were performed in keeping with the principals of human care of animals 
approved by IACUC.    
 
Flow cytometry analysis 
At the end of the treatment with vehicle control or BMS-345541, splenocytes 
were collected and stained with fluorescent antibodies; CD19-PerCP-Cy5, CD21-APC, 
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CD23-PE, IgM-FITC and AA4.1-PECy7 (BD Pharmigen) to analyze mature and 
immature B cell populations. Flow cytometry analysis was performed on these 
splenocytes to examine mature B cell subsets such as, marginal zone 
(CD19+IgMhiAA4.1-CD23-CD21+), follicular zone (CD19+IgMlowAA4.1-CD23+CD21int) and; 
immature B cell subsets such as, T1 (CD19+IgMhiAA4.1hiCD23-CD21lo) and T2 
(CD19+IgMhiAA4.1+CD23+CD21int). In addition, splenic T cell population was examined in 
these treated and control mice by staining with CD3-FITC (BD Pharmigen: 110-81-31). 
Flow cytometry analysis was performed using Beckman coulter machine.  
 
Measurement of immunoglobin levels in BMS-345541 treated mice 
To study the effect of BMS-345541 on B cell functions, the basal level of 
immunoglobulins from sera of BMS-345541 or vehicle treated mice was measured.  
Sera collected from mice were diluted 1:100 in 1xPBS and the immunoglobulin level was 
determined by ELISA (Southern Biotech 5300-01; 5300-05), following the manufacture’s 
protocol.  
 
Results 
Although the effect of BMS-345541 was tested using human melanoma cells, its 
effect has not been determined using a mouse melanoma cell line such as MelA/MIP2. 
To examine the drug effect on this cell line in vitro, cells were treated with a range of 
drug concentrations (25µM to 100µM) or DMSO. Figure 21A shows that BMS-345541 
kills MelA/MIP2 tumor cells in vitro in a dosage dependent manner.   
Although the effect of BMS-345541 on tumor growth in immunodeficient mice 
was tested using human melanoma cells, the effect of the drug had not been determined 
in immunocompetent mice. To determine whether systemic IKKβ inhibition in 
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immunocompetent mice would inhibit tumor growth, we examined the effect of 
BMS345541 on the growth of the Mel/MIP2 cell in C57Bl/6 mice. Once palpable tumors 
were formed, we treated tumor-bearing mice with vehicle control or BMS-345541 for 15 
days. There was not a statistically significant difference in tumor size between control 
and BMS-345541 treated mice (Figure 21B). Long-term treatment, a larger sample size 
and/or a higher dosage of the drug may be necessary to observe a significant response 
of melanoma to the drug.  
 
Effect of systemic IKKβ inhibition on the host immune system 
As IKKβ is crucial for the development and survival of B and T cells, how the 
IKKβ inhibitor may affect the host adaptive immune system was determined by 
examining the composition of splenic B-cells and T-cells. Splenocytes from PBS and 
BMS-345541 treated mice were stained with B220, IgM, AA4.1, CD21 and CD23 to 
examine B cell population or with CD45, CD3 and 7AAD to examine T cell population. 
Figure 21C suggests that marginal zone and immature T1 cell populations are slightly 
diminished in BMS-345541 treated mice compared to the PBS treatment group. These 
data agree with the studies reporting that interfering IKKβ activity by genetic disruption or 
pharmacological inhibition using MLN120B (300mg/kg) leads to apoptosis in B cell 
population (Li et al., 2003; Nagashima et al., 2006; Pasparakis et al., 2002; Ren et al., 
2002). Likewise, total T cell population was slightly decreased in drug treated mice 
(Figure 21E). These data suggest that IKKβ inhibition may have an effect on the host 
immune system.  
As IKKβ is involved in antibody production (Ren et al., 2002), basal 
immunoglobulin response was measured in mice treated with PBS or BMS-345541. No 
apparent difference was observed in basal immunoglobulin production between these 
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two groups, suggesting that BMS-345541 does not have a significant effect on antibody 
production (Figure 21D). 
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Figure 21. Effects of BMS-345541 on melanoma tumor growth and the host 
immune system. A. BMS-345541 causes MelA/MIP2 tumor cell death in vitro. 
0.1x106 cells were plated in a 12-well plate and treated with different concentrations 
of BMS-345541. After 48 and 72 h, cells were trypsinized and counted using a 
hemacytometer. DMSO was used a control. B. Tumor size of control and BMS-
345541 treated mice over time. MelA/MIP2 cells were subcutaneously injected into 
C57/BL6 mice. Once the tumors reached a palpable size, mice were treated with 
BMS-345541 or 1xPBS for 15 days (50mg/kg, twice a day). C.   Compared to the 
control, immature T1 B cell (CD19+IgM+CD21lo) and marginal zone B cell number 
(CD19+CD23-CD21hi) decrease in mice treated with BMS-345541. There is no 
statistically significant difference in number of follicular (CD19+CD23+CD21int) and 
T2 (CD19+IgM+CD21int) cells between treated and untreated groups.  
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D. Immunoglobulin response by B cells was not affected by treatment with BMS-
345541. Serum was collected from mice treated with either PBS or BMS-345541 
after 15days of treatment. Immunoglobulin levels were determined by ELISA 
(SouthernBiotech). E. The total number of T-cells (CD45+CD3+7-AAD-) in BMS-
345541 treated mice is reduced compared to the control mice treated with PBS. 
(PBS: n=7, BMS-345541: n=8). Tumor bearing C57/BL6 mice were treated with 
either PBS or BMS-345541 (75mg/kg twice per day) for 15days. On the 16th day, 
mice were treated with either PBS or BMS-345541 three hours before they were 
sacrificed. Subsequently, splenocytes were isolated from these mice and stained 
with A) CD45, CD3 and 7-AAD or B) IgM, CD19, CD21, CD23 and AA4.1, followed 
by FACS analysis. The data was analyzed by Mann-Witney test (n=7 in PBS 
treated; n=8 in BMS-345541 treated). 
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Effect of IKKβ inhibition on immune infiltrates in melanoma 
 As IKKβ and NF-κB are important in tumor associated immune cells, we 
hypothesized that the composition of immune infiltrates would be different in BMS-
345541 treated tumors. This hypothesis was tested using nude mice carrying Hs294T 
human melanoma xenograft tumors. Hs294T cells were subcutaneously injected into 
nude mice and they were treated with BMS-345541 for 30 days once the tumors 
reached palpable sizes. Vehicle treatment was used as a control. Tumors were 
harvested at the end of the treatment, sectioned and immuno-stained with antibodies 
against neutrophil antigen or F4/80 (macrophages). A marked increase in the number of 
immune infiltrates (both neutrophils and macrophages) was observed in BMS-345541 
treated tumors (Figure 22A and B). These data suggest that inhibiting IKKβ may 
influence the immune effectors during melanoma growth, thereby altering the tumor 
response to the drug.  
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Figure 22. Effects of BMS-345541 on the immune infiltrates of melanoma tumors. A 
and B. The amount of the macrophage (A) and neutrophil (B) infiltrates is higher in 
tumors treated with BMS-345541 compared to the vehicle control. Hs294T 
melanoma cells were injected into nude mice (1×106 cells per mice). After about two 
weeks, treatment of tumor bearing mice with vehicle or BMS-345541 (100mg/kg, 
twice per day) was initiated. After 30 days of treatment, mice were sacrificed and 
tumors were embedded in paraffin. Tumor slides were stained with antibodies to the 
neutrophil marker (Abcam: ab2557-50) or the F4/80 macrophage marker (Serotec: 
MCAP497). Images were taken at 20x and 20 fields per slide were counted for the 
positive staining. A total of four tumor sections were counted for each stain analysis. 
Mann-Witney test was performed to assess the statistical significance.  
BA 
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Discussion and Conclusions 
 The activity of NF-κB potently promotes tumorigenesis in various cancer types 
due to its role as a master regulator of many growth factors, cytokines and chemokines 
and pro-survival proteins (Basseres & Baldwin, 2006). In parallel, its functions are vital to 
many normal biological functions including immune regulation. Therefore, disruption of 
NF-κB through IKKβ inhibitor may not only inhibit tumor growth but also alter the tumor 
microenvironment through regulation of the immune system. The role of NF-κB in tumor 
immunology has been increasingly apparent. Yet, the controversy of whether NF-κB 
activity in immune constituents is pro-tumorigenic or anti-tumorigenic remains unsettled. 
For example, whether NF-κB activation in TAMs is growth promoting or cytotoxic for 
tumor cells is a topic of dispute (Lawrence, 2011). Cancer is a complex disease, 
constantly evolving along with its microenvironment. Hence, altering its 
microenvironment can immensely change the tumor biology. As we have now begun to 
understand that chronic inflammation can lead to cancer progression and that NF-κB is a 
molecular link to inflammation (Balkwill & Coussens, 2004), better elucidation of the role 
of NF-κB in tumor immunology will advance the field of cancer therapy. 
Here, we demonstrated that inhibition of IKKβ using BMS-345541 diminishes the 
number of some B-cell subsets in the host and increases immune infiltrates into 
melanoma tumors. Although the results are preliminary, our data suggest that the use of 
BMS-345541 in cancer therapy should proceed with caution as it may influence the 
tumor immunology and host defense mechanism. Further analysis of the effects of IKKβ 
inhibition on tumor immunology is warranted to provide insight into appropriate ways to 
use combination therapy to achieve optimal efficacy.  
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CHAPTER VI 
 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
Conclusions 
In our efforts to find an improved therapy for melanoma, we have identified the 
transcription factor NF-κB and its major regulator IKKβ kinase as potential therapeutic 
targets. NIK is one of the upstream kinases of NF-κB which offers a therapeutic 
opportunity. We hypothesized that NIK is important for melanoma tumorigenesis and 
that disruption of NIK attenuates melanoma growth. In this study, we have demonstrated 
that NIK expression is up-regulated in dysplastic nevi, primary melanoma and metastatic 
melanoma compared to benign nevi. NIK depletion in melanoma decreases proliferation, 
increases apoptosis, and results in a cell cycle progression defect. Gene expression 
analysis of NIK knock-down melanoma cells and xenograft tumors suggests that NIK 
modulates expression of pro-tumorigenic genes such as CXCR4, c-MYC, c-MET and 
LIN28B. In addition to these genes, NIK regulates the expression of some pro-survival 
proteins such as cIAP1, survivin and BCL2. By modulating the expression of above 
mentioned genes, NIK contributes to multiple aspects of cancer progression, as detailed 
in the “Hallmarks of Cancer” by Hanahan and Weinberg (Hanahan & Weinberg, 2000) 
such as evasion from apoptosis, self-sufficiency in growth signals and limitless 
replicative potential (Figure 23).  
We also show for the first time that NIK modulates the occupancy of β-catenin on 
the survivin promoter, thereby regulating the expression of this pro-survival/pro-
tumorigenic protein. We also show that NIK may modulate the stability of β-catenin 
through ubiquitination. Intriguingly, nuclear accumulation of β-catenin is lower in NIK 
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deficient cells. These data suggest that NIK regulates the sub-cellular localization of β-
catenin, either directly or indirectly.  
Here, we identify novel NIK-associating proteins by mass spectrometry analysis. 
In addition to known NIK interacting proteins including IKKα, IKKβ and IKKγ, novel 
proteins such as Hsp90, RPS3 and DDX5, which play important roles in NF-κB or β-
catenin activation, are identified. Further analysis of these interactions should reveal 
novel functions of NIK and may give additional insight into the biological functions and 
potential pro-tumorigenic roles of NIK. Increased understanding of these protein 
interactions will be useful when considering NIK as a target for cancer therapy.  
Due to an interest in using IKKβ inhibitor in treating melanoma or cancer with 
aberrant NF-κB activation, determining the effects of the inhibitor on the host is of 
interest. Here, we demonstrate that an IKKβ inhibitor, BMS-345541, alters the host 
immunity as well as immune responses to tumors. Specifically, BMS-345541 treatment 
decreases subsets of B cell and total T cell population. It also alters the composition of 
immune infiltrates to the tumors. Although detailed mechanisms need to be explored to 
determine whether IKKβ inhibition creates a pro- or anti-tumor microenvironment, these 
results generate new hypotheses regarding the role of NF-κB and IKKβ in tumor 
immunology of melanoma.  
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Modified from Hanahan and Weinberg, Cell. 2000. 
Figure 23. Working model of NIK roles in melanoma tumorigenesis. We 
demonstrate that NIK mediates melanoma tumor growth and expression of genes 
crucial for tumorigenesis. We also demonstrate, for the first time, that NIK can 
regulate expression of some pro-survival genes through the β-catenin pathway. By 
regulating pro-tumorigenic/pro-survival gene expression, NIK impacts on some 
important processes of cancer progression (self-sufficiency in growth signals, 
evasion from apoptosis and limitless replicative potential). As NIK regulates the 
expression of pro-survival factors, yet is not an essential kinase for the canonical 
NF-κB pathway, our data suggest that NIK offers a promising therapeutic target for 
malignant melanoma.  
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Future Directions 
 
Contribution of NIK to melanoma tumorigenesis 
Although we have demonstrated that NIK plays an important role in melanoma 
growth, many questions remain unanswered. Most importantly, mouse models to verify 
the importance of NIK in melanoma are necessary before NIK can be pursued as a valid 
therapeutic target. Using the existing mouse models, NIK knock-out mice (Yin et al., 
2001) can be crossed with immunocompetent mice that spontaneously develop 
melanoma, HRasV12 in Ink4a/Arf-/- background (Chin et al., 1997). To specifically identify 
NIK oncogenic functions in melanocytes, mice with Nikf/f expressing Tyr-rtTA and TetO-
Cre genes, which will have a deletion of Nik only in melanocytes, are needed. Then, 
these mice can be interbred with mice carrying HRasV12 in Ink4a/Arf background. These 
in vivo models will confirm the necessity of NIK functions in Ras-mediated melanoma 
growth and progression. Similar studies might also be informative using the BRAF/PTEN 
mouse model where mutant BRAF is expressed in an inducible manner in melanocytes 
where PTEN is inducibly lost (Dankort et al., 2009).  Since this mouse model leads to 
metastatic phenotype, it will also address the question of whether or not NIK over-
expression is vital for metastatic potential of melanoma. It is interesting to note that NIK 
expression is elevated starting from the dysplastic nevus stage and its expression 
remains elevated in metastatic melanoma. Therefore, it is likely that the functions of NIK 
are necessary throughout the progression of melanoma.   
In vitro studies reported in this dissertation raise many biologically important 
questions. For example, we have not determined how NIK affects cell cycle progression 
of melanoma. It is likely that reduction of cyclinD2 and survivin in NIK deficient cells 
impairs some aspects of cell cycle. CyclinD2 is a cyclin that mediates progression from 
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G1 to S phase and survivin regulates mitosis as being part of the chromosomal 
passenger complex. To determine whether cell cycle progression in NIK deficient cells 
was impaired through the functions of cyclinD2 and survivin, these proteins can be re-
expressed in cells with NIK depletion followed by cell cycle analyses.   
Another interesting question is whether the non-canonical pathway of NF-κB 
contributes to the melanoma growth. It has been reported  that p100 or p52 is pro-
tumorigenic in some tissue types such as breast (Connelly et al., 2007; Demicco et al., 
2005). Some of the downstream targets of the non-canonical NF-κB pathway 
[CCL21/SLC, CCL19/ELC, CXCL13/BLC, BAFF (Bonizzi et al., 2004; Dejardin et al., 
2002), RANKL (Senftleben et al., 2001)] may play a more prominent role in in vivo, due 
to their interaction with appropriate receptors on cells in the microenvironment such as 
immune cells and tumor cells (Zlotnik et al., 2011). However, some genes that are 
downstream of p100/p52 [PIM2 (Chen et al., 2008; Lesley et al., 2004), CXCR4 (Luftig et 
al., 2004), CXCL12/SDF1 (Bonizzi et al., 2004; Dejardin et al., 2002), BCL2 (Viatour et 
al., 2003)] are more likely to have cell autonomous effects. Therefore, targeting p100 in 
melanoma cells will clarify whether the non-canonical pathway contributes to melanoma 
tumor growth.  
In this study, we have not addressed how NIK activation occurs in melanoma. 
Literature to date suggests that NIK can be phosphorylated at Thr559 to be activated or 
NIK stabilization leads to downstream functions such as p100 to p52 processing. Lack of 
reliable antibody to detect Thr559 on NIK makes it difficult to determine whether NIK 
phosphorylation is required for NIK pro-tumorigenic activity in melanoma or whether 
stabilization of NIK is sufficient to execute its subsequent functions. Mass-spectrometry 
analysis in combination with NIK immunoprecipitation may be employed to determine 
whether phosphorylation status of NIK is different in melanocytes compared to 
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melanoma cells. However, antibodies currently available to immunoprecipitate 
endogenous NIK are not highly reliable. Therefore, production of reliable phospho-NIK 
antibody will help greatly in answering many questions regarding NIK functions during 
cancer development.  
Mass spectrometry analysis to identify NIK associating proteins also generates 
interesting questions. While our study utilized HEK293 cells to identify NIK interacting 
proteins, if it were possible to do these experiments in melanoma tumor cells and normal 
melanocytes, additional insights might be gained. Due to the technical challenges of 
immunoprecipitating endogenous NIK, it will be useful to express a tagged NIK protein in 
melanoma cells to achieve this, possibly under the control of an inducible promoter to 
overcome any negative effects of long-term over-expression of NIK. 
 
Fundamental questions of NIK regulation 
Although NIK has been reported to be stabilized in different tumor types, two 
fundamental questions regarding NIK regulation remain unanswered. What is/are the 
lysine residue(s) on NIK that are responsible for NIK ubiquitination and degradation? 
Which ubiquitin ligases are absolutely necessary for NIK ubiquitination and degradation? 
As we have discussed extensively in Chapter I, four E3 ubiqiutin ligases cIAP1/2 and 
TRAF2/3, to date, have been reported to be responsible for NIK degradation. However, 
we have yet to identify which of these ligases conjugate a ubiquitin chain to NIK in an in 
vitro ubiquitination assay. In addition, mutagenesis study of different lysine residues on 
NIK in combination with mass spectrometry analysis will identify definite residue(s) 
leading to ubiquitination and degradation of the protein. In fact, it has not been 
demonstrated that endogenous NIK is ubiquitinated and we have inferred from 
ectopically expressed NIK ubiquitination (Liao et al., 2004) that endogenous NIK is poly-
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ubiquitinated. Answering the above mentioned questions will shed light on how to screen 
for mutations in NIK and/or other proteins which lead to NIK accumulation in many types 
of cancers, and subsequently how to rationally design targeted therapy to inhibit NIK 
activity.   
 
NIK regulation of β-catenin activity 
Since we have demonstrated that NIK influences β-catenin occupancy on the 
survivin promoter, more detailed mechanisms of how NIK regulates β-catenin will be 
intriguing to pursue. Our initial experiments show that NIK and β-catenin interact, and 
that loss of NIK results in diminished nuclear localization of β-catenin. Yet, detailed 
mechanisms still remain elusive. Does NIK directly interact with β-catenin and modulate 
its nuclear accumulation? Alternatively, is this modulation through another protein which 
is in complex with both β-catenin and NIK? Interestingly, NIK-interacting protein DDX5 
(reported in Chapter III) can determine the level of nuclear β-catenin (Yang et al., 
2006b). Therefore, verifying interaction between NIK and DDX5 and studying how this 
interaction may influence β-catenin will be worth pursuing.  
In addition to nuclear localization, NIK may regulate the stability and post-
translation modification of β-catenin. Increased β-catenin ubiquitination observed in NIK 
deficient cells is consistent with the model that NIK depletion destabilizes β-catenin 
through ubiquitination. To further support of this model, we have observed stabilization 
of β-catenin in NIK over-expressing cells. However, we have not observed consistently 
to date that β-catenin expression is decreased in NIK deficient cells. It is likely that β-
catenin expression is dynamic. The difference in expression may not be observed unless 
β-catenin protein expression levels are determined after treatment with MG132. Our 
preliminary data suggest that MG132 treatment fails to stabilize β-catenin expression in 
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NIK knock-down cells. Biochemical assays to monitor β-catenin half-life and to 
determine β-catenin post-translational modifications are necessary to determine whether 
or not NIK promotes β-catenin activity by regulating its stability. 
 
NIK as a therapeutic target 
 NIK is proposed to be a therapeutic target for diseases such as cancer due to its 
non-essential role in the canonical NF-κB activation crucial for diverse biological 
processes, while it has an essential role in the modulation of expression of pro-
tumorigenic genes. This proposal is further supported by findings in multiple myeloma 
and lymphoma which suggest that frequent genetic mutations in these tumors (such as 
TRAF3, cIAPs and MALT1-cIAP2 fusion protein) stabilize the expression of NIK, 
resulting in downstream oncogenic functions mediated through stabilized NIK. Here, we 
also demonstrated that NIK mediates melanoma growth and survival.    
While further analyses are in place to validate NIK as a target in cancer, effects 
of NIK systemic inhibition should also be examined when NIK inhibitors are used to treat 
diseases. Characterization of NIK knock-out mice or aly/aly mice, which have defective 
NIK, suggest that NIK plays a central role in many immunological processes such as 
antibody production (Garceau et al., 2000), regulation of Treg (Lu et al., 2005) and 
functions of Th17 (Jin et al., 2009). A recent report on NIK suggests that the activity of 
NIK is critical in DCs to stimulate effector functions of CD4+ T cells (Hofmann et al., 
2011).  In parallel, another recent report demonstrates that NIK supports the generation 
of follicular helper T cells by regulating inducible costimulator ligand (ICOSL) in B cells 
(Hu et al., 2011). Both of these reports suggest that systemic use of NIK inhibitors may 
impair T cell functions and subsequently weaken tumor rejection. In light of these recent 
reports and previous literature, NIK inhibitors should not be used long-term, when 
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utilized as a cancer therapy, since NIK orchestrates the proper functioning of the 
immune system. However, NIK knock-out mice are not embryonic lethal, suggesting that 
the deleterious effects from the use of NIK inhibitors can be alleviated. Thus, studies 
addressing the side effects of systemic inhibition of NIK will provide directions for the 
safe and efficacious use of NIK inhibitors. 
Although NIK is a non-essential kinase of the canonical NF-κB activation based 
on the genetic study (Yin et al., 2001), depletion of NIK in some cancers such as multiple 
myeloma and T cell leukemia decreases canonical NF-κB activity (Annunziata et al., 
2007; Keats et al., 2007; Saitoh et al., 2008). Yet, we did not observe a reduction of the 
canonical NF-κB activation in melanoma cells. As the canonical NF-kB acitivity plays 
more diverse roles in various cellular processes, it is important to closely examine the 
effects of NIK on the canonical NF-κB functions when NIK is targeted for cancer therapy. 
Understanding this aspect of NIK will be useful in assessing the safety of NIK inhibition.  
Recently, a new oncogenic mutant of NIK has been reported in lymphoma with 
MALT1-cIAP2 fusion protein (Rosebeck et al., 2011). This mutant form of NIK lacks 
TRAF3-binding domain and therefore it cannot be degraded. Yet, it still functions as a 
kinase, resulting in mis-regulated activity of NIK (Rosebeck et al., 2011). Discovery of 
this mutant expands our view on oncogenic potential of NIK. Not only stabilization of NIK 
but also dominant active NIK can be pro-tumorigenic. Similar dominant active forms of 
NIK may yet to be discovered in other types of tumors.  
In this dissertation, we have demonstrated that NIK plays a central role in 
melanoma growth and survival by modulating expression of genes crucial for different 
aspects of tumor progression. We also link NIK to another transcriptional regulator, β-
catenin and identify novel NIK-interacting proteins. This study has provided insights and 
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opportunities to advance the field in understanding NIK functions and its oncogenic 
potential.     
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APPENDIX 
 
 
First Run   
Protein Name Accession Number Peptides 
12 kDa protein IPI:IPI00373857.1 K.SDGIYIINLK.R 
  R.KSDGIYIINLK.R 
14-3-3 protein epsilon IPI:IPI00000816.1 K.LIC*C*DILDVLDK.H 
  R.NLLSVAYK.N 
25 kDa protein IPI:IPI00026138.4 K.FKLITEDVQGK.N 
  K.LIPDSIGKDIEK.A 
  K.TSYAQHQQVR.Q 
  R.EVQTNDLK.E 
40S ribosomal protein S10 IPI:IPI00008438.1 
K.AEAGAGSATEFQFR.
G 
  
K.KAEAGAGSATEFQFR
.G 
  R.DYLHLPPEIVPATLR.R
  R.IAIYELLFK.E 
40S ribosomal protein S11 IPI:IPI00025091.2 K.C*PFTGNVSIR.G 
  K.EAIEGTYIDKK.C 
  R.AYQKQPTIFQNK.K 
  R.DYLHYIR.K 
40S ribosomal protein S12 IPI:IPI00013917.1 K.ESQAKDVIEEYFK.C 
  K.LGEWVGLC*K.I 
  K.TALIHDGLAR.G 
40S ribosomal protein S13 IPI:IPI00221089.4 K.GLAPDLPEDLYHLIK.K
  K.GLSQSALPYR.R 
Table A1. Proteins identified in mass spectrometry analysis of HEK293 over-
expressing Flag-NIK. Proteins identified in IgG control or Flag 
immunoprecipitation using HEK293 without Flag-NIK over-expression are 
substracted. Peptide hits that were used to identify the protein were shown.  
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  K.GLTPSQIGVILR.D 
  K.KGLTPSQIGVILR.D 
  K.LTSDDVKEQIYK.L 
  R.DSHGVAQVR.F 
40S ribosomal protein S14 IPI:IPI00026271.4 
K.ADRDESSPYAAMLAA
QDVAQR.C 
  K.TPGPGAQSALR.A 
  R.C*KELGITALHIK.L 
  R.TKTPGPGAQSALR.A 
40S ribosomal protein S15a IPI:IPI00221091.8 K.WQNNLLPSR.Q 
  R.FDVQLKDLEK.W 
  R.M#NVLADALK.S 
40S ribosomal protein S16 IPI:IPI00221092.7 K.ALVAYYQK.Y 
  K.EIKDILIQYDR.T 
  K.GPLQSVQVFGR.K 
  K.LLEPVLLLGK.E 
40S ribosomal protein S18 IPI:IPI00013296.2 K.IAFAITAIK.G 
  K.IPDWFLNR.Q 
  K.RAGELTEDEVER.V 
  K.YSQVLANGLDNK.L 
  R.AGELTEDEVER.V 
  R.VITIMQNPR.Q 
  R.VLNTNIDGR.R 
40S ribosomal protein S19 IPI:IPI00215780.4 K.DVNQQEFVR.A 
  
K.HKELAPYDENWFYTR
.A 
  K.LKVPEWVDTVK.L 
  R.IAGQVAAANK.K 
  R.RVLQALEGLK.M 
  R.VLQALEGLK.M 
40S ribosomal protein S2 IPI:IPI00013485.3 K.AEDKEWMPVTK.L 
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  K.ATFDAISK.T 
  K.SLEEIYLFSLPIK.E 
  K.SPYQEFTDHLVK.T 
  K.TYSYLTPDLWK.E 
  R.GC*TATLGNFAK.A 
  R.GTGIVSAPVPK.K 
40S ribosomal protein S20 IPI:IPI00012493.1 K.DTGKTPVEPEVAIHR.I
  K.TPVEPEVAIHR.I 
  K.VC*ADLIR.G 
  R.LIDLHSPSEIVK.Q 
40S ribosomal protein S23 IPI:IPI00218606.6 K.ANPFGGASHAK.G 
  K.VANVSLLALYK.G 
  R.KGHAVGDIPGVR.F 
40S ribosomal protein S25 IPI:IPI00012750.3 K.LITPAVVSER.L 
  R.AALQELLSK.G 
  R.GSLARAALQELLSK.G
  R.NTKGGDAPAAGEDA.-
40S ribosomal protein S3 IPI:IPI00011253.3 K.AELNEFLTR.E 
  K.DEILPTTPISEQK.G 
  K.GC*EVVVSGK.L 
  K.IMLPWDPTGK.I 
  K.LLGGLAVR.R 
  R.AC*YGVLR.F 
  R.ELAEDGYSGVEVR.V 
  R.ELTAVVQKR.F 
  R.FGFPEGSVELYAEK.V
  R.GLC*AIAQAESLR.Y 
  R.TEIIILATR.T 
40S ribosomal protein S3a IPI:IPI00419880.5 K.AC*QSIYPLHDVFVR.K
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  K.APAM#FNIR.N 
  K.APAMFNIR.N 
  K.ATGDETGAKVER.A 
  K.DWYDVK.A 
  K.TTDGYLLR.L 
  R.LFC*VGFTK.K 
  
R.VFEVSLADLQNDEVA
FR.K 
40S ribosomal protein S4, X isoform IPI:IPI00217030.9 K.DANGNSFATR.L 
  
K.FDTGNLC*MVTGGAN
LGR.I 
  K.GIPHLVTHDAR.T 
  K.LTGVFAPR.P 
  R.EC*LPLIIFLR.N 
  R.HPGSFDVVHVK.D 
  R.LKYALTGDEVKK.I 
  R.LSNIFVIGK.G 
  R.TIRYPDPLIK.V 
40S ribosomal protein S5 IPI:IPI00008433.3 K.AQC*PIVER.L 
  
K.TIAEC*LADELINAAK.
G 
  R.VNQAIWLLC*TGAR.E
40S ribosomal protein S6 IPI:IPI00021840.1 K.DIPGLTDTTVPR.R 
  K.LFNLSKEDDVR.Q 
  K.LIEVDDER.K 
  K.NKEEAAEYAK.L 
  
R.M#ATEVAADALGEEW
K.G 
40S ribosomal protein S7 IPI:IPI00013415.1 K.DVNFEFPEFQL.- 
  
K.LTGKDVNFEFPEFQL.
- 
40S ribosomal protein S8 IPI:IPI00216587.8 K.ISSLLEEQFQQGK.L 
  K.LTPEEEEILNK.K 
 151
  K.NC*IVLIDSTPYR.Q 
  R.ADGYVLEGK.E 
  R.IIDVVYNASNNELVR.T
40S ribosomal protein S9 IPI:IPI00221088.4 K.LIGEYGLR.N 
  K.QVVNIPSFIVR.L 
  R.IGVLDEGK.M 
  R.LFEGNALLR.R 
  R.RLFEGNALLR.R 
  R.RLQTQVFK.L 
60S acidic ribosomal protein P0 IPI:IPI00008530.1 
K.AFLADPSAFVAAAPV
AAATTAAPAAAAAPAK.
V 
  K.C*FIVGADNVGSK.Q 
  K.IIQLLDDYPK.C 
  K.TSFFQALGITTK.I 
  R.GHLENNPALEK.L 
  R.GNVGFVFTK.E 
  R.GTIEILSDVQLIK.T 
60S ribosomal protein L10a IPI:IPI00412579.5 K.KYDAFLASESLIK.Q 
  K.VSRDTLYEAVR.E 
  K.YDAFLASESLIK.Q 
  R.DTLYEAVR.E 
60S ribosomal protein L12 IPI:IPI00024933.3 
K.EILGTAQSVGC*NVDG
R.H 
  K.IGPLGLSPK.K 
  
R.C*TGGEVGATSALAP
K.I 
  
R.QAQIEVVPSASALIIK.
A 
60S ribosomal protein L13 IPI:IPI00465361.3 K.LATQLTGPVM#PVR.N
  R.GFSLEELR.V 
60S ribosomal protein L13a IPI:IPI00304612.8 K.VFDGIPPPYDKK.K 
  K.YQAVTATLEEK.R 
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  R.LAAIVAK.Q 
60S ribosomal protein L18 IPI:IPI00215719.5 K.GC*GTVLLSGPR.K 
  K.ILTFDQLALDSPK.G 
  K.TAVVVGTITDDVR.V 
  
K.TAVVVGTITDDVRVQ
EVPK.L 
  R.TNRPPLSLSR.M 
  R.TNSTFNQVVLK.R 
  R.TNSTFNQVVLKR.L 
  R.VQEVPK.L 
60S ribosomal protein L18a IPI:IPI00026202.1 R.DLTTAGAVTQC*YR.D
  R.IFAPNHVVAK.S 
60S ribosomal protein L19 IPI:IPI00025329.1 K.LLADQAEAR.R 
  
K.VWLDPNETNEIANAN
SR.Q 
60S ribosomal protein L21 IPI:IPI00247583.4 
R.TNGKEPELLEPIPYEF
M#A.- 
  
R.TNGKEPELLEPIPYEF
MA.- 
  
R.VYNVTQHAVGIVVNK.
Q 
60S ribosomal protein L23 IPI:IPI00010153.5 K.GSAITGPVAK.E 
  K.NLYIISVK.G 
  
R.ISLGLPVGAVINC*AD
NTGAK.N 
  
R.LNRLPAAGVGDM#VM
#ATVK.K 
  
R.LPAAGVGDMVMATV
K.K 
60S ribosomal protein L23a IPI:IPI00021266.1 K.EAPAPPKAEAK.A 
  K.KLYDIDVAK.V 
  K.VNTLIRPDGEKK.A 
  R.LAPDYDALDVANK.I 
  
R.LAPDYDALDVANKIGII
.- 
60S ribosomal protein L24 IPI:IPI00306332.4 K.VFQFLNAK.C 
  R.AITGASLADIM#AK.R 
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  R.AITGASLADIMAK.R 
  R.TDGKVFQFLNAK.C 
60S ribosomal protein L27 IPI:IPI00219155.4 K.VVLVLAGR.Y 
  R.YSVDIPLDK.T 
60S ribosomal protein L3 IPI:IPI00550021.3 K.IGQGYLIK.D 
  K.NNASTDYDLSDK.S 
  
R.ERLEQQVPVNQVFG
QDEM#IDVIGVTK.G 
  R.HGSLGFLPR.K 
  
R.LEQQVPVNQVFGQD
EM#IDVIGVTK.G 
  
R.LEQQVPVNQVFGQD
EMIDVIGVTK.G 
60S ribosomal protein L30 IPI:IPI00219156.6 K.LVILANNC*PALR.K 
  K.SLESINSR.L 
  R.KSEIEYYAM#LAK.T 
  R.KSEIEYYAMLAK.T 
  
R.VC*TLAIIDPGDSDIIR.
S 
60S ribosomal protein L36 IPI:IPI00216237.4 R.EELSNVLAAMR.K 
  R.EVC*GFAPYER.R 
60S ribosomal protein L37a IPI:IPI00414860.5 K.KIEISQHAK.Y 
  
K.TVAGGAWTYNTTSAV
TVK.S 
60S ribosomal protein L4 IPI:IPI00003918.5 K.AAAAAAALQAK.S 
  K.M#INTDLSR.I 
  R.IEEVPELPLVVEDK.V 
  R.KLDELYGTWR.K 
  R.NIPGITLLNVSK.L 
  R.PLISVYSEK.G 
  
R.PLISVYSEKGESSGK.
N 
  
R.QPYAVSELAGHQTSA
ESWGTGR.A 
  
R.YAIC*SALAASALPALV
M#SK.G 
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60S ribosomal protein L5 IPI:IPI00000494.5 R.DIIC*QIAYAR.I 
  R.VTNRDIIC*QIAYAR.I 
  R.YLM#EEDEDAYKK.Q 
60S ribosomal protein L6 IPI:IPI00329389.7 K.AVDSQILPK.I 
  K.FVIATSTK.I 
  K.HLTDAYFK.K 
  R.HQEGEIFDTEK.E 
  
R.HQEGEIFDTEKEKYEI
TEQR.K 
  R.YYPTEDVPR.K 
60S ribosomal protein L7 IPI:IPI00030179.3 K.AGNFYVPAEPK.L 
  K.ASINMLR.I 
  K.EANNFLWPFK.L 
  K.SVNELIYK.R 
  K.SVNELIYKR.G 
  R.IALTDNALIAR.S 
  R.IVEPYIAWGYPNLK.S 
  R.KAGNFYVPAEPK.L 
60S ribosomal protein L7a IPI:IPI00299573.11 K.VPPAINQFTQALDR.Q
  R.AGVNTVTTLVENK.K 
  R.AGVNTVTTLVENKK.A
  
R.LKVPPAINQFTQALDR
.Q 
60S ribosomal protein L8 IPI:IPI00012772.7 R.AVVGVVAGGGR.I 
  R.KGAGSVFR.A 
60S ribosomal protein L9 IPI:IPI00031691.1 K.FLDGIYVSEK.G 
  
K.TILSNQTVDIPENVDIT
LK.G 
  R.TIC*SHVQNM#IK.G 
9 kDa protein IPI:IPI00176662.1 
R.LVQSPNSYFM#DVK.
C 
  R.LVQSPNSYFMDVK.C
ADP/ATP translocase 2 IPI:IPI00007188.4 K.DFLAGGVAAAISK.T 
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  K.EQGVLSFWR.G 
  K.LLLQVQHASK.Q 
  K.QIFLGGVDKR.T 
  R.AAYFGIYDTAK.G 
  R.GLGDC*LVK.I 
  R.LAADVGK.A 
  R.YFPTQALNFAFK.D 
ALB protein IPI:IPI00022434.2 
K.KVPQVSTPTLVEVSR.
N 
  K.YLYEIAR.R 
ATP-dependent RNA helicase A IPI:IPI00215638.6 K.LAAQSC*ALSLVR.Q 
  R.DFVNYLVR.I 
  
R.ELDALDANDELTPLG
R.I 
  R.LGGIGQFLAK.A 
ATP-dependent RNA helicase DDX3X IPI:IPI00215637.4 K.QYPISLVLAPTR.E 
  K.SPILVATAVAAR.G 
  R.VGSTSENITQK.V 
CDNA FLJ45706 fis, clone 
FEBRA2028457, highly similar to Nu IPI:IPI00444262.1 K.ALELTGLK.V 
  K.EVFEDAAEIR.L 
  K.FGYVDFESAEDLEK.A
  K.GIAYIEFK.T 
  K.NDLAVVDVR.I 
  K.TGISDVFAK.N 
  
K.VEGTEPTTAFNLFVG
NLNFNK.S 
  K.VTQDELK.E 
  
K.VTQDELKEVFEDAAEI
R.L 
  
R.KFGYVDFESAEDLEK.
A 
Chaperonin containing TCP1, subunit 8 
(Theta) variant IPI:IPI00302925.3 K.FAEAFEAIPR.A 
  K.LFVTNDAATILR.E 
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  R.DIDEVSSLLR.T 
DNA replication licensing factor MCM3 IPI:IPI00013214.1 K.VALLDVFR.E 
  R.SKDIFDQLAK.S 
DnaJ homolog subfamily A member 1 IPI:IPI00012535.1 K.QISQAYEVLSDAK.K 
  R.TIVITSHPGQIVK.H 
  R.YEEIVKEVSTYIK.K 
Elongation factor 1-gamma IPI:IPI00000875.5 K.ALIAAQYSGAQVR.V 
  R.ILGLLDAYLK.T 
Endoplasmin precursor IPI:IPI00027230.3 R.ELISNASDALDK.I 
  R.ELISNASDALDKIR.L 
F-actin capping protein alpha-1 subunit IPI:IPI00005969.2 
K.FITHAPPGEFNEVFND
VR.L 
  R.LLLNNDNLLR.E 
Far upstream element-binding protein 2 IPI:IPI00298363.2 K.DAFADAVQR.A 
  R.IGGGIDVPVPR.H 
GPI-anchored membrane protein 1 IPI:IPI00030910.1 K.YQEVTNNLEFAK.E 
  R.SFM#ALSQDIQK.T 
HECT domain and RCC1-like domain-
containing protein 5 IPI:IPI00008821.1 R.DQLM#PLPVK.V 
  
R.TTEM#M#PVYLDLNK.
A 
Heat shock 70 kDa protein 7 (Fragment) IPI:IPI00011134.1 
K.ATAGDTHLGGEDFDN
R.L 
  R.VEILANDQGNR.T 
Heat shock protein 86 (Fragment) IPI:IPI00031523.3 K.ADLINNLGTIAK.S 
  K.YIDQEELNK.T 
  R.ELISNSSDALDK.I 
Heterogeneous nuclear ribonucleoprotein 
R IPI:IPI00012074.3 K.AGPIWDLR.L 
  R.DLYEDELVPLFEK.A 
Histone H2B type 2-E IPI:IPI00003935.5 
K.AM#GIM#NSFVNDIFE
R.I 
  R.LLLPGELAK.H 
Hsp90 co-chaperone Cdc37 IPI:IPI00013122.1 
K.ASEAKEGEEAGPGDP
LLEAVPK.T 
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  K.DVQM#LQDAISK.M 
  
K.EGEEAGPGDPLLEAV
PK.T 
  K.TEEDSEEVREQK.H 
  
R.LGPGGLDPVEVYESL
PEELQK.C 
  R.SWEQKLEEM#R.K 
Hypothetical protein IPI:IPI00003362.2 K.DAGTIAGLNVM#R.I 
  K.DAGTIAGLNVMR.I 
  K.ELEEIVQPIISK.L 
  K.FEELNM#DLFR.S 
  
K.NQLTSNPENTVFDAK.
R 
  
K.SQIFSTASDNQPTVTI
K.V 
  
K.VTHAVVTVPAYFNDA
QR.Q 
  
R.IINEPTAAAIAYGLDK.
R 
  R.LIGDAAK.N 
  R.NELESYAYSLK.N 
  R.TWNDPSVQQDIK.F 
Importin beta-1 subunit IPI:IPI00001639.2 R.VAALQNLVK.I 
  R.VLANPGNSQVAR.V 
Inhibitor of nuclear factor kappa B kinase 
subunit beta IPI:IPI00024709.1 K.ALDDILNLK.L 
  
R.DLKPENIVLQQGEQR.
L 
  R.LGTGGFGNVIR.W 
  
R.M#M#ALQTDIVDLQR.
S 
Inhibitor of nuclear factor kappa-B kinase 
alpha subunit IPI:IPI00005104.1 K.IIDLGYAK.D 
  K.IIDLLPK.V 
  K.IIVHTVQSQDR.V 
  K.NTLISASQQLK.A 
  K.TVYEGPFASR.S 
  K.VEVALSNIK.E 
 158
  R.AAMLSLLR.Y 
  
R.DLKPENIVLQDVGGK.
I 
  R.GGPVDLTLKQPR.C 
  R.YNANLTK.M 
Interferon-induced 17 kDa protein 
precursor IPI:IPI00375631.5 K.IGVHAFQQR.L 
  R.LAVHPSGVALQDR.V 
  R.LTQTVAHLK.Q 
Interleukin enhancer-binding factor 2 IPI:IPI00005198.2 K.VLQSALAAIR.H 
  
R.NQDLAPNSAEQASIL
SLVTK.I 
Isoform 1 of 40S ribosomal protein S24 IPI:IPI00029750.1 
K.TTGFGM#IYDSLDYAK
.K 
  
K.TTGFGMIYDSLDYAK.
K 
Isoform 1 of Heterogeneous nuclear 
ribonucleoprotein Q IPI:IPI00018140.3 R.DLFEDELVPLFEK.A 
  R.NLANTVTEEILEK.A 
Isoform 1 of Plasminogen activator 
inhibitor 1 RNA-binding IPI:IPI00410693.3 
K.SAAQAAAQTNSNAAG
K.Q 
  
R.FDQLFDDESDPFEVL
K.A 
  
R.TDKSSASAPDVDDPE
AFPALA.- 
Isoform 1 of Polyadenylate-binding protein 
1 IPI:IPI00008524.1 K.EFSPFGTITSAK.V 
  K.FSPAGPILSIR.V 
  
K.GFGFVC*FSSPEEATK
.A 
  K.GFGFVSFER.H 
  
K.GYGFVHFETQEAAER
.A 
  K.SGVGNIFIK.N 
  R.AKEFTNVYIK.N 
  R.ALDTM#NFDVIK.G 
  R.ALDTMNFDVIK.G 
  
R.SKVDEAVAVLQAHQA
K.E 
  
R.SLGYAYVNFQQPADA
ER.A 
  R.YQGVNLYVK.N 
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Isoform 2 of Protein disulfide-isomerase A6 
precursor IPI:IPI00299571.5 K.GSFSEQGINEFLR.E 
  
K.LAAVDATVNQVLASR.
Y 
  R.TGEAIVDAALSALR.Q
Isoform 5 of Interleukin enhancer-binding 
factor 3 IPI:IPI00219330.2 K.AYAALAALEK.L 
  
K.VLQDM#GLPTGAEGR
.D 
  R.LNQLKPGLQYK.L 
Isoform Long of Double-stranded RNA-
binding protein Staufen IPI:IPI00000001.2 K.NAAIAVLEELKK.L 
  
R.ELLYGGTSPTAETILK.
N 
Isoform Long of Trifunctional purine 
biosynthetic protein a IPI:IPI00025273.1 K.AAVAGLDKAER.A 
  R.AIAFLQQPR.S 
Keratin 24 IPI:IPI00004550.5 R.LAADDFR.L 
  R.QSVEADINGLR.K 
Keratin, type II cytoskeletal 2 oral IPI:IPI00008359.1 K.KYEDEINKR.T 
  
K.QLDSLLGERGNLEGE
LK.S 
Lung cancer oncogene 7 IPI:IPI00641950.3 K.DVLSVAFSSDNR.Q 
  K.IIVDELKQEVISTSSK.A
  K.LTRDETNYGIPQR.A 
  R.DETNYGIPQR.A 
  R.LWDLTTGTTTR.R 
  R.VWQVTIGTR.- 
  R.YWLC*AATGPSIK.I 
Mitochondrial aspartate-glutamate carrier 
protein IPI:IPI00007084.2 
K.ASGDSARPVLLQVAE
SAYR.F 
  
R.AGQTTYSGVIDC*FR.
K 
  
R.IAPLEEGTLPFNLAEA
QR.Q 
  R.LQVAGEITTGPR.V 
Mitogen-activated protein kinase kinase 
kinase 14 IPI:IPI00016099.2 
K.EESGM#WEPLPLSSL
EPAPAR.N 
  
K.EESGMWEPLPLSSLE
PAPAR.N 
  
K.EGSEAGPAAISIIAQA
EC*ENSQEFSPTFSER.I
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  K.EQGC*LPEDR.A 
  K.HGQLENRP.- 
  K.IASEPPPVR.E 
  K.KQSSVYKLEAVEK.S 
  
K.LAC*VDSQKPLPDPHL
SK.L 
  K.LEAVEK.S 
  K.LEAVEKSPVFC*GK.W
  
K.QYSQSESLDQIPNNV
AHATEGK.M 
  K.SLAHAGVALAK.P 
  
K.SLAHAGVALAKPLPR.
T 
  
K.SLLTGDYIPGTETHMA
PEVVLGR.S 
  K.SPPLTLSK.E 
  K.SPVFC*GK.W 
  K.SPWRGEYKEPR.H 
  K.TEDNEGVLLTEK.L 
   
  
K.VGDIATGISSQIPAAAF
SLVTK.D 
  K.WEILNDVITK.G 
  
R.AEELM#AC*AGLTSPR
.I 
  R.ALQQVGGLK.S 
  R.ALQQVGGLKSPWR.G
  R.APGPRPAEETTGR.A 
  
R.APGPRPAEETTGRAP
K.L 
  
R.DTLSSGVHSWSSQA
EAR.S 
  R.EEVHWATHQLR.L 
  
R.EIPPSC*APLTAQAIQE
GLR.K 
  R.GEYKEPR.H 
  
R.GRPTDTPSYFNGVK.
V 
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  R.GSFGEVHR.M 
  R.IFIAGSK.Q 
  R.ILHGDVK.A 
  R.IVPLYGAVR.E 
  
R.M#EDKQTGFQC*AVK.
K 
  R.PAEETTGRAPK.L 
  
R.SREPSPKTEDNEGVL
LTEK.L 
  R.SSSWNM#VLAR.G 
  R.SSSWNMVLAR.G 
  
R.TPEQESC*TIPVQEDE
SPLGAPYVR.N 
  R.VKHGQLENRP.- 
  R.VSAAELGGK.V 
  R.VSAAELGGKVNR.A 
NCL protein IPI:IPI00183526.5 K.ATFIKVPQNQNGK.S 
  
K.GFGFVDFNSEEDAK.
A 
  K.GLSEDTTEETLK.E 
  
K.GLSEDTTEETLKESFD
GSVR.A 
  K.NSTWSGESK.T 
  K.TEADAEKTFEEK.Q 
  K.TFEEKQGTEIDGR.S 
  R.IVTDRETGSSK.G 
  R.LELQGPR.G 
  R.SISLYYTGEK.G 
NF-kappa-B essential modulator IPI:IPI00002411.3 
K.AQVTSLLGELQESQS
R.L 
  K.ELLQEQLEQLQR.E 
  
R.HVEVSQAPLPPAPAY
LSSPLALPSQR.R 
Nucleosome assembly protein 1-like 4 IPI:IPI00017763.4 K.FYEEVHDLER.K 
  
R.LDNVPHTPSSYIETLP
K.A 
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Phenylalanyl-tRNA synthetase alpha chain IPI:IPI00031820.2 K.LGITQLR.F 
  K.SLQALGEVIEAELR.S 
  R.LDAEPRPPPTQEAA.-
Probable ATP-dependent RNA helicase 
DDX5 IPI:IPI00017617.1 K.APILIATDVASR.G 
  K.QVSDLISVLR.E 
  R.GDGPIC*LVLAPTR.E 
Ribosomal protein homolog PD-1 IPI:IPI00394699.1 K.NAESNAELK.G 
  K.YLKDVTLQK.Q 
Stress-70 protein, mitochondrial precursor IPI:IPI00007765.5 K.DAGQISGLNVLR.V 
  K.VLENAEGAR.T 
  K.VQQTVQDLFGR.A 
  
K.VQQTVQDLFGRAPSK
.A 
  R.TTPSVVAFTADGER.L
T-complex protein 1 subunit beta IPI:IPI00297779.6 R.GATQQILDEAER.S 
  
R.VQDDEVGDGTTSVTV
LAAELLR.E 
TSR1, 20S rRNA accumulation, homolog IPI:IPI00292894.4 K.QIDAPGDPFPLNPR.G
  R.LEEM#FPDEVDTPR.D
chaperonin containing TCP1, subunit 3 
isoform b IPI:IPI00290770.3 R.IVLLDSSLEYK.K 
  R.NLQDAM#QVC*R.N 
  R.TLIQNC*GASTIR.L 
heterogeneous nuclear ribonucleoprotein 
H1 IPI:IPI00013881.6 
R.EGRPSGEAFVELESE
DEVK.L 
  
R.STGEAFVQFASQEIA
EK.A 
heterogeneous nuclear ribonucleoprotein 
M isoform a IPI:IPI00171903.2 
K.QGGGGGGGSVPGIE
R.M 
  
K.VGEVTYVELLMDAEG
K.S 
  R.AFITNIPFDVK.W 
  R.INEILSNALK.R 
  R.M#GAGM#GFGLER.M
  R.M#GANSLER.M 
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heterogeneous nuclear ribonucleoprotein 
U isoform b IPI:IPI00479217.1 K.NGQDLGVAFK.I 
  
K.SSGPTSLFAVTVAPP
GAR.Q 
  K.VSELKEELK.K 
  K.YNILGTNTIM#DK.M 
  
R.NFILDQTNVSAAAQR.
R 
insulin receptor substrate 4 IPI:IPI00020729.1 R.AAVSAFPTDSLER.D 
  R.GLDKEVSYNWDPK.D
insulin-like growth factor 2 mRNA binding 
protein 1 IPI:IPI00008557.4 K.ILAHNNFVGR.L 
  
K.LYIGNLNESVTPADLE
K.V 
  K.QQQVDIPLR.L 
  
K.TVNELQNLTAAEVVV
PR.D 
  R.DQTPDENDQVIVK.I 
  R.LLVPTQYVGAIIGK.E 
  R.M#VIITGPPEAQFK.A 
poly(rC)-binding protein 2 isoform b IPI:IPI00012066.2 R.AITIAGIPQSIIEC*VK.Q
  R.IITLAGPTNAIFK.A 
  R.INISEGNC*PER.I 
pyruvate kinase 3 isoform 2 IPI:IPI00220644.8 
K.GADFLVTEVENGGSL
GSK.K 
  K.IYVDDGLISLQVK.Q 
  R.APIIAVTR.N 
  
R.TATESFASDPILYRPV
AVALDTK.G 
ribosomal protein L11 IPI:IPI00376798.3 K.AEEILEK.G 
  K.VLEQLTGQTPVFSK.A
  K.YDGIILPGK.- 
similar to 40S ribosomal protein S7 IPI:IPI00008293.4 K.EIEVGGGR.K 
  R.ELNITAAK.E 
similar to 40S ribosomal protein SA IPI:IPI00398958.3 
R.ADHQPLTEASYVNLP
TIALC*NTDSPLR.Y 
  
R.FTPGTFTNQIQAAFR.
E 
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  R.LLVVTDPR.A 
similar to 60S ribosomal protein L7a IPI:IPI00075558.8 K.KVVNPLFEK.R 
  K.NFGIGQDIQPK.R 
similar to ribosomal protein L13 isoform 1 IPI:IPI00397611.2 K.EAAEQDVEK.K 
  K.KGDSSAEELK.L 
  K.STESLQANVQR.L 
  R.AKEAAEQDVEK.K 
  R.TIGISVDPR.R 
  R.VATWFNQPAR.K 
  R.VITEEEKNFK.A 
similar to ribosomal protein S15a IPI:IPI00156232.1 K.ILGFFF.- 
  K.IVVNLTGR.L 
ubiquitin and ribosomal protein S27a 
precursor IPI:IPI00179330.6 K.IQDKEGIPPDQQR.L 
  
K.TITLEVEPSDTIENVK.
A 
  R.TLSDYNIQK.E 
ubiquitin specific protease 9, X-linked 
isoform 4 IPI:IPI00003964.3 R.LAQQISDEASR.Y 
  R.VVIQSNDDIASR.A 
 
 
Second Run   
Protein Name Accession Number Peptides 
40S ribosomal protein S19 IPI:IPI00215780.4 R.ALAAFLKK.S 
  R.IAGQVAAANK.K 
  R.RVLQALEGLK.M 
  R.VLQALEGLK.M 
40S ribosomal protein S3 IPI:IPI00011253.3 
K.GGKPEPPAM#PQPVP
TA.- 
  
K.GGKPEPPAMPQPVPT
A.- 
  R.ELAEDGYSGVEVR.V 
60S ribosomal protein L23a IPI:IPI00021266.1 R.LAPDYDALDVANK.I 
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R.LAPDYDALDVANKIGII.
- 
60S ribosomal protein L24 IPI:IPI00306332.4 R.AITGASLADIM#AK.R 
  R.AITGASLADIMAKR.N 
60S ribosomal protein L4 IPI:IPI00003918.5 K.AAAAAAALQAK.S 
  K.M#INTDLSR.I 
  R.VDKAAAAAAALQAK.S
60S ribosomal protein L8 IPI:IPI00012772.7 R.KVGLIAAR.R 
  R.LRAVDFAER.H 
ADP/ATP translocase 2 IPI:IPI00007188.4 K.DFLAGGVAAAISK.T 
  R.LAADVGK.A 
Actin, aortic smooth muscle IPI:IPI00008603.1 K.AGFAGDDAPR.A 
  R.AVFPSIVGRPR.H 
CDNA FLJ45706 fis, clone 
EBRA2028457, highly similar to Nu IPI:IPI00444262.1 K.NDLAVVDVR.I 
  
K.NLPYKVTQDELKEVFE
DAAEIR.L 
  
K.TGISDVFAKNDLAVVD
VR.I 
EEF1A1 protein IPI:IPI00025447.6 
R.VETGVLKPGM#VVTFA
PVNVTTEVK.S 
  
R.VETGVLKPGMVVTFA
PVNVTTEVK.S 
Elongation factor 1-alpha 2 IPI:IPI00014424.1 K.IGGIGTVPVGR.V 
  K.STTTGHLIYK.C 
Heat shock 70 kDa protein 1 IPI:IPI00304925.4 K.FGDPVVQSDMK.H 
  
K.LDKAQIHDLVLVGGST
R.I 
  K.LLQDFFNGR.D 
  
K.NQVALNPQNTVFDAK.
R 
  
K.NQVALNPQNTVFDAK
R.L 
  R.ARFEELC*SDLFR.S 
  R.FEELC*SDLFR.S 
  R.IINEPTAAAIAYGLDR.T
  
R.LIGDAAKNQVALNPQN
TVFDAK.R 
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  R.LVNHFVEEFK.R 
  R.LVNHFVEEFKR.K 
  
R.MVQEAEKYKAEDEVQ
R.E 
Heat shock 70 kDa protein 1L IPI:IPI00301277.1 K.AFYPEEISSM#VLTK.L
  K.AFYPEEISSMVLTK.L 
  K.DAGVIAGLNVLR.I 
  K.NALESYAFNM#K.S 
  K.NALESYAFNMK.S 
  R.AMTKDNNLLGR.F 
  R.LSKEEIER.M 
  
R.NSTIPTKQTQIFTTYSD
NQPGVLIQVYEGER.A 
  
R.QATKDAGVIAGLNVLR
.I 
Heat shock 70 kDa protein 7 (Fragment) IPI:IPI00011134.1 
K.ATAGDTHLGGEDFDN
R.L 
  R.VEILANDQGNR.T 
Heat shock protein 86 (Fragment) IPI:IPI00031523.3 K.ADLINNLGTIAK.S 
  K.YIDQEELNK.T 
Histone H1.2 IPI:IPI00217465.4 
K.ALAAAGYDVEKNNSR.
I 
  K.ASGPPVSELITK.A 
  K.SLVSKGTLVQTK.G 
  R.KASGPPVSELITK.A 
  R.SGVSLAALKK.A 
Isoform 1 of Heat shock cognate 71 kDa 
otein IPI:IPI00003865.1 K.DAGTIAGLNVLR.I 
  K.ITITNDKGR.L 
  K.MKEIAEAYLGK.T 
  
K.NQVAMNPTNTVFDAK.
R 
  K.SFYPEEVSSMVLTK.M
  
K.STAGDTHLGGEDFDN
R.M 
  
K.TVTNAVVTVPAYFNDS
QR.Q 
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  K.VQVEYKGETK.S 
  R.ARFEELNADLFR.G 
  
R.IINEPTAAAIAYGLDKK.
V 
  R.LSKEDIER.M 
  
R.QATKDAGTIAGLNVLR
.I 
  R.TTPSYVAFTDTER.L 
  
R.TTPSYVAFTDTERLIG
DAAK.N 
Keratin, type I cytoskeletal 10 IPI:IPI00009865.1 K.VTM#QNLNDR.L 
  R.SQYEQLAEQNRK.D 
Mitogen-activated protein kinase kinase 
nase 14 IPI:IPI00016099.2 
K.ADNVLLSSDGSHAALC
DFGHAVCLQPDGLGK.S
  
K.GTAKEGSEAGPAAISII
AQAEC*ENSQEFSPTFS
ER.I 
  K.HGQLENRP.- 
  K.IASEPPPVR.E 
  
K.LAC*VDSPKPLPGPHL
EPSC*LSR.G 
  
K.LAC*VDSQKPLPDPHL
SK.L 
  
K.QYSQSESLDQIPNNVA
HATEGK.M 
  
K.SLAHAGVALAKPLPR.
T 
  
K.SLLTGDYIPGTETHMA
PEVVLGR.S 
  K.TEDNEGVLLTEK.L 
  
K.VGDIATGISSQIPAAAF
SLVTK.D 
  K.VQIQSLNGEHLHIR.E 
  K.WEILNDVITK.G 
  R.ALQQVGGLK.S 
  R.ALQQVGGLKSPWR.G
  
R.ALYYLGQALEGLEYLH
SR.R 
  R.APGPRPAEETTGR.A 
  
R.APGPRPAEETTGRAP
K.L 
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R.DTLSSGVHSWSSQAE
AR.S 
  R.GRPTDTPSYFNGVK.V
  R.IFIAGSK.Q 
  
R.NTPQFTKPLKEPGLG
QLC*FK.Q 
  
R.SREPSPKTEDNEGVLL
TEK.L 
  R.SSSWNM#VLAR.G 
  R.SSSWNMVLAR.G 
  R.VKHGQLENRP.- 
  
R.VKVGDIATGISSQIPAA
AFSLVTK.D 
  R.VSAAELGGK.V 
  R.VSAAELGGKVNR.A 
NCL protein IPI:IPI00183526.5 K.ALVATPGKK.G 
  K.GFGFVDFNSEEDAK.A
  
K.TLVLSNLSYSATEETL
QEVFEK.A 
  R.AIRLELQGPR.G 
  R.IVTDRETGSSK.G 
  R.LELQGPR.G 
  R.SISLYYTGEK.G 
Probable ATP-dependent RNA helicase 
DX5 IPI:IPI00017617.1 K.LLQLVEDR.G 
  R.MLDMGFEPQIR.K 
TUBA6 protein IPI:IPI00166768.2 K.DVNAAIATIK.T 
  R.AVFVDLEPTVIDEVR.T
Tubulin beta chain IPI:IPI00011654.2 
R.AILVDLEPGTM#DSVR.
S 
  
R.AILVDLEPGTMDSVR.
S 
  
R.ALTVPELTQQVFDAK.
N 
similar to 40S ribosomal protein SA IPI:IPI00398958.3 K.FAAATGATPIAGR.F 
  R.LLVVTDPR.A 
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Third Run   
Protein Name 
Accession 
Number Peptides 
40S ribosomal 
protein S2 IPI:IPI00013485.3 K.LLM#M#AGIDDC*YTSAR.G 
    K.SPYQEFTDHLVK.T 
40S ribosomal 
protein S3 IPI:IPI00011253.3 K.GGKPEPPAM#PQPVPTA.- 
    K.GGKPEPPAMPQPVPTA.- 
    K.KPLPDHVSIVEPKDEILPTTPISEQK.G 
    R.FGFPEGSVELYAEK.V 
40S ribosomal 
protein S3a IPI:IPI00419880.5 K.VERADGYEPPVQESV.- 
    R.VFEVSLADLQNDEVAFR.K 
40S ribosomal 
protein S5 IPI:IPI00008433.3 K.TIAEC*LADELINAAK.G 
    K.WSTDDVQINDISLQDYIAVK.E 
40S ribosomal 
protein S7 IPI:IPI00013415.1
K.IVKPNGEKPDEFESGISQALLELEM#NSDL
K.A 
    K.LTGKDVNFEFPEFQL.- 
40S ribosomal 
protein S8 IPI:IPI00216587.8 K.ISSLLEEQFQQGK.L 
    K.LTPEEEEILNKKR.S 
    R.ADGYVLEGKELEFYLR.K 
60S acidic 
ribosomal protein 
P0 IPI:IPI00008530.1
K.AFLADPSAFVAAAPVAAATTAAPAAAAAP
AK.V 
    
K.AFLADPSAFVAAAPVAAATTAAPAAAAAP
AKVEAK.E 
    R.GHLENNPALEK.L 
    R.GTIEILSDVQLIK.T 
60S ribosomal 
protein L3 IPI:IPI00550021.3 R.ERLEQQVPVNQVFGQDEM#IDVIGVTK.G 
    R.ERLEQQVPVNQVFGQDEMIDVIGVTK.G 
60S ribosomal 
protein L5 IPI:IPI00000494.5 K.GAVDGGLSIPHSTK.R 
    R.YLM#EEDEDAYKK.Q 
60S ribosomal 
protein L7 IPI:IPI00030179.3 K.TTHFVEGGDAGNREDQINR.L 
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    R.IALTDNALIAR.S 
60S ribosomal 
protein L8 IPI:IPI00012772.7 R.ASGNYATVISHNPETK.K 
    R.AVVGVVAGGGR.I 
85 kDa protein IPI:IPI00334775.6 K.AQALRDNSTMGYMMAK.K 
    K.EQVANSAFVER.V 
    K.HLEINPDHPIVETLR.Q 
    K.IDIIPNPQER.T 
    K.KHLEINPDHPIVETLR.Q 
    K.SIYYITGESKEQVANSAFVER.V 
    K.SLTNDWEDHLAVK.H 
    K.SLVSVTK.E 
    K.SLVSVTKEGLELPEDEEEKKKMEESK.A 
    R.GVVDSEDLPLNISR.E 
    R.NPDDITQEEYGEFYK.S 
    R.RAPFDLFENK.K 
    R.RLSELLR.Y 
    R.TLTLVDTGIGM#TK.A 
    R.YHTSQSGDEMTSLSEYVSR.M 
ATP-dependent 
RNA helicase A IPI:IPI00215638.6 K.LAQFEPSQR.Q 
    R.ELDALDANDELTPLGR.I 
    R.LGGIGQFLAK.A 
    R.RISAVSVAER.V 
Heat shock protein 
86 (Fragment) IPI:IPI00031523.3 K.ADLINNLGTIAK.S 
    K.YIDQEELNK.T 
    K.YIDQEELNKTKPIWTR.N 
Heat shock protein 
HSP 90-alpha 2 IPI:IPI00382470.3 K.DQVANSAFVER.L 
    K.ELHINLIPNKQDR.T 
    K.HIYYITGETK.D 
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    K.TLVSVTK.E 
    R.NPDDITNEEYGEFYK.S 
    R.RAPFDLFENR.K 
    R.YYTSASGDEMVSLKDYC*TR.M 
Histone H1x IPI:IPI00021924.1 K.ALVQNDTLLQVK.G 
    R.GAPAAATAPAPTAHK.A 
Hsp90 co-
chaperone Cdc37 IPI:IPI00013122.1 K.ASEAKEGEEAGPGDPLLEAVPK.T 
    
K.ASEAKEGEEAGPGDPLLEAVPKTGDEKD
VSV.- 
    K.DVQMLQDAISK.M 
    K.EGEEAGPGDPLLEAVPK.T 
    K.SM#PWNVDTLSK.D 
    K.TADRQYMEGFNDELEAFKER.V 
    R.C*IDSGLWVPNSK.A 
    R.LGPGGLDPVEVYESLPEELQK.C 
    R.LQAEAQQLR.K 
Inhibitor of nuclear 
factor kappa-B 
kinase alpha 
subunit IPI:IPI00005104.1
K.AC*DVPEELNILIHDVPLLAM#EYC*SGGD
LR.K 
    R.DLKPENIVLQDVGGK.I 
      
    R.ETGINTGSQELLSETGISLDPR.K 
    R.GGPVDLTLKQPR.C 
    R.IERETGINTGSQELLSETGISLDPR.K 
    R.RQGDLMESLEQR.A 
Interleukin 
enhancer-binding 
factor 2 IPI:IPI00005198.2 R.VKPAPDETSFSEALLK.R 
    R.VKPAPDETSFSEALLKR.N 
Isoform 1 of DNA-
binding protein A IPI:IPI00031801.4 R.SVGDGETVEFDVVEGEK.G 
    
R.SVGDGETVEFDVVEGEKGAEAANVTGPD
GVPVEGSR.Y 
 172
Isoform 1 of 
Keratin, type I 
cytoskeletal 13 IPI:IPI00009866.6 R.ALEEANADLEVK.I 
    R.LEQEIATYR.S 
Isoform 1 of 
Polyadenylate-
binding protein 1 IPI:IPI00008524.1 K.GFGFVC*FSSPEEATK.A 
    R.ALDTM#NFDVIK.G 
    R.KEFSPFGTITSAK.V 
    R.RSLGYAYVNFQQPADAER.A 
    R.SLGYAYVNFQQPADAER.A 
Isoform 1 of 
Polyadenylate-
binding protein 4 IPI:IPI00012726.4 K.EFSPFGSITSAK.V 
    R.KAHLTNQYMQR.V 
Isoform 1 of 
Probable ATP-
dependent RNA 
helicase DDX17 IPI:IPI00023785.5 R.GGGGLPPK.K 
    R.SSQSSSQQFSGIGR.S 
Isoform 1 of STIP1 
homology and U 
box-containing 
protein 1 IPI:IPI00025156.4 R.LNFGDDIPSALR.I 
    R.VGHFDPVTR.S 
Isoform 2 of 
Nucleophosmin IPI:IPI00220740.1 K.GPSSVEDIKAK.M 
    K.TPKGPSSVEDIKAK.M 
    K.VDNDENEHQLSLR.T 
    R.M#TDQEAIQDLWQWR.K 
    R.MTDQEAIQDLWQWR.K 
Isoform 5 of 
Interleukin 
enhancer-binding 
factor 3 IPI:IPI00219330.2 K.AYAALAALEK.L 
    K.VLAGETLSVNDPPDVLDR.Q 
Keratin, type I 
cytoskeletal 14 IPI:IPI00384444.4 K.DAEEWFFTKTEELNR.E 
    R.APSTYGGGLSVSSSR.F 
    R.GQVGGDVNVEM#DAAPGVDLSR.I 
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    R.ILNEMRDQYEK.M 
    R.LLEGEDAHLSSSQFSSGSQSSR.D 
Keratin, type I 
cytoskeletal 16 IPI:IPI00217963.2 K.TEELNKEVASNSELVQSSR.S 
    R.APSTYGGGLSVSSR.F 
      
    R.GQTGGDVNVEM#DAAPGVDLSR.I 
    R.LLEGEDAHLSSQQASGQSYSSR.E 
    R.TDLEM#QIEGLKEELAYLR.K 
Keratin, type II 
cytoskeletal 6B IPI:IPI00293665.6
R.ALYDAELSQM#QTHISDTSVVLSM#DNNR
.N 
    R.ATGGGLSSVGGGSSTIK.Y 
    R.SGFSSISVSR.S 
    R.SLYGLGGSKR.I 
Mitogen-activated 
protein kinase 
kinase kinase 14 IPI:IPI00016099.2
K.ADNVLLSSDGSHAALC*DFGHAVC*LQPD
GLGK.S 
    
K.ADNVLLSSDGSHAALCDFGHAVCLQPDG
LGK.S 
    K.ASQSSRDTLSSGVHSWSSQAEAR.S 
    
K.DGQPVRYDM#EVPDSGIDLQC*TLAPDGS
FAWSWR.V 
    K.EESGM#WEPLPLSSLEPAPAR.N 
    K.EESGMWEPLPLSSLEPAPAR.N 
    K.EESGMWEPLPLSSLEPAPARNPSSPER.K
    
K.EGSEAGPAAISIIAQAEC*ENSQEFSPTFS
ER.I 
    
K.GTAKEGSEAGPAAISIIAQAEC*ENSQEFS
PTFSER.I 
    K.IASEPPPVR.E 
    K.IASEPPPVREIPPSC*APLTAQAIQEGLR.K 
    
K.IASEPPPVREIPPSC*APLTAQAIQEGLRK.
E 
    K.KQSSVYKLEAVEK.S 
    K.LAC*VDSPKPLPGPHLEPSC*LSR.G 
    K.LAC*VDSQKPLPDPHLSK.L 
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    K.LHHPQDGGPLPLPTHPFPYSR.L 
    K.LKPVDYEYR.E 
    K.LKPVDYEYREEVHWATHQLR.L 
    K.QSSVYKLEAVEK.S 
    K.QSSVYKLEAVEKSPVFC*GK.W 
    K.QYSQSESLDQIPNNVAHATEGK.M 
    K.SLAHAGVALAKPLPR.T 
    K.SLLTGDYIPGTETHMAPEVVLGR.S 
    
K.SPPLTLSKEESGMWEPLPLSSLEPAPAR.
N 
    K.SPVFC*GKWEILNDVITK.G 
    K.SPWRGEYKEPR.H 
    K.TEDNEGVLLTEK.L 
    K.VQIQSLNGEHLHIR.E 
    K.WEILNDVITK.G 
    R.AEELM#AC*AGLTSPR.I 
    R.AEELMAC*AGLTSPR.I 
    R.ALQQVGGLK.S 
    R.ALQQVGGLKSPWR.G 
    R.ALQQVGGLKSPWRGEYKEPR.H 
    R.APGPRPAEETTGR.A 
    R.APGPRPAEETTGRAPK.L 
    R.DTLSSGVHSWSSQAEAR.S 
    R.EEVHWATHQLR.L 
    R.EIPPSC*APLTAQAIQEGLR.K 
    R.EPSPKTEDNEGVLLTEK.L 
    R.GRPTDTPSYFNGVK.V 
    R.GSFGEVHR.M 
    R.GSFGEVHRM#EDKQTGFQC*AVK.K 
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    R.GSFGEVHRM#EDKQTGFQC*AVKK.V 
    R.GSFGEVHRMEDKQTGFQC*AVK.K 
    R.HPPPNQANYHQTLHAQPR.E 
    R.IFIAGSK.Q 
    
R.IFIAGSKQYSQSESLDQIPNNVAHATEGK.
M 
    R.LEVFRAEELM#AC*AGLTSPR.I 
    R.M#EDKQTGFQC*AVK.K 
    R.MEDKQTGFQC*AVK.K 
    R.MEDKQTGFQC*AVKK.V 
    R.NTPQFTKPLKEPGLGQLC*FK.Q 
    R.SREPSPKTEDNEGVLLTEK.L 
    R.SSSWNM#VLAR.G 
    R.SSSWNMVLAR.G 
    R.TPEQESC*TIPVQEDESPLGAPYVR.N 
    R.VSAAELGGK.V 
    R.VSAAELGGKVNR.A 
NF-kappa-B 
essential modulator IPI:IPI00002411.3 K.AQVTSLLGELQESQSR.L 
    R.MQGQSVEAALR.M 
    R.QLESEREALQQQHSVQVDQLR.M 
Stress-induced-
phosphoprotein 1 IPI:IPI00013894.1 K.ALDLDSSC*KEAADGYQR.C 
    R.KAAALEAMKDYTK.A 
heterogeneous 
nuclear 
ribonucleoprotein M 
isoform a IPI:IPI00171903.2 K.GC*GVVKFESPEVAER.A 
    K.QGGGGGGGSVPGIER.M 
    R.M#GAGM#GFGLER.M 
    R.M#GPAM#GPALGAGIER.M 
    R.MGPAMGPALGAGIER.M 
    R.MGPLGLDHMASSIER.M 
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insulin receptor 
substrate 4 IPI:IPI00020729.1 R.GDNQAGGAAAAAAAPEPPPR.S 
    R.WFQPVANAADAEAVR.G 
insulin-like growth 
factor 2 mRNA 
binding protein 1 IPI:IPI00008557.4 K.SGYAFVDC*PDEHWAMK.A 
    K.TVNELQNLTAAEVVVPR.D 
    R.MVIITGPPEAQFK.A 
similar to 40S 
ribosomal protein 
SA IPI:IPI00398958.3 K.FAAATGATPIAGR.F 
    R.LLVVTDPR.A 
    R.YVDIAIPC*NNK.G 
tripartite motif-
containing 28 
protein IPI:IPI00438229.2
K.IVAERPGTNSTGPAPM#APPRAPGPLSK.
Q 
    K.LSPPYSSPQEFAQDVGR.M 
    K.VFPGSTTEDYNLIVIER.G 
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Name 
Log fold change  
(normalized to WT) 
p-
value 
hsa-miR-140-3p/mmu-miR-140*/rno-miR-140* 2.06 0.008
hsa-miR-382/mmu-miR-382/rno-miR-382 -1.78 0.009
hsa-miR-487b/mmu-miR-487b/rno-miR-487b -1.82 0.008
mmu-miR-1193 -1.89 0.008
mmu-miR-382* -1.94 0.010
mmu-miR-376a*/rno-miR-376a* -1.98 0.009
hsa-miR-196b/mmu-miR-196b/rno-miR-196b -2.01 0.007
mmu-miR-341/rno-miR-341 -2.06 0.008
hsa-miR-409-5p/mmu-miR-409-5p -2.12 0.006
hsa-miR-136/mmu-miR-136/rno-miR-136 -2.17 0.007
mmu-miR-540-5p -2.20 0.008
mmu-miR-329/rno-miR-329 -2.25 0.006
mmu-miR-673-5p -2.27 0.004
hsa-miR-380* -2.31 0.010
mmu-miR-434-3p/rno-miR-434 -2.44 0.007
hsa-miR-376c -2.44 0.006
mmu-miR-676 -2.44 0.004
mmu-miR-380-3p -2.49 0.008
hsa-miR-369-5p/mmu-miR-369-5p/rno-miR-369-5p -2.51 0.010
hsa-miR-431*/mmu-miR-431* -2.52 0.009
hsa-miR-154*/mmu-miR-154* -2.60 0.004
mmu-miR-136* -2.76 0.005
rno-miR-379* -2.79 0.010
mmu-miR-337-3p -2.98 0.008
hsa-miR-369-3p/mmu-miR-369-3p/rno-miR-369-3p -3.06 0.009
hsa-miR-431/mmu-miR-431/rno-miR-431 -3.12 0.004
hsa-miR-136*/rno-miR-136* -3.36 0.003
hsa-miR-376a -3.38 0.003
mmu-miR-299 -3.44 0.002
hsa-miR-433/mmu-miR-433/rno-miR-433 -3.45 0.003
mmu-miR-300/rno-miR-300-3p -3.48 0.002
mmu-miR-434-5p -3.54 0.002
mmu-miR-376c/rno-miR-376c -3.59 0.002
mmu-miR-540-3p/rno-miR-540 -3.66 0.004
rno-miR-337 -3.78 0.008
hsa-miR-127-5p/mmu-miR-127* -3.83 0.002
mmu-miR-337-5p -3.85 0.002
hsa-miR-299-5p/mmu-miR-299*/rno-miR-299 -3.87 0.004
hsa-miR-377/mmu-miR-377/rno-miR-377 -3.90 0.001
hsa-miR-410/mmu-miR-410/rno-miR-410 -4.03 0.004
hsa-miR-134/mmu-miR-134/rno-miR-134 -4.05 0.001
Table A2. miRNA array analysis of Nik+/+ and Nik-/-MEFs. Log fold changes 
represent the changes in Nik-/-MEFs normalized to Nik+/+ MEFS.  
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hsa-miR-495/mmu-miR-495/rno-miR-495 -4.17 0.001
hsa-miR-127-3p/mmu-miR-127/rno-miR-127 -4.50 0.003
hsa-miR-409-3p/mmu-miR-409-3p/rno-miR-409-3p -4.57 0.001
hsa-miR-10a/mmu-miR-10a/rno-miR-10a-5p -4.75 0.002
hsa-miR-379* -4.94 0.004
hsa-miR-411*/mmu-miR-411* -5.10 0.001
mmu-miR-376b/rno-miR-376b-3p -5.23 0.001
hsa-miR-379/mmu-miR-379/rno-miR-379 -5.25 0.001
hsa-miR-411/mmu-miR-411/rno-miR-411 -5.34 0.001
mmu-miR-376a/rno-miR-376a -5.41 0.001
mmu-miR-541/rno-miR-541 -5.63 0.001
mmu-miR-665 -1.52 0.028
hsa-miR-132/mmu-miR-132/rno-miR-132 -1.53 0.015
hsa-miR-1206 -1.65 0.028
hsa-miR-329 -1.69 0.048
mmu-miR-384-5p/rno-miR-384-5p -1.71 0.011
hsa-miR-381/mmu-miR-381/rno-miR-381 -1.97 0.042
hsa-miR-1197/mmu-miR-1197 -2.08 0.025
hsa-miR-539/mmu-miR-539/rno-miR-539 -2.11 0.022
mmu-miR-743b-3p -2.19 0.011
hsa-miR-376b -2.20 0.033
hsa-miR-641 -2.36 0.032
hsa-miR-335/mmu-miR-335-5p/rno-miR-335 -2.44 0.028
hsa-miR-378*/mmu-miR-378*/rno-miR-378* -2.46 0.027
rno-miR-148b-5p -3.20 0.043
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